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Abstract 
 
Introduction 
Obesity,  metabolic  syndrome  and  Type  2  diabetes  are  clinical  states  associated  with  insulin 
resistance and an increased risk of vascular disease. The prevalence of Type 2 diabetes is reaching 
epidemic proportions and there is a growing need for new therapeutic targets. There is a significant 
body of research that demonstrates an association between obesity, insulin resistance, endothelial 
dysfunction and accelerated atherosclerosis, but the molecular mechanisms underlying this link are 
incompletely understood. Biguanides and thiazolidinediones are widely used in the treatment of 
Type 2 diabetes to improve glycaemia but the precise site, mode and extent of their actions remain 
uncertain. For example, in the United Kingdom Prospective Diabetes Study (UKPDS), metformin 
treatment reduced the incidence of myocardial infarction by 39% in comparison with conventional 
treatment which is more than would have been predicted by the difference in achieved HbA1c 
(0.6%).  In  addition,  when  the  metformin  group  was  compared  with  a  group  treated  with 
sulphonylurea or insulin, to control for glycaemia, there was still a significant reduction in the 
incidence  of  stroke  and  any  other  diabetes-related  end-point.  The  enzyme  AMPK  is  a  novel 
therapeutic  target  in  Type  2  diabetes  and  the  development  of  specific  tissue  specific  AMPK 
activators is an attractive prospect for the future. We therefore investigated the role of AMPK in the 
action  of  biguanides  and  thiazolidinediones.  Accordingly,  the  aims of this project were to first 
determine if metformin improves vascular endothelial function and large artery stiffness in patients 
with Type 2 diabetes. In parallel, the thesis examines if metformin exerts its beneficial effects in 
patients with Type 2 diabetes in association with altered AMPK activity in human adipose. Finally, 
the thesis determines if insulin sensitizers such as metformin and the thiazolidinediones, acting 
directly on vascular endothelial cells, increase NO production by increasing AMPK activity thus 3 
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accounting for beneficial effects on endothelial function and, in metformin’s case, cardiovascular 
outcome.  
 
Methods 
Twenty men with Type 2 diabetes were randomised to metformin (500 milligrams three times daily 
for  ten  weeks)  and  gliclazide  (80  milligrams  twice  daily  for  ten  weeks)  in  a  double-blinded, 
glycaemia controlled, cross-over design. There was a six week run in and washout period. At the 
end of each ten week phase of therapy routine and non routine blood sampling (including plasma 
ADMA), PWV and an adipose biopsy were performed to determine resistance artery function and 
adipose AMPK activity. The effects of metformin, its closely related analogue phenformin and 
rosiglitazone  were  characterised  in  cultured  human  aortic  endothelial  cells  (HAECs).  AMPK 
activity was assessed using a peptide kinase assay and the quantification of phosphorylation of the 
AMPK substrate, acetyl-CoA carboxylase (ACC) in HAECs incubated in rosiglitazone, phenformin 
or metformin. Nitric oxide (NO) release was evaluated with a Sievers NO meter. 
 
Results 
The mean age and BMI of subjects in the clinical study was 56.5 years and 31kg/m
2. Mean HbA1c 
after metformin therapy was 8.3% compared with 7.8% following gliclazide therapy. There was no 
significant difference between resistance artery function and PWV. ADMA was marginally lower 
following metformin therapy (p=0.019). AMPK activity was 2 fold higher following metformin 
therapy when compared with gliclazide therapy (p=0.002). Stimulation of human aortic endothelial 
cells with phenformin and rosiglitazone resulted in the time- and dose-dependent stimulation of 
AMP-activated protein kinase activity and NO production with concomitant phosphorylation of 
endothelial  NO  synthase  at  Ser1177.    Infection  of  endothelial  cells  with  a  virus  encoding  a 
dominant  negative  AMPK  mutant  attenuated  both  phenformin  and  rosiglitazone-stimulated 4 
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Ser1177  phosphorylation  and  NO  production.  Furthermore,  the  stimulation  of  AMPK  and  NO 
synthesis  by  rosiglitazone  was  unaffected  by  the  peroxisome  proliferator-activated-receptor-
inhibitor,  GW9662.  Incubation  of  HAECs  with  metformin,  however,  had  no  effect  on  AMPK 
activity or NO synthesis. 
 
Conclusion 
Taken  together,  the  data  in  this  thesis  provides  further  insight  into  the  molecular  mechanisms 
underlying  the  interactions  between  insulin  sensitizing  drugs,  the  enzyme  AMPK  and  both  the 
human vascular endothelium and adipose. Further work leading to an increased understanding of 
the  molecular  mechanisms  by  which  anti-diabetic  drugs  activate  AMPK  in  both  the  vascular 
endothelium  and  adipose  tissue  may  identify  novel  therapeutic  targets  in  patients  with  Type  2 
diabetes.  
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1.1 Diabetes Mellitus, Insulin Resistance and the Metabolic Syndrome 
1.1.1 Diabetes Mellitus 
The key clinical features of diabetes mellitus were recognised as long ago as around 1500BC when 
Hindu scholars first described an illness featuring the familiar combination of polyuria, polydipsia, 
body  wasting  and  the  less  familiar  description  of  urine  sweet  enough  to  attract  flies  and  ants 
(Howlett and Bailey, 2007). Today, diabetes mellitus is a chronic disease that we can treat but not 
cure. There are an estimated 2.2 million patients with diabetes in the United Kingdom (UK) with a 
further  500,000  of  the  UK  population  undiagnosed  (Information  Centre  Quality  Outcomes 
Framework Data 2005/06). Diabetes Mellitus is estimated to cost the NHS £5.2 billion pounds per 
year. This represented a staggering 9.2% of the annual budget in 1997 (Currie et al 1997). Type 2 
Diabetes (T2DM), the most prevalent form of the disease, today affects some 250 million people 
worldwide with more than 380 million predicted by the year 2025. 
 
The  major  cause  of  morbidity  and  mortality  in  T2DM  is  cardiovascular  disease  (Zimmet  and 
Alberti 1997, Laakso 1999). The proportion of cardiovascular disease attributable to T2DM has 
increased  over  the  last  50  years  (Fox  et  al  2007).  In  addition  to  cardiovascular  disease; 
cerebrovascular, peripheral vascular and renovascular disease all contribute significantly to both 
vascular morbidity and mortality in diabetes mellitus (DeFronzo et al 2004). The cornerstone of all 
forms  of  diabetes  mellitus  is  abnormal  insulin  physiology.  In  Type  1  diabetes  this  constitutes 
insulin deficiency. In T2DM this constitutes resistance to insulin’s metabolic actions.  
 
1.1.2 Insulin Resistance 
Insulin resistance can be defined generically as reduced biological action of insulin at a certain 
concentration.  The  gold  standard  for  investigating  and  quantifying  insulin  resistance  is  the 
hyperinsulinaemic  euglycaemic  clamp,  so  called  because  it  measures  the  amount  of  glucose 29 
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necessary to compensate for an increased insulin level without causing hypoglycaemia (DeFronzo 
et al 1979). Given the complicated nature of the "clamp" technique (and the potential dangers of 
hypoglycaemia in some patients), alternatives have been sought to simplify the measurement of 
insulin resistance. One example is the Homeostatic Model Assessment (HOMA) which employs 
fasting insulin and glucose levels to calculate insulin resistance (Wallace et al 2004). 
 
Sensitivity to insulin-mediated glucose disposal varies more than six-fold in the general population 
(Yeni-Komshian et al 2000). When patients with insulin resistance cannot maintain the degree of 
hyperinsulinaemia needed to overcome the insulin resistance, T2DM develops (Warram et al 1990, 
Lilloja  et  al  1993).  However,  the  vast  majority  of  patients  with  insulin  resistance  continue  to 
secrete  the  large  amount  of  insulin  required  to  overcome  this  defect  in  insulin  action,  thereby 
maintaining normal or near-normal glucose tolerance.  
 
The mechanisms responsible for insulin resistance are poorly understood. Several factors appear to 
contribute to a patient’s metabolic susceptibility to insulin resistance. Age, physical activity, drugs, 
as well as ethnicity, racial status and family propensity are all important. At a more mechanistic 
level metabolic susceptibility to insulin resistance has been related the maldistribution of adipose 
tissue such as visceral adiposity (Lewis et al 2002).
   In fact, the mechanisms by which patients 
develop visceral adiposity have recently been the subject of intensive research. Visceral adipose 
tissue is very metabolically active and recent discoveries have shown that visceral adiposity is 
associated with abnormalities in the release of a variety of factors from adipose tissue including the 
adipocytokines and free fatty acids (FFA) (Hotamisligil et al 1993, Considine et al 1996, Boden et 
al 1997, Arita et al 1999). It has now been established that there is a close and dynamic relationship 
between  insulin  resistance  and  visceral  adiposity  and  that  insulin  sensitivity  is  modulated  by 
adiposity (Campbell et al 1993, Banerji et al 1995, Ludvik et al 1995, Abate et al 1996). This has 30 
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led to significant interest in the adipocytokines and FFA, which are proposed to play a pivotal role 
in the regulation of insulin signalling and action. 
 
1.1.2.1 Tumour necrosis factor – alpha 
Tumour necrosis factor – alpha (TNF-α) is expressed as a 26kDa cell surface protein and while it is 
produced in the most part by macrophages, it is also produced in adipose tissue (Kern et al 1995, 
Wajant et al 2003). TNF-α expression is increased in the adipose tissue of obese animals and 
humans  (Hotamisligil  et  al  1993,  Hotamisligil  et  al  1995).  Moreover,  TNF-α  expression  is 
positively correlated to BMI, percentage body fat, and hyperinsulinaemia (Kern et al 1995). It has 
also been shown than weight loss decreases TNF-α levels (Kern et al 1995). Infusion of anti-TNF-
α antibodies has been demonstrated to improve insulin sensitivity in animals, but is less effective in 
patients with obesity, impaired glucose tolerance or T2DM (Ofei et al 1996, Paquot et al 2000). 
Moreover, the use of recombinant soluble TNF-α receptor improves insulin sensitivity in insulin 
resistant animals (Hotamisligil et al 1993). Models using knock-out of the genes encoding TNF-α 
protein or its receptor in mice show improved insulin sensitivity (Uysal et al 1997).  
 
1.1.2.2 Leptin 
Leptin is a 16kDa protein secreted by adipocytes in proportion to the total amount of adipocytes 
present (Considine et al 1996). Leptin is proposed to act as a signal that informs the hypothalamus 
of the body’s fat reserve. In patients without visceral adiposity or insulin resistance it is proposed 
that as food is eaten, absorbed and stored, serum leptin concentrations increase, cross the blood-
brain barrier and promote satiety (Mizuno et al 1998, Schwartz et al 1996, Schwartz et al 1998). 
Children  with  frameshift  mutations  in  the  leptin  (ob)  gene  are  leptin  deficient  and  display 
hyperphagia, obesity and hyperinsulinaemia (Farooqi et al 2002). 31 
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1.1.2.3 Interleukin-6 
Interleukin-6 (IL-6) is a 26 kDa protein produced by adipose tissue among many other tissues 
(Mohamed-Ali et al 1997, Podor et al 1989). Adipose tissue has been postulated to contribute a 
significant proportion of the total circulating IL-6 (Mohammed-Ali et al 1997, Yudkin et al 1999). 
Elevated IL-6 concentrations are associated with insulin resistance and obesity (Yudkin et al 1999). 
The addition of IL-6 to cell lines and mice has been shown to inhibit insulin action in skeletal 
muscle, hepatic and adipose tissue (Senn et al 2002, Rotter et al 2003, Kim et al 2004, Nieto-
Vasquez et al 2008). IL-6 pre treatment inhibited the insulin stimulated signalling cascade in both 
hepatic and adipose tissue with a reduction in insulin stimulated glycogen formation and glucose 
uptake demonstrated (Senn et al 2002, Rotter et al 2003). Furthermore, the addition of IL-6 to mice 
attenuated  both  insulin  related  suppression  of  hepatic  gluconeogenesis  and  insulin  stimulated 
glucose uptake in skeletal muscle (Kim et al 2004, Nieto-Vasquez et al 2008).  
 
1.1.2.4 Adiponectin 
Adiponectin is a protein secreted exclusively and abundantly by adipose tissue (Scherer et al 1995), 
with plasma levels negatively correlated with insulin resistance, obesity and cardiovascular disease 
(Arita et al 1999, Weyer et al 2001, Hotta et al 2000). This is in contrast to many of the other major 
adipocytokines such as TNF-α, leptin and IL-6, whose levels have been shown to increase with 
increasing  adiposity.  Adiponectin  exists  in  3  or  more  different  higher  order  complexes:  high 
molecular weight form (HMW, 12 to 36mer), low molecular weight form (hexamer) and trimeric 
form. The ratio of HMW to the other forms of adiponectin serves as an independent predicting 
factor for metabolic disorders (Fisher et al 2005, Wang et al 2007). Adiponectin levels are reduced 
in patients with insulin resistance (Yudkin et al 1999, Weyer et al 2001). Interestingly, studies of 
the Pima Indian population have shown that in normal healthy individuals low levels of adiponectin 
predict the likelihood of developing T2D later in their life (Lindsay et al 2002).  32 
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1.1.2.5 Free Fatty Acids  
Visceral adiposity is associated with elevated FFA due to increased activity of hormone-sensitive 
lipase. Accumulation of intracellular lipid in the cell is proposed to contribute to insulin resistance 
at a cellular level and increases in FFA concentration are frequently found in patients with T2DM 
due to increased release from adipose tissue and reduced skeletal muscle uptake (Kelley et al 1994, 
Boden et al 1997, Dresner et al 1999). Free fatty acids stimulate reactive oxygen species (ROS) 
production and inhibit the insulin-stimulated signalling cascade (Muniyappa et al 2007, Chinen et 
al 2007). Consequently, visceral adiposity and its associated effect on FFA and the adipocytokines 
may be important in the pathogenesis of insulin resistance (Lebovitz et al 2005, Miles et al 2005).  
 
1.1.3 The Metabolic Syndrome 
More recently a ‘pre-diabetes’ clinical state termed the metabolic syndrome has been described 
which combines increased adiposity, hypertension, insulin resistance and dyslipidaemia (Alberti et 
al 2005) and is associated with increased cardiovascular risk (Hu et al 2004). There have been 
numerous  definitions  of  the  metabolic  syndrome  which  has  led  to  confusion  and  subsequent 
criticism. In both Adult Treatment Panel III (Grundy et al 2005) and the International Diabetes 
Federation (IDF), (Alberti et al 2005) formulations of the risk of the metabolic syndrome include 
the following surrogates: 
 
-  Serum triglyceride >1.7mmol/l 
-  High density lipoprotein (HDL) <1.0mmol/l (men), <1.3mmol/l (women) 
-  Blood pressure (BP) greater than or equal to 130/85 mmHg OR on medication 
-  Fasting serum glucose greater than or equal to 5.6mmol/l 
-  Increased waist circumference (population and sex dependent thresholds) 
 33 
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Each criteria requires at least 3 surrogates for the diagnosis of metabolic syndrome with the IDF 
combining  lipids  as  one  surrogate  criteria  and  requiring  waist  circumstance  as  one  of  the  3 
surrogates. 
 
It  is  often  considered  uncertain  whether  the  presence  of  the  metabolic  syndrome  adds  to 
cardiovascular disease prediction beyond the contribution of more than the sum of its individual risk 
factor parts. In a prospective study involving patients with and without diabetes who were followed 
up  for  an  average  of  11  years,  the  risk  of  incident  coronary  heart  disease  associated  with  the 
syndrome was no greater than that explained by its components (McNeil et al 2005). Moreover, in 
the  secondary  analysis  of the West of Scotland Coronary Prevention Study (WOSCOPS) study 
(Sattar et al 2003) demonstrated that the metabolic syndrome was not a significant predictor of 
coronary heart disease when corrected for its component factors. This evidence suggests that the 
metabolic syndrome is essentially just the equivalent of the sum of its component parts and brings 
into question its value to the clinician in the day to day practice of a diabetes clinic. 
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1.2 Insulin 
1.2.1 Insulin: Structure and function 
Insulin consists of 2 linked polypeptide chains secreted by the β cells of the pancreas in response to 
glucose  and  amino  acids  (Sanger  2001).  Insulin  is  the  most  potent  anabolic  hormone  known, 
promoting  the  synthesis  and  storage  of  carbohydrates,  lipids  and  proteins  and  inhibiting  their 
degradation and release back into the circulation. The major sites of action are skeletal muscle, 
hepatocytes and adipocytes (Borge et al 2002). It is now also recognised that insulin receptors are 
present in many other tissues including the vascular endothelium (Steinberg et al 2002).  
 
1.2.2 Insulin receptor tyrosine kinase 
The insulin receptor is a tetrameric membrane glycoprotein comprised of two α and two β subunits 
that belongs to the large class of tyrosine kinase receptors (Saltiel et al 2002). The insulin receptor 
(IR) is expressed in most tissues of the body (including muscle, liver, adipose and the endothelial 
cell surface). Predictably, the IR has a high affinity for insulin and is necessary for insulin action 
(Zeng et al 1996, Kido et al 2001). When insulin binds to its membrane receptor this results in the 
stimulation of an intra-cellular signalling cascade in insulin sensitive tissues. To be more precise, 
insulin binds to the extracellular α-subunit inducing a conformational change resulting in receptor 
autophosphorylation (Hubbard et al 1994, Hubbard et al 1997). This in turn enables interaction with 
and subsequent phosphorylation of the insulin receptor substrate (IRS) family of proteins (White et 
al 1985, White et al 1985, White et al 1998).  
 
1.2.3 Insulin receptor substrate proteins 
The process of insulin signalling is incompletely understood. It is currently the subject of intensive 
research effort and a large number of proteins have been implicated in the process (Saltiel et al 
2002). The IRS group of proteins have been the focus of a significant body of research recently due 35 
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to their key role in insulin signalling. Of the 4 members identified (IRS-1, IRS-2, IRS-3, IRS-4), 
IRS-1 and IRS-2 have been subject to the most research. While all 4 members are present in rats, 
only IRS-1, 2, and 4 are present in humans (White 2002). The exact role of each member is yet to 
be determined.  
 
IRS-1 is thought to be important in mediating the metabolic and mitogenic effects of insulin in 
peripheral tissues such as skeletal muscle and adipose tissue as well as being key in insulin action in 
the endothelium (Abe et al 1998). IRS-1 is not thought to have a significant role in insulin action in 
the liver (Yamauchi et al 1996). Mice lacking IRS-1 are insulin resistant but not overtly diabetic 
(Tamemoto  et  al  1994,  Yamauchi  et  al  1996).  Novel  IRS-1  phosphorylation  sites  have  been 
identified that regulate the action of insulin, and have the potential to be modified in pathological 
states and facilitate altered signalling (Zhang et al 2008).  Key phosphorylation sites identified on 
IRS-1 include the tyrosine residues 612 and 632 required for IRS-1 / phosphatidylinositol 3-kinase 
(PI3-K)  interaction  (Montagnani  et  al  2002).  IRS-Ser312  (akin  to  residue  Ser307  in  mice)  is 
proposed to inhibit the downstream insulin signalling cascade (Danielsson et al 2005). Moreover, 
Ser636 and Ser318 appear to act as a stimulator of insulin action and a negative feedback regulator 
respectively (Weigert et al 2005, Luo et al 2007). Furthermore, IRS-1 gene polymorphisms are 
associated with the development of T2DM in humans (Sesti et al 2001). 
 
IRS-2  is  thought  to  have  an  important  role  in  the  mediation  of  insulin  action  in  the  liver  and  
adipose tissue (Withers et al 1998, Withers et al 1999). IRS-2 is thought to mediate pancreatic beta 
cell  function  and  therefore  insulin  secretion  (Diabetes  et  al  2000).  IRS-2  should,  therefore,  be 
important in the pathogenesis in both Type 1 diabetes (T1DM) and T2DM as defective insulin 
secretion is common to both conditions in time. Indeed, mice lacking the IRS-2 protein exhibit 
diabetes (Withers et al 1998). 36 
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1.2.4 Insulin signalling cascade in skeletal muscle, hepatocytes and adipocytes 
Insulin  binding  to  its  receptor  results  in  receptor  autophosphorylation  on  tyrosine  residues  and 
subsequent phosphorylation of IRSs. This allows association of IRS-1 with the regulatory subunit of 
PI3K. PI3K consists of an 85kDa regulatory subunit and an 110kDa catalytic subunit that interacts 
with IRS-1 upon activation by the IR (Montagnani et al 2002) via an SH2 domain. Activation of 
catalytic subunit of PI3K results in the production of phosphatidylinositol(3,4,5)trisphosphate (PIP3) 
and activation of the downstream kinase phosphoinositide - dependent kinase-1 (PDK1), (Bevan 
2001).  Protein  kinase  B  (PKB)  or  Akt  (v-akt  murine  thymoma  viral  oncogene  homologue),  a 
serine/threonine kinase is then activated in response to phosphorylation by PDK1 at site threonine 
308 (DeFronzo et al 2004). Mammalian TOR (mTOR) is the target for the immunosuppressant drug 
rapamycin and acts as an intracellular nutrient sensor that controls protein synthesis and growth 
(Brown  et  al  1994).  Indeed,  PKB  is  also  phosphorylated  at  site  serine  473  by  mTOR  and  its 
associated protein, rictor (which form the complex mTORc2), (Sarbassov et al 2005). PKB also 
regulates  the  activity  of  mTOR  with  PKB  activating  mTORc1  (complex  of  mTOR  and  its 
associated  protein  raptor),  (Vander  Harr  et  al  2007).  PKB  also  phosphorylates  and  inactivates 
nutrient sensing protein, tuberous sclerosis complex 2 (TSC2) (Potter et al 2002). Indeed, TSC2 has 
been shown to inhibit cell growth and size and antagonise insulin signalling (Ito and Rubin 1999, 
Gao and Pan 2001, Potter et al 2001, Tapon et al 2001). In skeletal muscle and adipose tissue 
activation of PKB results in translocation of GLUT-4 to the plasma membrane thereby allowing the 
uptake of glucose in the cell (Kohn et al 1996, Sano et al 2003), (figure 1.1). In hepatic tissue, PKB-
mediated phosphorylation inactivates glycogen synthase kinase 3 (GSK-3) resulting in activation of 
glycogen synthase and therefore glycogen synthesis (Sutherland et al 1993, Cross et al, 1995, Van 
Weeren et al 1998), (figure 1.1). In addition, the inhibition of GSK3 by PKB is a key step in insulin 
induction  of  glycogen  synthesis  in  muscle  (McManus  et  al  2005).  Moreover,  GSK-3  is  also 
important for the regulation of hepatic gene transcription by insulin. For example, GSK-3 regulates  37 
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Figure 1.1 Insulin signalling in skeletal muscle, adipocytes and hepatocytes. Insulin binding to its 
receptor  results  in  receptor  autophosphorylation  on  tyrosine  residues  and  subsequent 
phosphorylation of IRSs. This allows association of IRS-1 with the regulatory subunit of PI3K. 
Activation  of  catalytic  subunit  of  PI3K  results  in  the  production  of  PIP3  and  activation  of  the 
downstream kinase PDK1. PKB or Akt is then activated in response to phosphorylation by PDK1. 
In skeletal muscle and adipose tissue activation of PKB results in translocation of GLUT-4 to the 
plasma  membrane  thereby  allowing  the  uptake  of  glucose  in  the  cell.  In  hepatic  tissue,  PKB-
mediated  phosphorylation  inactivates  GSK-3  resulting  in  activation  of  glycogen  synthase  and 
therefore glycogen synthesis. GRB2 and SHP2 adaptor proteins interact with IRS molecules and 
activate mitogen activated protein kinases (MAPK) and stimulate mitogenic responses in the form 
of gene transcription.  38 
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the  transcription  of  PEPCK  and  G6Pase  genes,  two  rate  controlling  steps  in  gluconeogenesis 
(Lochhead  et  al  2001).  Thus,  the  IRS/PI3K/PDK1/PKB  pathway  is  very  important  to  insulin’s 
ability to regulate metabolism and promote growth.  
 
While it is recognised that the IRS group of proteins mediate a significant proportion of the insulin 
stimulated signalling events through PI3K it is also important to note that insulin also has the ability 
to regulate a number of adaptor proteins (GRB2 and SHP2). These adaptor proteins interact with 
IRS molecules and activate mitogen activated protein kinases (MAPK) and stimulate mitogenic 
responses in the form of gene transcription. (Bevan 2001, Coggins et al 2001, DeFronzo et al 2004).  
 
Insulin  resistant  states  therefore  lead  to  less  insulin  stimulated  glucose  uptake  as  well  as  less 
inhibition  of  hepatic  gluconeogenesis  (Yki-Jarvinen  1995).  This  combination  results  in 
hyperglycaemia and the development of impaired glucose tolerance and ultimately the diagnosis of 
T2DM.  
 
1.2.5 Insulin signalling cascade in the vascular endothelium  
Insulin receptors have been demonstrated to be expressed at the endothelial cell surface (40,000 IR 
per cell) and insulin stimulates an intracellular signalling cascade in the human endothelium with 
resultant nitric oxide production (NO) (Zeng and Quon 1996).  
 
As  with  the  other  insulin-sensitive  tissues,  the  IRS  proteins are key components of the insulin 
signalling cascade in the vascular endothelium (Figure 1.2). Indeed, overexpression of IRS-1 in 
endothelial cells causes a 3-fold increase in NO production in response to a maximally stimulating 
dose of insulin compared to wild type controls not infected with IRS-1 (Montagnani et al 2002) 39 
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Figure 1.2 Schematic diagram of insulin signalling in the endothelium 
Insulin (I) binds to its receptor and stimulates and intracellular signalling cascade involving IRS-1, 
PI3K, PIP3 production and PDK-1 activation. PKB is activated leading to increased eNOS activity. 40 
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while  over-expression  of  a  mutant  IRS-1  inhibited  insulin-stimulated  NO  production  and  PI3K 
recruitment  to  IRS-1  (Montagnani  et  al  2002).  Furthermore,  PI3K,  PDK-1  and  PKB  are  also 
components of the insulin signalling cascade in the vascular endothelium. The key role of PI3K in 
insulin stimulated NO production in endothelial cells is demonstrated in studies using the PI3K 
inhibitor wortmannin (Zeng and Quon 1996, Hartell et al 2005). PDK-1 activity is also required for 
insulin  stimulated  NO  production  in  bovine  aortic  endothelial  cells  (BAEC)  (Montagnani  et  al 
2002). PKB directly phosphorylates endothelial NO synthase (eNOS) at residue serine 1177 and 
increases  enzyme  activity  in  endothelial  cells  (Dimmeler  et  al  1999).  Insulin  stimulated  eNOS 
activation  is  independent  of  calcium  concentration  but  requires  PKB  mediated  eNOS  Ser1177 
phosphorylation (Montagnani et al 2001). The regulation of eNOS is complex, as eNOS exists as a 
monomer  but  following  the  binding  of  essential  cofactors  including  tetrahydrobiopterin  (BH4), 
calmodulin (CaM), flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) an active 
enzyme  dimer  is  formed  resulting  in  NO  and  L-citrulline  synthesis  from  L-arginine,  O2  and 
nicotinamide  adenine  dinucleotide  phosphate  (NADPH),  (reviewed  in  Forstermann  and  Munzel 
2006, figure 1.3). 
 
The importance of eNOS to insulin action has been reinforced in knockout studies involving mice. 
For example, eNOS deficient mice are insulin resistant, hypertensive and have defects in fatty acid 
metabolism and dyslipidaemia. They also have impaired insulin stimulated glucose uptake (Duplain 
et al 2001, Nisoli et al 2005, Le Gouill et al 2007).  
 
The adipocytokines are thought to be important in the pathogenesis of T2DM and it has been 
suggested  that  they  play  a  role  in  the  insulin  signalling  cascade  in  the  vascular  endothelium. 
Adiponectin has also been demonstrated to increase nitric oxide production (Hattori et al 2003) by  41 
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Figure 1.3 Endothelial Nitric Oxide Synthase activation 
 
Panel A: Endothelial nitric oxide synthase is synthesised as a monomer. Each monomer 
contains both a reductase and an oxidase domain. Monomers bind calmodulin and are able 
to transfer electrons from NADPH through FAD and FMN and have a limited capacity to 
synthesise O2. Monomers are unable to bind BH4 or L-arginine and therefore unable to 
produce NO. The binding of haem allows eNOS dimerisation and the formation of a 
functional enzyme capable of producing NO. This also allows the interaction of the 
reductase and oxidase domains allowing transfer of electrons from the flavins to the haem 
of the opposite monomer. This dimer (in the absence / relative deficiency of BH4 and L-arginine) 
can produce O2
.- more effectively. 
 
Panel B: When sufficient BH4 and L-arginine are available, NO and L-citrulline 
are produced. (Adapted from Forstermann and Munzel 2006). 42 
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a pathway involving PI3K and PKB activation by AMPK (Ouchi et al 2004, Chen et al 2003). 
Furthermore, when TNF-α is added to endothelial cells there is inhibition of insulin-stimulated NO 
production with impairment of the insulin stimulated signalling cascade (Kim et al 2001). Finally, 
the exposure of endothelial cells to IL-6 results in inhibition of insulin-stimulated NO production 
with impairment of the insulin stimulated signalling cascade (Andreozzi et al 2007).  
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1.3 AMP activated protein kinase 
1.3.1 Structure of AMPK 
AMP activated protein kinase (AMPK) is an enzyme ubiquitously expressed in mammalian tissues, 
consisting of 3 subunits (α- [catalytic], ß- [regulatory], γ-[regulatory]) with 2-3 genes encoding each 
subunit (Towler and Hardie 2007). The α subunits contain a protein kinase catalytic domain at the 
N-terminus and a C-terminal regulatory domain that is involved in binding to the β and γ subunits 
(Hardie 2003). All three subunits are encoded by multiple genes (α1, α2, β1, β2, γ1, γ2, γ3) yielding 
12  heterotrimeric  combinations,  with  splice  variants  adding  to  the  diversity  (Hardie  2004).  All 
possible combinations of the heterotrimer appear to be expressed in mammals. The potential for a 
number  of  different  heterotrimeric  combinations  can  lead  to  tissue-specific  enzyme  diversity 
(Towler and Hardie 2007). It is still unclear what cellular consequences the composition of AMPK 
isoforms  may  have  on  the  function  of  each  AMPK  complex  in  relation  to  their  particular 
localisation and specific downstream targets. For example a recent study investigated the isoform 
composition  of  AMPK  complexes  in  human  skeletal  muscle  and  found  that  only  3  of  the  12 
theoretically possible AMPK complexes were present (α2β2γ1, α2β2γ3 and α1β2γ1), (Birk et al 
2006, Treebak et al 2007).  
 
1.3.2 Regulation of AMPK 
To sustain metabolism, intracellular ATP levels must be maintained within a narrow range. This is 
achieved by the regulation of cellular catabolic and anabolic pathways. This may be co-ordinated by 
AMPK which acts as a sensor of cellular energy status, a fuel gauge or metabolic master switch 
(Winder et al 1999, Hardie DG 2003). AMPK can be allosterically activated by AMP (Munday et al 
1988).  Aminoimidazole  carboxamide  ribonucleotide  (AICAR)  is  an  adenosine  analogue  which 
activates AMPK through direct binding, followed by allosteric modification. It is initially taken up 
by  adenosine  transporters  and  subsequently  phosphorylated  by  adenylate  kinase  to  produce  the 44 
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AMP analogue ZMP within the cell. ZMP mimics AMP in AMPK signalling but may induce some 
actions that are independent of AMPK (Merrill et al 1997). Furthermore, AMPK is activated in 
response  to  environmental  or  nutritional  stress  factors,  which  deplete  intracellular  ATP  levels 
including heat shock, hypoxia, ischaemia, glucose deprivation or prolonged exercise (Hardie 2004, 
Musi  et  al  2001).  This  results  in  an  increase  in  the  AMP:ATP  ratio  which  inhibits 
dephosphorylation of AMPK and therefore potentiates AMPK  mediated phosphorylation by an 
upstream kinase LKB-1 (a tumour suppressor gene whose germline mutations in humans are the 
cause of Peutz-Jeghers syndrome) which is considered to be constitutively active (Hardie 2004), 
(Figure  1.4).  Under  conditions  in  which  cellular  energy  demands  are  increased  or  when  fuel 
availability is decreased, intracellular ATP is reduced and AMP levels rise (Hardie 2004). In cells, 
adenylate kinase maintains the reaction  
 
                2ADP         ATP + AMP              
 
close to equilibrium such that the AMP:ATP ratio is proportional to the square of the ADP:ATP 
ratio and is therefore considered to be a more sensitive indicator of compromised energy status than 
the ADP:ATP ratio. In addition to increased AMP, AMPK is activated by increased intracellular 
calcium  concentration,  mediated  by  calcium/CaM-dependent  protein  kinase  kinase  (CaMKK), 
which phosphorylates and activates AMPK at Thr-172, the same site phosphorylated by LKB1 
(Towler  and  Hardie  2007,  Long  and  Zierath  2006).  Furthermore, binding of AMP inhibits the 
dephosphorylation of Thr-172 by protein phosphatases and high concentrations of ATP inhibit the 
activation of AMPK by antagonising binding of AMP (Sanders et al 2007, Riek et al 2008). 
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Figure 1.4 Structure and regulation of AMPK. AMPK is a heterotrimeric complex consisting of 
an  α,  β,  and  γ  subunits  and  is  activated  by  the  upstream  kinases  CaMKK  and  LKB1  via 
phosphorylation of Thr172. Activation of AMPK by CaMKK is dependent on intracellular calcium 
whereas  LKB1  activity  is  constitutive.  Generally,  AMPK  restores  energy  balance  by  activating 
processes that produce energy (e.g., lipid oxidation and glucose uptake) while inhibiting those that 
consume energy (for example fatty acid, cholesterol and protein synthesis) (Long and Zierath 2006). 46 
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1.3.3 Role of AMPK in Energy Homeostasis  
Activation of AMPK triggers catabolic pathways that produce energy, while turning off anabolic 
pathways that consume energy thereby maintaining cellular energy stores. For example, AMPK  
inhibits  lipid  and  triglyceride  synthesis  in  both  liver  and  adipose  tissue  and  stimulates  skeletal 
muscle glucose uptake, glycolysis and fatty acid oxidation (Towler and Hardie 2007), (Figure 1.5). 
Stimulation of fatty acid oxidation occurs when AMPK directly phosphorylates and inactivates the 
downstream target, acetyl-coA carboxylase (ACC). ACC synthesizes malonyl-CoA which inhibits 
the rate-controlling step of fatty oxidation involving the transfer of fatty acids into the mitochondria 
by the enzyme carnitine palmitoyltransferase 1 (CPT1) (Trumble et al 1995, Ruderman et al 1999). 
During  exercise,  activated  AMPK  inhibits  ACC  to  reduce  malonyl-CoA  concentration,  thereby 
driving  the  entry  of fatty acids into the mitochondria for β-oxidation to restore energy balance 
(Winder et al 1996). The ability of AMPK to induce lipid oxidation and thus the amount of fat 
deposited in skeletal muscle and liver is considered an important feature of AMPK activation. It 
suggests  that  AMPK  and  insulin  signalling  pathways  may  oppose  each  other  and  that  AMPK 
activation  is  insulin  sensitising.  Therefore  it  may  be  that  AMPK  plays  an  important  role  in 
controlling the whole body energy homoeostasis including the regulation of plasma glucose levels 
and  body  weight.  The  control  of  AMPK  activity  provides  an  attractive  target  for  therapeutic 
intervention in metabolic disorders such as T2DM and obesity. Indeed, a number of physiological 
and pharmacological factors that are beneficial in these disorders have been shown to act, at least in 
part, through the activation of AMPK. The importance of AMPK in regulating whole body energy 
metabolism  is  also  emphasized  by  studies  on  AMPK  α2  knockout  (KO)  mice.  Deletion of α2 
results in mild insulin resistance and an insulin-secretory defect (Viollet et al 2003, Jorgensen et al 
2004). Glucose intolerance in the α2 KO mice is not due to a defect in skeletal-muscle glucose 
uptake, but probably results from both impaired insulin action and inhibition of insulin secretion 
(Viollet et al 2003). The molecular basis for this defect is not understood. In a recent study, AMPK  47 
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Figure 1.5 Role of AMPK in the regulation of whole-body glucose homeostasis. Stimulation of 
AMPK  activates  ATP-generating  processes,  while  inactivating  ATP-consuming  processes.  In 
skeletal muscle, acute activation of AMPK increases glucose uptake and lipid oxidation. Activation 
of AMPK inhibits glucose and lipid synthesis in the liver but increases lipid oxidation. Lipolysis 
and lipogenesis in adipose tissue are also reduced by AMPK activation. Together, activation of 
AMPK  in  skeletal  muscle,  liver,  and  adipose  tissue  results  in  decreased  circulating  glucose, 
reduced plasma lipid, and ectopic fat accumulation, as well as enhanced insulin sensitivity and 
therefore makes AMPK an attractive target for the treatment of T2DM. Activation of pancreatic 
AMPK  is  associated  with  decreased  insulin  secretion,  likely  a  protective  measure  to  prevent 
hypoglycaemia although this needs to be considered in pharmaceutical targeting of AMPK for the 
treatment of T2DM (Adapted from Long and Zierath 2006). 48 
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α2  knockout  mice  fed  with  a  high-fat  diet  have  been  shown  to  exhibit  increased  body  weight 
coupled with an increase in fat when compared with wild-type animals (Villena et al 2004). At 
present, the mechanism underlying this response is not known. 
 
1.3.4 Role of AMPK in the regulation of peripheral tissues 
1.3.4.1 Skeletal muscle 
A large proportion of insulin stimulated glucose disposal occurs in skeletal muscle and insulin 
resistance at this site is thought to contribute to the pathogenesis of T2DM (Petersen et al 2007). 
Insulin increases glucose uptake in muscle by stimulating the translocation of glucose transporter 
GLUT4 from intracellular vesicles to the cell surface. It has been shown that muscular AMPK 
activation stimulates muscle glucose uptake either by exercise or by AICAR. Exercise stimulates 
glucose  uptake  independently  of  the  traditional insulin pathway but the molecular mechanisms 
remain  incompletely  understood  (Ploug  et  al  1984).  Electrical  contraction  of  skeletal  muscle 
increases glucose uptake and increase AMPK activity (Hutber et al 1997). Furthermore, activation 
of AMPK with AICAR increases glucose uptake in the skeletal muscle of rodents (Merill et al 
1997). Interestingly, AICAR-mediated glucose uptake is not attenuated by inhibition of the insulin-
dependent PI3K pathway with wortmannin and, like exercise, appears to utilise separate pathways 
from  insulin  stimulated  glucose  uptake  in  skeletal  muscle  (Merill  et  al  1997).  AICAR  can 
effectively increase glucose transport and GLUT4 translocation in skeletal muscle in patients with 
T2DM (Koistinen et al 2003). Thus, an AMPK-dependant increase in glucose transport is observed 
in skeletal muscle of both rodents and humans. Moreover, in AMPK α2 knockout mice the glucose 
lowering effects of AICAR are abolished (Mu et al 2001). There is, however, conflicting evidence 
as to whether AMPK is required for exercise induced glucose uptake in skeletal muscle (Jorgensen 
et al 2004, Sakamoto et al 2005). Activation of AMPK with metformin is associated with increased 
glucose uptake in isolated rat skeletal muscle (Zhou et al 2001). Significantly, metformin increases 49 
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AMPK  activity,  ACC  phosphorylation  and  glucose  disposal  in  isolated  skeletal  muscle  from 
patients with T2DM (Musi et al 2002). Therefore, the beneficial metabolic effects of metformin in 
T2DM patients may also be partly mediated by the activation of AMPK in skeletal muscle.  
 
1.3.4.2 Heart 
In myocardial ischaemia and left ventricular dysfunction an increase in the AMP/ATP ratio results 
in an increase in AMPK activity (Russell et al 2004). In rat cardiac myocytes AMPK increases FFA 
uptake and increased translocation of GLUT4 (leading to increased glucose uptake) in a manner 
that is independent of the PI3K pathway. (Russell et al 1999, Luiken et al 2003). Indeed, in isolated 
hearts of AMPK knockout mice glucose uptake following ischaemia was reduced when compared 
to wild type mice (Xing et al 2003).  Intriguingly, it has been recently demonstrated that an increase 
in  AMPK  activity  by  acute  metformin  therapy  results  in  decreased  myocardial  injury  in  both 
diabetic and non-diabetic mice after ischaemia and reperfusion (Calvert et al 2008). Moreover, 
chronic metformin therapy in mice improves left ventricular function and survival after ischaemia 
and reperfusion (Gundewar et al 2009).  This evidence suggests that AMPK may play a role in 
cardiac  ischaemia  and  therapeutic  targeting  of  AMPK  in  patients  with  angina,  acute  coronary 
syndrome or myocardial infarction may be of value. The important role of AMPK in the heart is 
further  reinforced  by  the  finding  of  a  novel  mutation  (Arg531Gly)  in  the  AMPK  γ2  subunit 
(PRKAG2 gene) to be responsible for Wolff–Parkinson–White Syndrome which is associated with 
ventricular pre-excitation and the early onset of atrial fibrillation and conduction disease (Gollob et 
al 2001). Indeed, transgenic mice with a cardiac specific expression of this mutation were found to 
have cardiac hypertrophy, impaired contractile function, electrical conduction abnormalities and 
marked glycogen accumulation (Davies et al 2006).  
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1.3.4.3 Liver 
AMPK  suppresses  both  liver  gluconeogenesis  and  lipogenesis.  AMPK  also  increases  fatty  acid 
oxidation and in turn reduces hepatic lipid deposition (Carling 2004, Khan et al 2005). Activating 
AMPK  in  the  liver  is  therefore  an  attractive  target  for  those  with  T2DM  as  it  could  improve 
glycaemia,  body  weight  and  the  lipid  profile.  Euglycaemia  can  be  maintained  if  hepatic 
gluconeogenesis matches insulin mediated glucose uptake in peripheral tissue and when insulin 
resistance creates an imbalance, T2DM can ensue (DeFronzo et al 1989, Basu et al 2000). Hepatic 
gluconeogenesis is regulated in part by the enzymes phosphoenolpyruvate carboxykinase (PEPCK) 
and glucose-6-phosphatase (G6Pase) (Saltiel et al 2001). The role of AMPK in inhibiting hepatic 
gluconeogenesis is thought to be related to its ability to mimic insulin and downregulate the genes 
encoding  both  PEPCK  and  G6Pase  (Lochhead  et  al  2000).  As  previously  stated,  GSK-3  is 
important for the regulation of hepatic gene transcription by insulin and regulates the transcription 
of PEPCK and G6Pase genes, two rate controlling steps in gluconeogenesis (Lochhead et al 2001).  
Indeed, AMPK activation increases GSK-3 phosphorylation and reduces PEPCK gene expression in 
the liver of rodents (Horike et al 2008). Furthermore, liver AMPK α2 or LKB1 knockout mice 
exhibit hyperglycaemia perhaps due to the increased activity of PEPCK and G6Pase (Shaw et al 
2005,  Andreeli  et  al  2006).  In  rat  hepatocytes,  activation  of  AMPK  by  AICAR  or  metformin 
increases fatty acid oxidation via inhibition of ACC (Zhou et al 2001). Moreover, when AMPK is 
activated by metformin in cultured human hepatocytes intracellular lipid content is reduced. This 
effect is abrogated after infection of hepatocytes with adenoviruses expressing a dominant negative 
mutant AMPK (Zang et al 2004).  
 
1.3.4.4 Adipose Tissue 
Visceral adiposity is associated with elevated FFA due to increased activity of hormone-sensitive 
lipase  which  is  the  rate  limiting  step  of  lipolysis  (Meijjssen  et  al  2001).  Accumulation  of 51 
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intracellular lipid is proposed to contribute to insulin resistance at a cellular level. Insulin is thought 
to  control  the  release  of  FFA  from  adipose  tissue  by  inhibition  of  hormone-sensitive  lipase 
(Meijssen et al 2001). FFA are also reported to stimulate reactant oxygen species (ROS) production 
which in turn inhibits insulin signalling (Muniyappa et al 2007, Chinen et al 2007). Consequently, 
visceral adiposity and its associated effect on FFA may be important in the pathogenesis of T2DM 
by causing insulin resistance in skeletal muscle and liver in addition to inhibiting insulin secretion. 
(Bayes et al 2004, Lebovitz et al 2005, Miles et al 2005). AMPK is thought have important role in 
adipose tissue by inhibiting lipolysis and lipogenesis. Indeed, AMPK has been implicated in the 
regulation of lipolysis through direct phosphorylation of hormone-sensitive lipase (Garton et al 
1989). Lipolysis and lipogenesis are inhibited in rat adipocytes when using the AMPK activator 
AICAR, (Sullivan et al 1994). It is also suggested that when the regulation of lipid metabolism by 
AMPK is absent, then weight gain and insulin resistance prevail. Indeed when AMPK α2 knockout 
mice were fed with a high-fat diet they were shown to exhibit increased body weight, increased 
adiposity and a degree of insulin resistance when compared with wild-type mice (Viollet et al 2003, 
Jorgensen et al 2004, Villena et al 2004). It has also been recently shown that glucocorticoids 
inhibit AMPK activity in adipose tissue of insulin resistant patients with Cushing’s syndrome (Kola 
et al 2008). Moreover, metformin has been found to prevent the glucocorticoid effects on ex vivo 
cultured  human  adipocytes  (Christ-Crain  et  al  2008).  The  effect  of  insulin  sensitizers  such  as 
metformin or the thiazolidinediones on AMPK activity in human adipose tissue has not yet been 
investigated. Further work is required to examine whether metformin exerts its beneficial metabolic 
effects in patients with T2DM in part by increasing AMPK activity in human adipose. 
 
1.3.4.5 Pancreas 
Evidence suggests that AMPK has a role in the release of insulin perhaps as a sensor of cellular 
energy store. High glucose concentrations stimulate insulin release and it has been proposed that an 52 
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increase in glucose increases in the cellular ATP/ADP ratio. This in turn activates ATP-sensitive 
K+ channels, causing depolarization of the plasma membrane, opening of voltage gated calcium 
channels, an influx of calcium ions and subsequent exocytosis of secretory granules which is a 
critical step in the secretion of insulin (Rahan et el 1990). An increase in glucose levels represses 
AMPK  activity  in  β  cell  lines  (Salt  et  al  1998,  Leclerc  et  al  2004),  whereas  when  AMPK  is 
activated by AICAR, insulin release in response to high glucose is attenuated (Zhang et al 1995). 
Furthermore, overexpression of a constitutively active form of AMPK results in a reduction in 
insulin release from β cell lines while overexpression of a dominant negative form of AMPK leads 
to an increase in insulin release (Da Silva Xavier et al 2003). Moreover, when metformin is added 
to  β  cell  lines,  AMPK  is  activated  and  insulin  secretion  in  response  to  glucose  is  attenuated 
(Leclerc et al 2004). The activation of pancreatic AMPK is therefore associated with decreased 
insulin secretion which could have a negative effect on glycaemic control in patients with T2DM. 
This effect may, however, be a protective effect during periods of hypoglycaemia, where AMPK is 
activated and insulin secretion falls to maintain euglycaemia. Nevertheless, the exact role of AMPK 
in insulin release remains incompletely understood and further work is required before AMPK can 
targeted by drug therapy. 
 
1.3.4.6 Hypothalamus 
The hypothalamus plays a key role in the regulation of energy balance. It does so by using AMPK 
as a fuel gauge that can respond to both hormones, anorexia or an excess of food. (Schwartz et al 
2000,  Andersson  et  al  2004).  Injection  of  leptin  into  rodents  inhibits  AMPK  activity  in  the 
hypothalamus whereas administration of ghrelin stimulates AMPK activity (Andersson et al 2004). 
Moreover,  fasting  stimulates  AMPK  activity  whereas  hyperglycaemia  and  refeeding  inhibits 
AMPK activity in the hypothalamus (Minokowski et al 2004). Therefore, it appears that activating 
AMPK can stimulate food intake through its action in the hypothalamus. While this effect probably 53 
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represents a physiological response in glucose homeostasis, the prospect of patients gaining weight 
through the pharmacological targeting of AMPK for the treatment of T2DM is unattractive and 
along  with  AMPK’s  documented  role  in  the  pancreas,  presents  a  significant  challenge  to  the 
pharmaceutical industry. 
 
1.3.4.7 Vascular Endothelium 
AMPK  has  an  important  role  in  the  release  of  NO  from  the  vascular  endothelium.  AICAR 
stimulates eNOS Ser1177 phosphorylation and NO production in human aortic endothelial cells 
(HAECs)  (Morrow  et  al  2003).  Indeed,  AMPK  activation  has  been  demonstrated  to  stimulate 
muscle glucose uptake in a NO-dependent manner and NO production has been proposed to be 
largely responsible for insulin-independent glucose uptake during exercise (Chen et al 2000, Fryer 
et al 2000, Hawley et al 2002). AMPK also has a role in angiogenesis. Vascular endothelial growth 
factor (VEGF) is a key regulator of angiogenesis and stimulates differentiation, survival, migration, 
proliferation and vascular permeability (Ferrara et al 2003). VEGF rapidly stimulates endothelial 
NO synthesis and does so in an AMPK dependent manner (Reihill et al 2007). The ability of 
insulin  sensitizers,  such  as  metformin  and  the  thiazolidinediones,  to  act  directly  on  vascular 
endothelium via AMPK is discussed in sections 1.6 and 1.7 respectively. 
 
1.3.4.8 Interaction with the adipocytokines 
The adipocytokines such as leptin and adiponectin are thought to be important in the pathogenesis 
of T2DM and it has been suggested that AMPK plays a role in mediating their metabolic and 
vascular effects. 
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Figure  1.6  Integration  of  intertissue  signalling  by  AMPK.  Leptin  reduces food intake though 
inhibition of hypothalamic AMPK. Leptin increases skeletal muscle fatty acid oxidation via direct 
activation of AMPK and the hypothalamus–sympathetic nervous system axis. The involvement of 
hypothalamic  AMPK  in  leptin-induced  skeletal  muscle  lipid  oxidation  and  glucose  uptake  is 
unknown. Adiponectin is secreted by adipose tissue and increases skeletal muscle lipid oxidation 
and glucose uptake, as well as suppressing liver glucose production by activating AMPK. (Adapted 
from Long and Zierath 2006) 
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1.3.4.8.1 Leptin 
The adipocytokine leptin diminishes adiposity by reducing food intake (Halaas et al 1995) and 
improves insulin sensitivity (Khan et al 2000). Leptin induces fatty acid oxidation and glucose 
uptake in peripheral tissues, two metabolic responses that are also triggered by AMPK activation 
(Muoio et al 1996, Haque et al 1999). AMPK may therefore be a candidate in the mediation of 
leptin responses with skeletal muscle, liver and the hypothalamus being cited as peripheral targets 
(Minokoshi  et  al  2002),  (Figure  1.6).  AMPK  is  also  thought  to  regulate  food  intake  via  the 
hypothalamus. Indeed, in contrast to the effect on peripheral tissues, leptin inhibits AMPK activity 
in the hypothalamus. This is thought to be important for the hormone’s ability to reduce food intake 
and promote satiety (Minokoshi et al 2004).  
 
1.3.4.8.2 Adiponectin 
Plasma levels of adiponectin negatively correlate to insulin resistance, obesity and cardiovascular 
disease. The effects of the adiponectin are partly accounted for by adiponectin induced AMPK 
activation  which  results  in  stimulation  skeletal  muscle fatty acid oxidation and glucose uptake 
(Tomas  et  al  2002,  Yamauchi  et  al  2002).  Furthermore,  activation  of  AMPK  by  adiponectin 
suppresses  hepatic  gluconeogenesis.  (Yamauchi  et  al  2002).  Adiponectin  has  also  been 
demonstrated to increase nitric oxide production (Hattori et al 2003), by a pathway proposed to 
involve the direct phosphorylation of eNOS by AMP-activated protein kinase (AMPK), and also by 
a parallel pathway involving PI3K and PKB activation by AMPK (Chen et al 2003, Tan et al 2004, 
Ouchi et al 2004, Chen et al 2005), (figure 1.7). Furthermore, adiponectin has been shown to 
reduce  infarct  size  and  improve  left  ventricular  function  and  coronary  blood  flow  following 
ischaemia and reperfusion of isolated rat hearts by a mechanism involving AMPK and NO release 
(Gonon  et  al  2008).  Moreover,  AMPK  may  be  necessary  for  adiponectin  to  exert  its  cardio 
protective effect as ischaemia and reperfusion caused a larger myocardial infarct and enhanced  56 
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Figure 1.7 Potential signalling mechanisms by which adiponectin exerts its effects in human 
endothelial  cells.  Adiponectin  stimulates  NO  production  via  a  signalling  cascade  initiated  by 
binding to either isoform of its receptor. AMPK is activated (with a parallel signalling pathway 
utilising PKB activated also) with resultant eNOS activation (Adapted from Goldstein and Scala 
2004). 57 
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myocardial apoptosis in adiponectin knockout mice when compared with wild type mice (Shibata 
et al 2005). Adiponectin knockout mice have been shown to have progressive cardiac remodelling 
in  a  pressure-overloaded  condition  due  to  reduced  AMPK  signalling  and  increased  insulin 
resistance when compared with wild type mice (Liao et al 2005). Therefore, AMPK appears to be 
important in mediating both the metabolic and the vascular effects of adiponectin but as yet the 
exact signalling mechanisms have not been clarified.  
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1.4 Vascular function and endothelium 
1.4.1 Background 
Atherosclerosis is the process of disruption of normal vascular homeostasis leading to occlusive 
vascular disease. It is one of the most common diseases of the modern age, and is increasing in 
incidence and prevalence. This places a great burden on the health care resources of the world 
(Bonow  et  al  2002).  Atherosclerosis  predominantly  manifests  as  ischaemic  heart  disease, 
cerebrovascular disease and peripheral vascular disease. Endothelial dysfunction is proposed to be 
the triggering event of this process (Hansson 2005, Ross 1999). The vascular endothelium is an 
important mediator of the tone of smooth muscle surrounding the artery and therefore affects local 
blood  flow  as  well  as  blood  pressure  (Behrendt  et  al  2002).  Many  factors  associated  with 
endothelial  dysfunction  have  been  identified  which  predispose  to  the  development  of 
cardiovascular disease (Grundy et al 1999). These include diabetes, hypertension, family history, 
hypercholesterolemia and cigarette smoking.  
 
1.4.2 Vascular anatomy 
1.4.2.1. The vascular tree 
The arterial vascular tree is composed of a series of bifurcating vessels, which progressively reduce 
in diameter with each generation. All arteries have three layers, termed the tunica intima, the tunica 
media and tunica adventitia. These three layers are clearly defined in the large arteries, and become 
progressively less distinct as the size of artery decreases. The largest arteries are termed elastic 
arteries, and include the aorta and its major branches - the innominate, subclavian, and the proximal 
common  carotid  and  pulmonary  arteries.  These  vessels  are  characterised  by  a  tunica  media 
(muscular layer) rich in elastic tissue (Mulvany et al 1990). This elastic layer provides resilience, 
absorbing  energy  during  systole  and  releasing  this  energy  during  diastole,  aiding  forward 
propulsion of blood through the circulation (O’Rourke et al 2002). Loss of elasticity is pathological 59 
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and a natural part of ageing. As vessel size decreases, the quantity of elastic tissue within the tunica 
media  decreases.  At  this  point,  vessels  are  termed  muscular,  or  medium-sized,  arteries.  The 
adventitia of these vessels contains many more nerve-endings than in elastic arteries, reflecting the 
increased importance of autonomic control of these vessels. Small arteries retain the three layers of 
the arterial wall, becoming progressively less distinct to the level of the capillaries, which are 
characterised by a single cell wall (Ross 1999). 
 
1.4.2.2 The resistance artery 
Resistance  to  flow  (impedance)  is  related  to  vessel  size  (McDonald  et  al  1959).  Pressure 
measurements made along the vascular tree have shown that the majority of the pre-capillary drop 
in blood pressure occurs in vessels 100 - 500 micrometers (µm) in size (Bohlen 1986, Mulvany 
1990). Thus, this calibre of vessel accounts for the majority of peripheral resistance within the 
vasculature, and consequently are termed resistance arteries (Schiffrin 1992, Davis et al 1986). The 
peak of resistance within the vasculature coincides with a fall in blood pressure. The tunica media 
of the resistance artery consists of circumferentially arranged smooth muscle cells and connective 
tissue,  with  the  intima  consisting  of  longitudinally  arranged  endothelial  cells.  The  adventitia 
consists  of  collagen,  sympathetic  nerves  and  fibroblasts  (Mulvany  2002).  Although  physically 
discrete, the vascular endothelium (the intima) and the vascular smooth muscle layer (the media) 
are functionally coupled, as detailed in later sections of this thesis. A great deal of scientific effort 
has been directed towards a better understanding of the means by which endothelial cells influence 
the activity of the smooth muscle cells of the tunica media.  
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1.4.3. Vascular physiology and the pulse wave 
1.4.3.1. Autoregulation 
The vasculature is constrained by tight haemodynamic limitations. The majority of organs rely on 
mean arterial pressure to maintain perfusion. Excursions of pressure above such a pressure leads to 
vessel rupture and potentially life-threatening haemorrhage. Conversely, a drop in blood pressure 
may  lead  to  a  reduction  in  perfusion  of  vital  organs.  Blood  pressure  must  therefore  be  kept 
relatively  stable  within  tolerable  levels.  Maintenance  of  pressure  homeostasis  is achieved by a 
variety of mechanisms. The larger arteries which are elastic and muscular are unable to respond 
acutely  to  changes  of  pressure.  Regulation  is  therefore  predominantly  achieved  by  changes  in 
cardiac output and systemic resistance. The latter is achieved by a change of the physical properties 
of resistance arteries (ie. resistance artery calibre) within various peripheral vascular beds (Nichols 
et al 2001). This implies a change in the tone of the smooth muscle of the resistance artery tunica 
media  and  implies  the  involvement  of  the  resistance  artery  endothelium.  Endothelial  cells  of 
resistance arteries are therefore of critical importance in the maintenance of normal blood pressure, 
and  endothelial  dysfunction  has  been  implicated  as  a  primary  mediator  of  the  development  of 
vascular disease. 
 
1.4.3.2. The pulse wave 
The  assessment,  by  palpation,  of  the  arterial  pulse  wave  is  one  of  the  most  fundamental 
examinations performed in clinical practice. In recent years there has been a resurgent appreciation 
of the information that can be obtained from the measurement and analysis of the pulse pressure 
wave. The basic properties of the radial and carotid pulse waves were described in the late 19th 
Century (Mahomed 1872). The relationship between the physical properties of arterial walls and 
the pulse wave had been identified by the early 1920s (Bramwell et al 1922). 
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1.4.3.3. Pulse wave morphology 
The central arterial pulse wave is composed two major components; a forward travelling wave 
generated by left ventricular systolic contraction and a reflected wave, arriving from the periphery. 
The  reflected  wave  adds  to  the  amplitude  of  the  forward  travelling  wave  by  the  principle  of 
superimposition. The properties of the forward travelling wave are dependent upon the physical and 
mechanical  properties  of  the  central  large  arteries.  The  properties  of  the  reflected  wave  are 
dependent  on  physical  and  mechanical  properties  of  the  whole  arterial  tree,  the  transmission 
velocity of the incident wave, and the distance to the major reflecting site(s) (Nichols et al 2002). 
Within the vascular tree, the majority of reflections occur at bifurcations, although the tapering 
observed in larger arteries is also a source of reflections. 
 
An increase in the stiffness of arterial walls causes an increase in the transmission velocity of both 
the  incident  pressure  wave  and  the  reflected  wave.  As  the  overall  pulse  wave  morphology  is 
dependent on the superimposition of the incident and reflected pressure waves, an early return of 
the reflected component leads to an increase in the amplitude of the pulse pressure. 
 
1.4.3.4. Definition and measurement of arterial stiffness  
‘Arterial stiffness’ is a general term that requires definition. There are several measurable physical 
parameters of the arterial wall that may contribute to the degree of stiffness of the wall including 
pressure, diameter and height of the vessel wall (O’Rourke 1995). In the general literature, arterial 
stiffness is used to describe the overall rigidity of the arterial walls (MacKenzie et al 2002). Several 
established  techniques  are  used  to  measure  arterial  stiffness.  Pulse  Wave  Velocity  is  used  to 
measure arterial stiffness in this thesis and detailed discussion of this technique can be found in 
2.2.2.3.4 
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1.4.4. The vascular endothelium 
1.4.4.1 Introduction 
All blood vessels are lined with a monolayer of cells collectively termed the vascular endothelium. 
For many years this layer of cells was thought to be relatively inert. It is now recognised, however, 
that these cells are metabolically active with important paracrine, endocrine and autocrine functions, 
indispensable for the maintenance of vascular homeostasis (Vallance et al 2001, Bonetti et al 2003). 
Abnormal  endothelial  cell  function  is  a  key  step  in  the  development  of  vascular  disease 
(Stenhouwer et al 1997). The relevant normal physiology of the endothelium of the resistance artery 
will be outlined, and the mechanisms and implications of endothelial dysfunction considered. 
 
1.4.4.2 Insulin resistance, diabetes mellitus, endothelial dysfunction and atherosclerosis. 
The  vascular  endothelium  is  a  highly  active  organ  that  secretes  a  number  of  vasoconstrictor 
substances  (endothelin-1)  and  vasodilator  substances  (nitric  oxide  and  prostacyclin).  The 
monolayer of endothelial cells that line the luminal surface of the vasculature play a central role in 
vascular homeostasis and their dysfunction is thought to play a pivotal role in the development of 
atherosclerosis (Wheatcroft et al 2003). Endothelial dysfunction is found in people with insulin 
resistance,  obesity  and  T2DM  but  the  molecular  mechanisms  that  underlie  this  association are 
poorly characterised (Cleland et al 2000). A key player in vascular homeostasis is NO. NO is 
produced in endothelial cells from L-arginine which is catalysed by the enzyme eNOS (Muniyappa 
et al 2007). NO regulates vascular tone, inhibits cell adhesion, platelet aggregation and smooth 
muscle proliferation, giving an overall anti-thrombogenic effect (Wheatcroft et al 2003). Obesity 
and metabolic syndrome are associated with increased cardiovascular risk compared with healthy 
controls  which  may  be  present  years  before  hyperglycaemia  is  clinically  apparent  (figure  1.8). 
Endothelial  dysfunction  is  the  initiating  step  leading  to  atherosclerosis.  Endothelial  injury  or 
dysfunction (e.g. a reduction in bio-available NO leads to an inflammatory response at which time 63 
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Figure 1.8 Metabolic changes in the evolution of Type 2 diabetes. 
A schematic diagram representing the metabolic changes seen during the evolution of T2DM. The 
vasculature may be exposed to an increasingly atherogenic environment for many years before 
diabetes becomes clinically apparent (adapted from Wheatcroft et al 2003). 64 
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there is a loss of balance and the production of vasoconstrictor substances predominates (Hattori et 
al 2004). After injury, the expression of cell adhesion molecules (E-selectin, P-selectin, L-selectin, 
intercellular adhesion molecule-1 [ICAM-1] and vascular cell adhesion molecule-1 [VCAM-1] on 
the surface of the endothelium increases (Ross 1999). White blood cells bind to the cell adhesion 
molecules  and  the  endothelium  become  pro-coagulant  with  increased  cell  permeability  (Ross 
1999). White blood cells invade the arterial media and then intima where they differentiate into 
macrophages and promote arterial remodelling.  The macrophages subsequently take up lipids and 
become foam cells (Ross 1999). Ultimately the foam cells degrade to become fatty streaks and then 
the lipid core of an atherosclerotic plaque resulting in reduced luminal diameter (Boisvert et al 
1998). The lipid core is covered by a fibrous cap which can rupture into the lumen causing transient 
or permanent occlusive thrombosis formation of the vessel which may result in acute coronary 
syndrome, transient ischaemic attacks, myocardial infarction and cerebrovascular accidents (Ross 
1999).  Macrovascular  complications  occur  in  T2DM  and  give  rise  to  coronary  artery, 
cerebrovascular and peripheral vascular disease (DeFronzo et al 2004). 
 
1.4.4.3 Nitric oxide 
Initial experiments suggesting the importance of the endothelium as a regulator of vascular tone 
resulted in the identification of the endothelium-derived relaxing factor (EDRF) as NO. This work 
to identify NO was subsequently recognised with the Nobel Prize for Physiology or Medicine 1998 
(Raju 2000). NO is synthesised within endothelial cells during conversion of the amino acid L-
arginine to L-citrulline by eNOS (Vallance 2001). The endothelium controls vascular tone and plays 
a  key  role  in  maintaining  vascular  homeostasis.  This  process  is  mediated  by  release  of  NO, 
prostacyclin,  and  endothelium  derived  hyperpolarizing factors. Nitric oxide has an overall anti-
atherogenic effect on the vasculature, regulating blood pressure, inhibiting leukocyte activation, 
vascular smooth muscle proliferation, and platelet aggregation (Figure 1.9) (Moncada et al 1993,  65 
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Figure 1.9 Endothelium derived nitric oxide synthesis and action (Adapted from Moncada and 
Higgs 1993). 66 
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Shimokawa  et  al  1995).  NO  is  a  potent  vasodilator  and  there  is  clear  evidence  that  basal  NO 
dependent vasodilatation occurs in humans (Moncada et al 1993).  
 
NO is generated from L-arginine by a family of NOS (Harrison 1997) Three different isoforms of 
NOS occur in humans. Endothelial (eNOS, NOS III) and neuronal (nNOS, NOS I) isoforms are 
constitutively expressed and synthesise small amounts of nitric oxide (NO) under basal conditions 
as well as following stimulation by various stimuli e.g. insulin, shear stress, acetylcholine (Ach) or 
a rise in intracellular calcium concentration (Michel and Feron 1997). nNOS and iNOS are soluble 
whereas eNOS is membrane bound (Liu et al 1995).  
 
NO  production  by  eNOS  requires  numerous  cofactors  including  FMN,  FAD,  BH4  and  CaM 
(Moncada 1993). The half-life of NO is short (less than 4 seconds). It is rapidly metabolised to 
nitrite and then to nitrate before being excreted in the urine (Moncada 1993). NO passes from the 
endothelial cell to the vascular smooth muscle cell by diffusion. Once in the smooth muscle cell, it 
activates guanylate cyclase leading to an increase in intracellular guanosine-3,5-monophosphate 
(cGMP) concentrations, leading to a reduction in smooth muscle tone and vasodilation (Vallance et 
al  2001).  The  importance  of  NO  as  a  mediator  of  vascular  tone  was  initially demonstrated in 
experiments in both rabbit aorta ex vivo and the human forearm in vivo, in which application or 
infusion of the eNOS inhibitor, L-NMMA, was shown to produce vasoconstriction (Vallance et al 
1989). Abnormalities of endothelium-mediated vascular function have since been reported in a 
large number of studies in various cardiovascular disease states, including heart failure (Maguire et 
al  1998),  hyperlipidaemia  (Chowienczyk  et  al  1992),  diabetes  (Schofield  et  al  20002)  and 
hypertension (Taddei et al 2002). An impairment of endothelium-derived NO-mediated reduction 
in  smooth  muscle  tone  in  states  of  cardiovascular  disease  and  endothelial  dysfunction  may  be 67 
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caused  by  either  decreased  formation  or  accelerated  breakdown  of  NO.  Each  of  these  will  be 
addressed in turn.  
 
1.4.4.3.1 Decreased formation of NO 
eNOS activity within the endothelial cell may also be modulated by circulating factors including 
insulin. Insulin has important physiological effects on the endothelium, increasing NO availability, 
stimulating vasodilatation and is proposed to act in an anti-atherogenic manner (Muniyappa et al 
2007).  Insulin-stimulated  endothelial  dependent  vasodilatation  is  impaired  in  insulin  resistance 
(Cleland  et  al  2000,  Wheatcroft  et  al  2003).  Cultured  human  umbilical  vein  endothelial  cells 
(HUVECs)  demonstrate  acutely  increased  activity  of  eNOS  and  consequent  NO  production  in 
response to insulin incubation (Zeng et al 1996, Yki-Jarvinen et al 1998). A fall in the circulating 
concentration of insulin, or a decreased sensitivity of intracellular signalling mechanisms could 
lead to a reduction in eNOS activity and therefore in NO production. eNOS may be inhibited by 
endogenous  products  of  arginine  metabolism  with  some  similar  properties  to  L-NMMA, 
particularly asymmetric dimethylarginine (ADMA) (Vallance et al 2001). ADMA, a guanidino-
substituted analogue of L-arginine, is a potent endogenous competitive inhibitor of eNOS. ADMA 
is produced by methylation of L-arginine which is catalysed by protein arginine methyltransferases 
(Achan et al 2003). Symmetric dimethylarginine is also produced by methylation of L-arginine but 
does not exert effects on the production of NO by NOS. The predominant mode of elimination of 
ADMA occurs via enzymatic degradation by dimethyl arginine dimethyl amino hydrolase (DDAH) 
to  citrulline  and  dimethylamine  (Achan  et  al  2003).  Increased  levels  of  ADMA  reduce  NO 
formation and are associated with endothelial dysfunction. Plasma levels of ADMA have been 
found  to  be  increased  in  hypercholesterolaemia  (Boger  et  al  1998),  hypertriglyceridaemia 
(Lundman et al 2001), hyperhomocyst(e)inemia (Stuhlinger et al 2003), obesity (McLaughlin et al 
2006), Type 1 diabetes mellitus (Altinova et al 2007), Type 2 diabetes mellitus (Abbasi et al 2001), 68 
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gestational  diabetes  (Mittermayer  et  al  2002)  and,  most  recently,  polycystic  ovary  syndrome 
(Heutling et al 2008). There is a close relationship between concentrations of ADMA and insulin 
resistance (Stuhlinger et al 2002). Indeed, in several prospective studies, ADMA has been noted to 
be an independent predictor of cardiovascular events (Valkonen et al 2001, Mittlemayer et al 2006, 
Krzyzanowska  et  al  2007).  These  substances  may  act  as  endogenous  competitive  inhibitors  of 
eNOS and provide a credible mechanism by which NO bioavailability may be impaired in states of 
cardiovascular disease. 
 
1.4.4.3.2 Accelerated breakdown of NO  
Accelerated  degradation  of  NO  by  reactive  oxygen  species  is  probably  the  major  mechanism 
impairing NO bioavailability in states of cardiovascular disease (Harrison 1997, Behrendt et al 
2002).  The  most  important  mediators  of  increased  oxidative  stress  are  increased  generation  of 
superoxide anion, and oxidised LDL cholesterol which react with endothelial NO before it reaches 
the vascular smooth muscle cell and therefore reduce total NO-mediated vasodilation (Kojda et al 
1999). 
 
1.4.4.4 Prostacyclin 
Prostacyclin  (PGI2)  is  the  major  metabolite  of  arachadonic  acid  produced  by  cyclooxygenase 
(COX-1) in the endothelium. PG12 acts as a vasodilator. Clinical and experimental models of 
diabetes are associated with decreased secretion of PGI2 (Feletou and Vanhoutte 2006, Muniyappa 
et al 2007) 
 
1.4.4.5 Endothelium derived hyperpolarising factor 
NO  has  been  shown  to  be  an  important  endothelium-dependent  mediator  of  vascular  tone  in 
relatively  large  arteries  and  larger  arterioles.  There  are,  however,  certain  arteries  in  which 69 
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endothelium-mediated  vasodilation  is  predominately  affected  by  endothelium-dependent 
hyperpolarisation of vascular smooth muscle cells which persists in the presence of inhibitors of 
eNOS and prostacyclin (Feletou et al 1988, Garland et al 1992). This suggested that a separate 
mechanism is partially responsible for endothelium dependent vasodilation of these arteries. The 
exact  identity  of  the  chemical  (or  other)  mediator(s)  involved  in  this  mechanism  is  unclear  at 
present.  This  non-prostanoid,  non-NO  dependent  endothelium-dependent  hyperpolarisation 
characterised  by  the  EDHF  pathway  does  not appear to represent any one substance, and it is 
therefore  likely  that  there  are  several  endothelium-derived  factors  responsible  (Feletou  and 
Vanhoutte 2006). 
 
The relative importance of the EDHF mediated mechanisms to NO mediated mechanisms alters 
with vessel size, and appears to increase as vessel size decreases (Shimokawa et al 1996). At the 
level of the aorta, reduced NO bioavailability is proposed to be the main marker for endothelial 
dysfunction. In resistance arteries, NO, prostacyclins and EDHFs are thought to be involved in 
mediating endothelial function (Kang et al 2007).  
 
1.4.4.6  Measurement of endothelial function 
Several established techniques are used to measure endothelial function. Wire myography is used to 
measure endothelial function in this thesis and detailed discussion of this technique can be found in 
2.2.2.4.1 
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1.5 Metformin 
1.5.1 Galegine (isoamylene guanidine) 
Galega officinalis has been used since medieval times for medicinal purposes by French monks to 
control what was described as “intense urination” (Witters 2001). The therapeutic properties of 
Galega Officinalis for the management of patients with diabetes was ultimately developed in the 
early 1900’s with the knowledge that the plant was a source of guanidine which induced glucose 
lowering biological effects. Guanidine proved to be too toxic and the less toxic derivative galegine 
or isoamylene guanidine was identified (Figure 1.10). Guanidine was subsequently shown to reduce 
blood glucose levels in both animals and humans (Bailey et al 2004). The clinical application of 
Galegine was limited, however, due to its short duration of action, differing efficacy and safety 
concerns (Bailey et al 2004).  
 
1.5.2 The discovery of metformin 
Following a hiatus in research into diabetes after the discovery of insulin, work by the French 
clinician Sterne and colleagues lead to the discovery of dimethylbiguanide (metformin), (Sterne 
1964).  Sterne  also  made  some  important  discoveries  in  metformin’s  mechanism  of  action.  He 
demonstrated  that  the  presence  of  the  pancreas  and  diabetes  (Sterne  1964)  was  required  for 
metformin to lower blood glucose.  
 
At  a  similar  time  other  investigators  in  the  United  States  were  working  on  the  more  potent 
biguanide  phenformin  (phenylethylbiguanide)  (Unger  et  al  1960).  (Figure  1.11).  A  typically 
effective  dose  of  phenformin  would  be  around  100  mg  rather  than  2000  mg  with  metformin. 
Reports of phenformin associated lactic acidosis (Walker et al 1959) and evidence of increased 
cardiovascular mortality in those with T2DM with phenformin (Goldner et al 1971) resulted in 
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Figure  1.10  Structure  of  galegine  (3-methyl-2-butenylguanine/isoamylene  guanidine)  and 
metformin (dimethylbiguanide) 
Galegine 
Metformin 72 
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Figure  1.11  Chemical  structure  of  biguanides.  Buformin  (butylbiguanide)  is  less  potent  than 
phenformin but there are case reports of associated lactic acidosis (Krishnamurhty et al 2004) and 
this drug is not used in the United Kingdom. 73 
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phenformin’s withdrawal from clinical use from most countries in the 1970’s. This proved to be a 
major challenge to the introduction of metformin and it was not introduced into clinical practice in 
the Unites States until 1995, almost 40 years after it was first introduced as a treatment of T2DM in 
Europe  in  1957.  This  coincided  with  evidence  that  the  risk  of  lactic  acidosis  associated  with 
metformin is considerably lower than other biguanides and is probably no higher than other anti-
diabetic drugs when prescribed correctly (Misbin 2004). The spectre of increased cardiovascular 
mortality  associated  with  biguanides  in  1971  was  finally  dispelled  when the results of the UK 
Prospective Diabetes Study (UKPDS) where published in 1998. 
 
1.5.3 Structure and action of metformin 
As outlined above, three biguanides have been used widely in patients with T2DM: metformin, 
phenformin and buformin; but only metformin remains part of today’s worldwide pharmacopoeia. 
While there are close similarities between these drugs the unique properties of metformin explain 
its longer lasting appeal. Both metformin and phenformin are guanidine derivatives with one mono-
substitution  as  already  shown  in  Figure  1.10.  As  shown  phenformin  has  a  phenyl  ethyl  ring 
substituted at the terminal amino group rather than metformin’s two methyl groups. Metformin is of 
smaller molecular weight, more chemically stable, freely soluble in water and does not undergo 
substantial metabolism in vivo (Karttunen et al 1983).  
 
Metformin acts by countering insulin resistance, which is thought to occur in principally in liver and 
muscle (Hundal et al 2000). Metformin acts mainly to reduce hepatic gluconeogenesis and also to 
increase  peripheral  insulin  sensitivity  in peripheral insulin sensitive tissues such as muscle and 
adipose. Finally, metformin has protective effects on the cardiovascular system which cannot be 
fully  explained  by  its  blood  glucose  lowering  properties  (UKPDS  1998).  There  is  evidence  to 
suggest that that metformin’s beneficial effects are attributable to disruption of respiratory chain 74 
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oxidation  in  mitochondria  (El  Mir  et  al  2000,  Owen  2000),  enhanced  insulin  tyrosine  kinase 
receptor  activity  (Dominguez  et  al  1996),  enhanced  GLUT4  translocation  to  the  membrane 
(Matthaei et al 1993, Hundal et al 1992) and finally the focus of this thesis, activation of AMPK 
(Zhou et al 2001, Musi et al 2002).  
 
1.5.4 Efficacy 
As detailed above metformin has been used in the treatment of patients with T2DM since 1957 in 
Europe and 1995 in the Unites States. It is now the most commonly prescribed oral hypoglycaemic 
worldwide. This section outlines the therapeutic profile of metformin and further details effects on 
blood glucose, weight, lipid profile and the focus of this thesis, the cardiovascular system. 
 
1.5.4.1 Glucose lowering 
The  UKPDS  study  showed  that  the  addition  of  metformin  to  diet  resulted  in  a  dramatic 
improvement in glycaemic control over a few years compared with patients on diet alone (UKPDS 
1998). Evidence also suggests that the hypoglycaemic properties of metformin are dose dependent 
with the largest study of 451 patients concluding that 2000 mg of metformin was the optimal daily 
dose with a mean change in HbA1C from baseline -0.7% after 14 weeks (Garber et al 1997). In 
Europe the maximum recommended dose is 3000 mg and in the UKPDS study a median daily 
dosage of 2550 mg was used (UKPDS 1998). 
 
Before considering how metformin reduces blood glucose in patients with T2DM it is important to 
consider how glucose is regulated in normal physiology. Following a meal, insulin concentrations 
rise  and  stop  glucose  production  in  the  liver  and  lipolysis  in  the  adipocytes.  Glucose  uptake 
peripherally  in  insulin  sensitive  tissue  such  as  skeletal  muscle  and  adipocytes  increases  as  the 
elevated insulin concentrations improve GLUT4 translocation to their plasma membranes. In T2DM 75 
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this mechanism of regulating blood glucose is disrupted years before diagnosis (DeFronzo et al 
1992). The liver, skeletal muscle and adipocytes become less responsive to the insulin which results 
in a compensatory hyperinsulinaemia. This can control blood glucose levels for a period until the 
pancreas can no longer secrete enough insulin to maintain normal blood glucose levels and the 
patient develops T2DM (DeFronzo et al 1992).  
 
The principal way in which metformin exerts its glucose lowering effects is by reversing insulin 
resistance and not, like the sulphonylurea class of drugs, by increasing insulin secretion. This occurs 
by  reducing hepatic glucose production (Johnson et al 1993, Tikkainen et al 2004), improving 
peripheral insulin action (Johnson et al 1993), increasing intestinal glucose uptake (Bailey et al 
1994, Mithieux et al 2006) and reducing lipolysis in adipocytes (Perriello et al 1994, Abbasi et al 
1998,  Tikkainen  et  al  2004).  Exactly  how  metformin  improves  insulin  action,  however,  is  not 
completely understood after more than 50 years of clinical use.   
 
1.5.4.2 Weight 
The vast majority of patients with T2DM are overweight or obese (Daousi et al 2006). There is 
considerable variability between studies on the effect of metformin on weight loss but reductions in 
body weight are often observed.  Two meta-analyses of controlled studies, however, concluded that 
there was no difference in metformin, placebo or diet on body weight or BMI in patients with 
T2DM (Johansen 1999, Saenz et al 2005). This conclusion is reinforced by the UKPDS study, the 
longest randomised evaluation of metformin effects on weight in overweight patients, where after 
10 years, weight was not significantly different between metformin and placebo (UKPDS 1998). 
There was, however, a significant difference in weight in a recent meta-analysis (Saenz et al 2005) 
comparing metformin with sulphonylurea and in the UKPDS study (UKPDS 1998). 
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1.5.4.3 Lipid profile 
Metformin is associated with modest improvements in the lipid profile. This is usually reflected in 
reductions in total cholesterol, LDL – cholesterol and mainly triglycerides. HDL – cholesterol is 
generally unaffected by metformin (Wulffele et al 2004).  While the beneficial effects of metformin 
on the lipid profile would tend to reduce cardiovascular risk when the reductions are entered into 
the UKPDS risk engine, the overall benefits to 10 year risk of macrovascular end-points are modest.  
 
1.5.4.4 Blood pressure 
In some animal models, metformin appears to have a vascular action. In spontaneously hypertensive 
rats, it has been reported to reduce blood pressure (BP), possibly via modulation of adrenergic tone 
(Peuler et al 1999). In man, blood pressure responses to intravenous infusions of norepinephrine 
and angiotensin II are blunted in the presence of metformin (McAuley et al 1997). Reductions in 
blood pressure have been observed in patients treated with metformin (Chan et al 1993) but the 
overwhelming body of evidence including a meta-analysis suggest that metformin does not alter BP 
in man (Saenz et al 2005). 
 
1.5.4.5 Macrovascular Benefits 
T2DM confers a 2 to 4 fold greater risk of heart disease and stroke when compared with the general 
population. Moreover, life expectancy in patients with T2DM is thought to fall by anything from 5 
to 10 years. The United Kingdom Prospective Diabetes Study (UKPDS) study, initiated in 1977 and 
reported in 1998, was the first randomised trial to demonstrate improved outcome with metformin 
treatment. Randomisation to metformin was associated with dramatic relative risk reductions in 
diabetes-related  death  (-42%),  myocardial  infarction  (-39%),  stroke  (-42%)  any  diabetes related 
end-point (-32%) and all cause mortality (-36%) when compared with diet. This is in contrast to the 
relative risk reductions with sulphonylurea or insulin in diabetes-related death (-20%), myocardial 77 
 
77 
 
infarction (-21%), stroke (+14%) any diabetes related end-point (-7%) and all cause mortality (-8%) 
when  compared  with  diet.  The  benefits  observed and could not be explained by differences in 
glycaemia. Mean HbA1c after follow up in the diet group and metformin group were 8% and 7.4% 
respectively and there was no clear difference in the glucose lowering effect between metformin, 
sulphonylurea and insulin. Given that the glucose lowering effects on metformin, sulphonylurea and 
insulin were similar, it has been proposed that metformin must confer additional vascular benefits 
beyond those of glycaemia alone. The reason why metformin has beneficial cardiovascular effects 
in overweight diabetic patients in UKPDS remains unanswered. 
 
1.5.4.6 Endothelial function  
Despite  50  years  of  research  the  exact  mechanisms  of  action  of  metformin  remain  poorly 
understood and have yet to be fully elucidated. It is likely that no single cellular effect can explain 
metformin’s cardioprotective effect. As outlined above it is unlikely that changes in the usual risk 
factors of hyperglycaemia, dyslipidaemia, obesity and hypertension with metformin are enough to 
account for its cardiovascular benefits and therefore other mechanisms must therefore be involved.  
 
There is evidence that metformin improves endothelial function. In a placebo controlled study in 44 
patients  with  T2DM  metformin  improved  endothelial-dependent  vasodilation  as  assessed  by 
forearm  plethysmography  during  an  infusion  of  acetylcholine  (Mather  et  al  2001).  This  is 
completed by evidence from a randomised placebo controlled cross-over study in patients with 
insulin T2DM in which there were significant reductions in the circulating cell adhesion molecules 
VCAM-1 and E-selectin, reflecting suppression of endothelial activation unexplained by changes in 
glucose (De Jager et al 2005). These results have also been reproduced in patients with impaired 
glucose tolerance (Caballero et al 2004), metabolic syndrome (Vitale et al 2005), polycystic ovary 
syndrome (Diamanti-Kandarakis et al 2005, Orio et al 2005), cardiac syndrome X (Jadhav et al 78 
 
78 
 
2006) as well as the first degree relatives of patients with T2DM (De Aguiar et al 2006). There is 
also, however, conflicting evidence demonstrating no effect on endothelial function with metformin 
(Natali et al 2004).  
 
1.5.4.7 AMPK 
Recent clinical studies have shown that the effects of metformin may go beyond improving HbA1c 
and may include reductions in cardiovascular end points in T2DM. Perhaps the most intriguing 
development  in  elucidating  metformin’s  cellular  mechanism  of  action  in  recent  years  is  the 
proposed involvement of AMPK. The metabolic and cardio-protective effects of metformin may be 
attributable to the activation of AMPK and its downstream pathways.  
 
The precise mechanisms of how metformin activates AMPK are still poorly understood. Metformin 
has not been shown to bind directly to AMPK or regulate phosphorylation and dephosphorylation in 
cell-free assays (Hawley et al 2002). One hypothesis is that it activates AMPK by weakly inhibiting 
complex I of the respiratory chain resulting in an increase in the AMP/ATP ratio (El-Mir et al 2000, 
Owen  et  al  2000,  Hawley  et  al  2002).  The  increase  in  the  AMP/ATP  ratio  inhibits 
dephosphorylation of AMPK thereby potentiating the phosphorylation of AMPK by LKB1, whose 
activity  is  thought  to  be  constitutive  (Hawley  et  al  2003).  There  is  also  contrasting  evidence 
suggesting  that  AMPK  can  be  activated  by  metformin  without  changes  in  the  AMP/ATP  ratio 
(Hawley et al 2002). Interestingly, it has been shown that LKB1 is necessary for metformin to 
activate AMPK in the liver and in turn decrease blood glucose in obese rodents (Shaw et al 2005).  
 
Metformin is not metabolised but is transported by at least two organic cation transporters. Organic 
cation  transporter-1  (OCT-1)  is  mainly  expressed  in  the  cell  membrane  of  hepatocytes  and  is 
thought to play an important role in the uptake of metformin from intestinal cells (Wang et al 2002, 79 
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Dressler et al 2002, Kirmura et al 2005). Organic cation transporter-2 (OCT-2) is mainly expressed 
in the cell membrane of the distal renal tubules and is thought to play an important role in the renal 
tubular excretion of metformin. In contrast, phenformin enters cell membranes by passive diffusion 
without  the  need  for  active  transport.  In  mouse  hepatocytes,  deletion  of  OCT-1  resulted  in 
attenuation of the effects of metformin on AMPK phosphorylation and gluconeogenesis (Shu et al 
2007). It should be noted that there was significant metformin uptake and AMPK activation despite 
deletion of OCT-1 suggesting that other mechanisms such as passive diffusion or other as yet, 
undiscovered transporters may contribute to metformin’s action in liver or indeed in other tissues. It 
is important to note that in OCT-1 deficient mice the glucose lowering effects of metformin were 
abolished suggesting that OCT-1 in the liver plays an important role in mediating metformin’s 
ability  to  reduce  hepatic  glucose  production  (Shu  et  al  2007).  Moreover,  it  has  been  recently 
observed that OCT-1 mediates lactic acidosis, the major adverse effect of metformin (Wang et al 
2003). When mice were given metformin, the blood lactate concentration significantly increased in 
wild type mice compared with OCT-1 knockout mice. As previously stated, metformin is a weak 
inhibitor of complex I of the respiratory chain (Hawley et al 2002) and this mechanism of action is 
likely to explain the life-threatening side effect of lactic acidosis that led to the withdrawal of the 
sister drug, phenformin, from human use. Recently, genetic polymorphisms of OCT-1 have been 
found to be associated with variations in metformin’s action. Several nonsynonymous and deletion 
variants have been identified in the human OCT-1 gene (encoded by SLC22A1). It is noteworthy 
that 2 variants that reduce transport of metformin, 420del and R61C, are common polymorphisms 
of OCT-1 with allele frequencies of 19% and 7.2% respectively in those of European descent (Shu 
et al 2003). In addition the effects of metformin on glucose tolerance tests were significantly lower 
in 12 healthy volunteers carrying reduced function polymorphisms of OCT-1 (Shu et al 2007). 
Identification  of  polymorphisms  in  genes  encoding  cation  transporter  proteins  may,  therefore 
explain differences in T2DM patients’ tolerance and response to metformin therapy (Jonker et al 80 
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2004).  Interestingly, in a recently published retrospective study, the 420del and R61C variants 
failed to have any effect on metformin ability to lower HbA1c in a large cohort of patients with 
T2DM (Zhou et al 2009). Large scale prospective studies, however, are necessary to confirm the 
clinical  relevance  of  personalised  metformin  therapy  based  on  OCT-1  gene  polymorphisms. 
Nevertheless, the prospect of the pharmacological tissue specific targeting of influx transporters and 
AMPK in the management of T2DM is an attractive one (Shu et al 2007).  
 
Metformin increases skeletal muscle glucose disposal and decreases hepatic glucose production. 
Metformin has been shown to activate AMPK in myocytes and skeletal muscle cells (Zhou et al 
2001,  Yang  et  al  2006).  Therapeutic  doses  of  metformin  have  been  shown  to increase AMPK 
activity  with  an  associated  decrease  in  ACC  activity  in  serial  muscle  biopsies  in  patients  with 
T2DM (Musi et al 2002). Levels of metformin in the skeletal muscle of OCT-1 knockout mice and 
wild type mice are no significantly different, suggesting that the uptake of metformin in skeletal 
muscle may involve other transporters (Wang et al 2003, Shu et al 2007). Metformin has been 
reported to activate AMPK in hepatocytes (Zhou et al 2001) and 3T3-LI adipocytes (Huypens et al 
2005),  yet  an  effect  of  metformin  on  AMPK  in  human  liver  or  adipose  tissue  has  not  been 
investigated. Indeed, as is the case with skeletal muscle, the transporter(s) involved in the uptake of 
metformin in adipose tissue remains unknown.  
 
It  has  recently  been  reported  that  metformin  stimulates  NO  synthesis  in  an  AMPK-dependent 
manner in BAECs (Zou et al 2004). This is in contrast to data that suggests that the incubation of 
BAECs with phenformin activates AMPK without altering Ser1177 phosphorylation (Mount et al 
2005). Further work has demonstrated that metformin acts to phosphorylate AMPK and ACC in 
HUVECs (Hattori et al 2006). However in HAECs, metformin failed to show any effect on AMPK 
activity within 2 hours (Morrow et al 2003). The reasons for these conflicting data remain elusive 81 
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but may be explained by species- and tissue-specific factors. Moreover, the neutral results with 
metformin may reflect the reduced lipophilicity compared with phenformin, such that phenformin 
rapidly accumulates in cells and subsequently has a more rapid effect on metabolism compared with 
metformin.  Therefore, a longer incubation period with a higher concentration of metformin may be 
required to stimulate AMPK and NO synthesis in HAECs.  Furthermore, the neutral results with 
metformin  may  also  be  explained  by  the  possibility  of  cells  either  carrying  reduced  function 
polymorphisms of OCT-1 or not expressing OCT-1 at all. 
 
Exactly how metformin improves insulin action, lowers body weight, improves the lipid profile, 
improves  endothelial  function  and  reduces  the  incidence  of  myocardial  infarction  remains 
incompletely understood. Further work is required to examine if biguanides mediate these effects by 
stimulating AMPK activity in human adipose tissue and vascular endothelial cells. 
 
1.5.4.8 ADMA 
Metformin has been reported to decrease the plasma ADMA concentrations in poorly controlled 
subjects with Type 2 diabetes in an open labelled, uncontrolled study without a placebo arm; the 
fall in ADMA concentration was associated with improved fasting plasma glucose, although the 
study  failed  to  demonstrate  a  relationship  between  the  decrease  in  ADMA  concentrations  and 
improvement in glycaemic control (Asagami et al 2002). Importantly, no assessment of vascular 
function was made in this study. Furthermore, in a recent study, a subgroup of women with PCOS 
who  received  metformin  demonstrated  reductions  in  ADMA  concentration  independent  of  a 
reduction  in  BMI  and  fasting  blood  glucose  (Heutling  et  al  2008).  There  was  a  marginal 
improvement in carotid intima media thickness in favour of metformin therapy. However, once 
again, this was also an uncontrolled study involving a small subset of patients without the benefit 
of a placebo arm and it is clear that more data are required to clarify whether metformin mediated 82 
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reduction in ADMA concentration is genuine and, if so, whether this change can lead to beneficial 
effects on vascular function in overweight subjects with Type 2 diabetes. Interestingly, patients 
with T2DM randomised to the second generation sulphonylurea glibencamide were found to have 
no change in ADMA concentration after six months of therapy (Kelly et al 2007). Further work is 
required to determine if metformin therapy improves vascular endothelial function in association 
with lower circulating concentrations of ADMA. 
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1.6 Sulphonylureas 
The  sulphonylureas  are  derived  from  sulphonic  acid  and  urea  and  were  introduced  to  the 
pharmacopeia in 1950s with gliclazide being the most popular in the United Kingdom at present 
(Gerich et al 1989). All sulphonylureas contain a central S-phenylsulfonylurea structure with p-
substitution  on  the  phenyl  ring  and  various  groups  terminating  the  urea  N'  end  group.  The 
sulponylureas are effective pancreatic insulin secretagogues that can rapidly improve glycaemic 
control  (Haupt  et  al  1971).  They  control  blood  glucose  levels  by  directly  stimulating  insulin 
secretion  in  the  pancreatic  beta  cells  (Gorus  et  al  1988).  Sulphonlyureas  bind  to  a  receptor 
associated with the ATP-sensitive potassium channel (KATP; a 140 kDa membrane protein) on the 
plasma membrane which results in closure of the channel (Sturgess et al 1985, Schmid-Antomarchi 
et al 1987). This in turn depolarizes the membrane and triggers the opening of voltage-sensitive 
calcium channels, leading to the rapid influx of calcium. Increased intracellular calcium causes an 
alteration in the cytoskeleton, and stimulates translocation of insulin-containing secretory granules 
to the plasma membrane and the exocytotic release of insulin (Hu et al 2000). Differences in the 
binding, retention in islets and drug half lives result in different patterns of insulin release (Hu et al 
2000).  
Gliclazide for example affects first and second phase of insulin secretion and therefore has the 
advantage of affecting fasting blood glucose and post prandial blood glucose levels (Korytkowski 
et  al  2002).  In  general,  experience  suggests  the  sulpohylureas  lower  blood  glucose  by  around 
3mmol/l  corresponding  to  a  drop  in  HbA1C  of  around  1.5  to  2%  (Inzucchi  et  al  1998). 
Sulphonylureas are predictably associated with weight gain. In UKPDS, there was an increase in 
body weight of 2 to 3kg which was maximal within 1 year of the study and maintained for the 
entire ten year follow up. In terms of blood pressure and plasma lipid profile, sulphonylureas are 
generally neutral (Inzucchi et al 1998). Improved glycaemic control reduces the progression of 84 
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microvascular complications but the effect of sulphonylureas on macrovascular complications is 
less clear. In the UKPDS study, where sulphonylureas or insulin were compared with conventional 
therapy in patients with T2DM (with median results of HbA1C of 7% and 7.9% respectively), there 
was  a  significant  25%  reduction  in  all  microvascular  end-points  as  well  as  a  significant  12% 
reduction in any diabetes-related endpoint. The effect of sulphonylureas on macrovascular disease 
is less certain. In UKPDS, there was no difference in all cause mortality or diabetes-related death. It 
is important to note that there was a reduction in myocardial infarction and cardiovascular mortality 
that failed to reach statistical significance (p = 0.052). Overall there was no significant difference 
between those treated with insulin or sulphonylureas and it was concluded that lowering blood 
glucose alone is insufficient to reduce macrovascular events in this high risk group. This is in 
contrast to the reduction in myocardial infarction and cardiovascular mortality in obese patients 
with  T2DM  randomised  to  metformin  which  could  not  be  fully  explained  by  a  reduction  in 
glucotoxicity.  Sulphonylureas  are  not  thought  to  activate  AMPK,  indeed  the  third  generation 
sulphonylurea,  glimepiride  had  no  effect  on  AMPK  activity  when  incubated  with  cultured 
adipocytes and muscle cells (Inukai et al 2005). Thus, the sulphonylureas are an appropriate control 
in studies examining metformin’s ability to stimulate AMPK in patients with T2DM.  
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1.7 Thiazolidinediones 
The peroxisome proliferator activated receptor-γ (PPAR-γ) agonists such as the thiazolidinediones 
(TZDs),  rosiglitazone  and  pioglitazone,  are  an  important  class  of  compounds  used  in  the 
management of T2DM. TZDs are thought to work by the binding to and activating of the PPAR-γ 
receptor (Lehmann et al 1995). The PPAR-γ receptor is a nuclear receptor that is thought to have a 
regulatory role in the differentiation of cells and is present in many tissues including adipose, liver, 
muscle and the vascular endothelium. Indeed, TZDs main action is to promote differentiation of 
pre-adipocytes to adipocytes and redistribute lipids. The ability of TZDs to lower blood glucose is 
well  established  and  they  have  similar  efficacy  to  other  oral hypoglycaemic drugs. They lower 
glucose by lowering insulin resistance in muscle and adipose, increasing insulin related glucose 
disposal and reducing hepatic glucose production (Semple et al 2006). While TZDs are effective in 
reducing blood glucose levels they also cause weight gain and peripheral oedema (Nissen et al 
2007). 
 
The ability of TZDs to reduce cardiovascular events in patients with diabetes has attracted much 
interest. A number of studies have demonstrated that TZDs have the capacity to improve endothelial 
function in non-diabetic subjects (Wang et al 2004, Hetzel et al 2005) and subjects with T2DM 
(Satoh et al 2003, Natali et al 2004, Pitrosh et al 2004).  The beneficial effects of TZDs have been 
reported to be independent of glycaemia, inferring a direct effect on vascular tissues (Satoh et al 
2003,  Pitrosh  et  al  2004).    The  endothelial  effects  of  TZDs  may  be  relatively  rapid;  indeed 
rosiglitazone  has  been  reported  to  improve  endothelial  function  within  24  h  in  healthy  human 
subjects (Hetzel et al 2005).  
 
The mechanism of action by which TZDs improve vascular endothelial function remains uncertain. 
Recent studies have suggested that TZDs also directly improve NO bioavailability in endothelial 86 
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cells (Calnek et al 2003, Cho et al 2004, Polikandroitis et al 2005, Kim et al 2006).  Previous 
studies have demonstrated that incubation of HUVECs with rosiglitazone for 48h stimulated NO 
synthesis  and  phosphorylation  of  eNOS  at  Ser  1177  (Polikandroitis  et  al  2005).    Similarly, 
troglitazone has been reported to stimulate NO synthesis within 3h and eNOS phosphorylation at 
the equivalent site (Ser 1179) in BAEC’s (Cho et al 2004). In HUVECs, rosiglitazone-stimulated 
NO synthesis and eNOS Ser 1177 phosphorylation were reported to be completely inhibited in the 
presence  of  the  PPAR-γ  inhibitor,  GW9662  (Polikandroitis  et  al  2005).  In  BAECs,  however, 
troglitazone-stimulated  NO  synthesis  and  eNOS  Ser  1179  phosphorylation  was  only  partially 
inhibited in the presence of the PPAR-γ inhibitor, BADGE (Cho et al 2004). Several protein kinases 
have been demonstrated to phosphorylate eNOS at Ser 1177
 in endothelial cells, including protein 
kinase B (PKB) and AMPK (Fulton et al 1999, Dimmeler et al 1999; Chen et al 1999, Morrow et al 
2003), but the protein kinase and signalling mechanism responsible for phosphorylation of eNOS in 
response to TZDs is as yet undetermined.  TZDs have been demonstrated to activate AMPK in 
muscle, liver and adipose (Fryer et al 2002, Saha et al 2004, Konrad et al 2005; Lebrasseur et al 
2006). Indeed, rosiglitazone associated AMPK activation has been shown to be via an AMP/ATP 
dependent pathway in muscle (Hawley et al 2002). TZDs can also activate AMPK by stimulating 
the release and expression of circulating adiponectin from adipose tissue or indirectly by increasing 
the cellular AMP/ATP ratio by a similar mechanism to metformin (Yamauchi et al 2002, Tomas et 
al 2002, Brunmair et al 2004). Further work is required to examine if TZDs mediate their beneficial 
effects by stimulating AMPK in vascular endothelial cells.  
 
Despite  the  TZD  related  improvements  in  vascular  biology  and  endothelial  function  described 
above,  it  is  important  to  note  that  metformin  remains  the  only  oral  hypoglycaemic  drug  to 
demonstrate  good  evidence  for  cardiovascular  protection  in  a  randomised  trial.  Since  UKPDS 
reported  in  1998,  the  thiazolidinediones  had  been  proposed  to  have  beneficial  cardiovascular 87 
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effects. This was assessed by randomisation to pioglitazone to high risk patients with T2DM in the 
Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive) study (Dormandy et 
al 2005). The PROactive study was a prospective randomised controlled trial in 5238 patients with 
T2DM  who  have  evidence  of  cardiovascular  disease.  Patients  were  randomised  to  45mg  of 
pioglitazone versus placebo and continued to take other glucose lowering drugs with an absolute 
reduction in HbA1c of 0.5% in the pioglitazone group versus placebo. However, pioglitazone was 
not associated with cardiovascular benefit as defined by the primary composite cardiovascular end-
point  of  all-cause  mortality,  non-fatal  myocardial  infarction,  stroke,  acute  coronary  syndrome, 
amputation  or  revascularisation  (Dormandy  et  al  2005).  Indeed,  there  was  only  a  modest  10% 
reduction that failed to reach statistical significance (p=0.92). It is worth noting that the “main” 
secondary end-point of all cause mortality and non-fatal myocardial infarction was reduced by 16% 
and did reach statistical significance (p=0.027).  
 
There has been concern that rosiglitazone may be associated with additional cardiovascular risk in 
patients with Type 2 diabetes mellitus. This was related to a recent meta-analysis suggested an 
increase in adverse cardiovascular outcomes in patients randomised to rosiglitazone compared to 
any other treatment (Nissen et al 2007). The meta-analysis included 42 randomised trials (duration 
of 24 weeks or more) and found that randomisation to metformin was associated with a significant 
(p=0.03)  increase  in  the  risk  of  myocardial  infarction  of  43%,  while  a  64%  increase  in 
cardiovascular death just failed to reach statistical significance (p=0.06). The meta-analysis was 
limited, however, by a small event rate and the inclusion of a number of small trials. Following 
publication  of  this  meta-analysis,  the  European  Medicines  Evaluation  Agency  (EMEA)  for 
Medicinal Products for Human Use adopted a scientific opinion in January 2008 recommending the 
inclusion of a new warning stating that the use of rosiglitazone in patients with ischaemic heart 
disease and/or peripheral arterial disease is not recommended. In the Unites States, the Federal Drug 88 
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Administration (FDA) also issues a “black box” warning stating that the drug could increase the 
risk of heart attacks.  
 
Until very recently, no adequately powered randomised cardiovascular morbidity and mortality trial 
evaluating  rosiglitazone  has  been  published.  The  largest  randomised  examining  the  effects  of 
rosiglitazone on cardiovascular morbidity and mortality has now been published (Home et al 2009). 
Rosiglitazone  Evaluated  for  Cardiac  Outcomes  and  Regulation  of  Glycaemia  in  Diabetes 
(RECORD). The results of the trial were largely consistent with those of a non pre-specified interim 
analysis published in 2007 (Home et al 2007). In the trial's 4447 patients with type 2 diabetes, who 
were  randomized  to  receive  either  rosiglitazone  on  top  of  either  metformin  or  sulphonylurea 
(n=2220)  or  a  metformin  and  sulphonylurea  combination  (n=2227),  the  rate  of  cardiovascular 
hospitalisation or death from cardiovascular causes was 14.5% in both groups over a mean follow-
up of 5.5 years. The rosiglitazone versus active control hazard ratio (HR) for that primary end point 
met  RECORD's  prospectively  stated  criteria  for  non-inferiority.  There  were  no  significant 
differences  between  the  groups  in  risk  of  the  individual  end  points  of  cardiovascular  death, 
myocardial infarction, or stroke, although the HR for myocardial infarction was elevated by a non 
significant 14% in the rosiglitazone group.  
 
As previously documented in the PROactive study, there was increase in the incidence of heart 
failure with a HR of 2.10 (1.35–3.27, p=0.001). This data were supported in a recent meta-analysis 
that reported that TZDs increased the risk of developing heart failure (relative risk, 1.72, P=0.002) 
(Lago et al 2007). It was, however, acknowledged that the RECORD study had limited statistical 
power for individual components of the primary end point because it was not designed to address 
these questions. In addition, the risk of any bone fracture was increased with rosiglitazone by 57% 
(p<0.0001) overall and by 82% in women and 23% in men. The authors stated the rosiglitazone is 89 
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not recommended for patients with a history of heart failure or with previous problems that might 
have  led  to  myocardial  dysfunction  and  recommended  that  rosiglitazone  should  be  used  with 
caution in women at high risk of fractures. They also acknowledged that although the evidence was 
insufficient to rule out a small increased risk of myocardial infarction caused by rosiglitazone when 
compared with other glucose-lowering agents, rosiglitazone does not increase overall cardiovascular 
morbidity or mortality. It is clear that the molecular mechanisms by which rosiglitazone and other 
thiazolidinediones have their effects on the cardiovascular system are complex and it remains to be 
seen  if  either  the  EMEA  or  the  FDA  review  their  position  on  the  cardiovascular  safety  of 
rosiglitazone following the publication of the RECORD data. 
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1.8 Objectives 
Biguanides and thiazolidinediones are widely used in the treatment of Type 2 diabetes but the site 
and precise mode of their action remain uncertain. The prevalence of Type 2 diabetes is reaching 
epidemic proportions and there is a growing need for new therapeutic targets. AMPK is a novel 
therapeutic target and the development of specific tissue specific AMPK activators is an attractive 
prospect for the future. The aims of this thesis are: 
 
i.  To  determine  if  metformin  improves  vascular  endothelial  function  in 
association with lower circulating concentrations of ADMA.  
ii.  To determine if metformin exerts beneficial metabolic effects in patients with 
T2DM in association with altered AMPK activity in human adipose. 
iii.  To  determine  if  insulin  sensitizers  such  as  metformin  and  the 
thiazolidinediones,  acting  directly  on  vascular  endothelial  cells,  increase  NO 
production by increasing AMPK activity thus accounting for beneficial effects 
on endothelial function and, in metformin’s, case cardiovascular outcome. 
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Chapter 2 Materials and Methods 
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2.1 Materials 
All  reagents  used  were  of  the  highest  quality  available  and  were  obtained  from  the  following 
suppliers: 
 
2.1.1 General Reagents 
Acros Organics, Loughborough, Leicestershire, UK 
Glacial acetic acid (nitrogen flushed) 
Sodium iodide (nitrogen flushed) 
Sodium nitrite 
 
Amersham Biosciences, Little Chalfont, Buckinghamshire, UK 
Amersham ECL Western Blotting detection kit 
Protein G Sepharose  
 
Axxora UK Ltd, Nottingham, UK 
GW9662  
 
BDH Laboratory Supplies, Poole, Dorset, UK 
Calcium chloride 
Coomassie Brilliant Blue G -250 
Disodium hydrogen phosphate 
Magnesium sulphate 
Orthophosphoric acid 
Potassium chloride 
Sodium dihydrogen orthophosphate 93 
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Sodium dodecyl sulphate (SDS) 
Sodium pyrophosphate 
 
Calbiochem, Beeston, Nottingham, UK 
A23187 (from Streptomyces chartreusensis) 
 
Fisher Scientific, Loughborough, Leicestershire, UK 
Dimethylsulphoxide (DMSO) 
Ethanol 
D-Glucose 
Glycine 
4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid (HEPES) 
Methanol 
Potassium dihydrogen phosphate 
Tris (hydroxymethyl) -aminothane (Tris base) 
 
GlaxoSmithkline Stevenage, UK 
Rosiglitazone was a generous gift from Dr Phil Amberry 
 
Melford Laboratories Ltd, Chelsworth Ipswich, UK 
Dithiothreitol (DTT) 
 
National Diagnostics, Hull, UK 
Ecoscint™ A scintillation solution 
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Riedel de Häen, Seelze, German 
Ammonium persulphate 
Ethylenediamine tetraacetic acid (EDTA) 
Glycerol 
Sodium hydrogen carbonate 
 
Schleicher & Schuell, Brunswick Way, London, UK. 
Protran Nitrocellulose membrane 
Whatman 3MM Filter paper 
Whatman P-81 phosphocellulose paper 
 
Severn Biotech Ltd., Kidderminster, Worcestershire, UK 
30% (w/v) Acrylamide (Acrylamide to Bis-Acrylamide ratio 19:1) 
 
Sigma-Aldrich Chemical Company Ltd., Poole, Dorset, UK 
Adenosine 5’-triphosphate (ATP) 
L-arginine 
Benzamidine 
Bovine serum albumin (BSA) 
Brij-35 
Bromophenol blue 
Caesium chloride 
Ethylene glycol-bis (a -aminoethylether)-N,N,N’,N’-tetra acetic acid (EGTA) 
D-Mannitol 
NG-Nitro-L-Arginine Methyl Ester (L-NAME) 95 
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N,N,N’,N’,-tetramethylethylenediamine (TEMED) 
Oxypurinol 
Phenylmethylsolfonyl fluoride (PMSF) 
Sodium chloride 
Sodium fluoride 
Sodium orthovanadate 
1:1 tri-n-octylamine 
Triton X-100 
Trypsin inhibitor, from soyabean (SBTI) 
Tween 20 
Wortmannin 
Metformin 
Phenformin 
 
2.1.2 Antibodies 
The following antibodies were used in this study, with the conditions used for immunoblotting 
included. 
 
Cell Signalling Technology, Hitchin, Hertfordshire, UK. 
 
Anti-phospho-AMPKα (Thr172),  catalogue  number 2531. A rabbit polyclonal antibody raised 
against a synthetic phospho-peptide (KLH-coupled) corresponding to residues surrounding Thr172 
of  human  AMPK-α.  The  antibody  detects  levels  of  both  human  α-1  and  α-2  isoforms  of  the 
catalytic subunit (diluted 1: 1000 in 5% w/v BSA, incubated at 4°C overnight). 
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Anti-phospho-Acetyl-CoA  carboxylase  (Ser 80), catalogue number 3661. A rabbit polyclonal 
antibody  raised  against  a  synthetic  phospho-peptide  (KLH-coupled)  corresponding  to  residues 
surrounding Ser80 of human Acetyl CoA carboxylase (diluted 1: 500 in 5% w/v milk powder 
solution, incubated at 4°C overnight). 
 
Anti-phospho-eNOS  (Ser1177),  catalogue  number  9571.  A  rabbit  polyclonal  antibody  raised 
against a synthetic phospho-peptide (KLH-coupled) corresponding to residues surrounding Ser1177 
of human eNOS, (diluted 1: 1000 in 5% w/v BSA, incubated at 4°C overnight).  
 
Sigma-Aldrich Chemical Company Ltd., Poole, Dorset, UK 
 
Anti-Endothelial  Nitric  Oxide  Synthase,  catalogue  number  N2643.  A  rabbit  antibody  raised 
against a synthetic peptide (KLH-coupled) corresponding to amino acids 596-609 of the bovine 
eNOS sequence. The immunogenic sequence is identical to the human eNOS sequence, (diluted 1: 
5000 in 1% w/v BSA, incubated at 4°C overnight). 
 
Upstate Cell Signaling Solutions, Lake Placid, New York. 
 
Anti-PKBα, catalogue number 07-416. A rabbit polyclonal antibody raised against a 15 residue 
synthetic peptide (C -RPHFPQFSYSASGTA) corresponding to the C-terminal residues (466-480) 
of rat PKBα (this sequence is strongly conserved in humans). The antibody has species cross-
reactivity with human PKBα, (diluted 1: 1000 in 5% w/v BSA, incubated at 4°C overnight). 
 97 
 
97 
 
Anti-phospho-eNOS  (Thr495),  catalogue  number  07-384.  A  rabbit  antibody  raised  against  a 
synthetic phosphopeptide (KLH-coupled) corresponding to amino acids 489-501 
 
Sheep subunit isoform specific anti-AMPKα α α α1 and anti-AMPKα α α α2 antibodies were a generous 
gift from Prof Grahame Hardie, University of Dundee, and have been described previously (Woods 
et al., 1996), (diluted 1: 1000 in 5% w/v milk powder solution, incubated at 4°C overnight) 
 
2.1.3 Radioactive materials 
Amersham Pharmacia Biotech, Little Chalfont, Buckinghamshire, UK 
[γ-
32P] adenosine 5’-triphosphate 
 
2.1.4 Peptides 
SAMS peptide (HMRSAMSGLHLVKRR) was purchased from Pepceuticals Ltd, 
Nottingham, UK. 
 
2.1.5 Adenoviruses 
Control  and  dominant  negative  AMPK  adenovirus  (Ad.α1-DN)
  were  a  generous  gift  from  Dr 
Fabienne Foufelle, Paris, France and have been described previously (Morrow et al., 2003).  
 
2.1.6 Cell Culture Plastics 
Corning, NY, USA 
Costar® 25ml, 10ml, 5ml, 1ml sterile pipettes 
75cm
2 tissue culture flasks 
150cm
2 tissue culture flasks 
Falcon, Becton Dickinson Labware, Franklin Lakes, NJ, USA 98 
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6-well tissue culture plates 
12-well tissue culture plates 
100mm tissue culture plates 
 
2.1.7 General Buffers 
 
ECL reagent protocol: Solution a: 0.1M Tris-HCl (pH 8.5), 2.5mM Luminol, 80nM Coumaric 
acid. Solution b: 0.1M Tris-HCl (pH 8.5), 0.06% (v/v) hydrogen peroxide. 
 
Electrode buffer: 25mM Tris, 192mM glycine, 0.1% (w/v) SDS 
 
HEPES-Brij buffer: 50mM HEPES-NaOH, pH 7.4, 1mM DTT, 0.02% (v/v) Brij 35 
 
IP buffer: 50mM Tris -HCl, pH 7.4 at 4°C, 150 mM NaCl, 1% (v/v) Triton X-100, 1% (v/v) 
glycerol,  50mM  NaF,  5mM  Na4P2O7,  1mM  Na3VO4,  1mM  EDTA,  1mM  EGTA,  1mM  DTT, 
Complete protease inhibitor cocktail. 
 
KRH buffer: 119mM NaCl, 20mM Hepes-NaOH pH 7.4, 5mM NaHCO3, 4.8mM KCl, 2.5mM 
CaCl2, 1.2mM MgSO4, 5mM Glucose, 1.2mM, NaH2PO4, 0.1mM arginine 
 
Wire Myography buffer (KPSS): 118.4mM KCl, 1.2mM MgSO4, 24.9mM NaHCO3, 2.5mM  
CaCl2, 11.1mM glucose, 0.023mM EDTA pH 7.4. 
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Lysis  buffer:  50mM  Tris  -HCl  pH7.4  at  4°C,  50mM  NaF,  1%  (v/v)  Triton  X-100,  250mM 
mannitol,  1mM  Na4P2O7,  1mM  Na3VO4,  1mM  EDTA,  1mM  EGTA,  1mM  DTT,  Complete 
protease inhibitor cocktail. 
 
Biopsy collection buffer (PSS): 118.4mM NaCl, 4.7mM KCl, 1.2mM MgSO4, 24.9mM NaHCO3, 
2.5mM CaCl2, 11.1mM glucose, 0.023mM EDTA pH 7.4. 
TBS: 20mM Tris-HCl pH 7.4, 137 mM NaCl 
 
TBST: 20mM Tris-HCl pH 7.4, 137 mM NaCl, 0.1% (v/v) Tween-20 
 
Transfer Buffer: 25mM Tris, 192mM glycine, 20% (v/v) methanol 
 
4 x sample buffer: 200mM Tris-HCl (pH 6.8), 400mM DTT, 8% (w/v) SDS, 0.4% 
(w/v) bromophenol blue, 40% (v/v) glycerol 
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2.2 Methods 
 
2.2.1 Identification and recruitment of subjects 
Twenty men with Type 2 diabetes (duration > 6 months) were recruited from Diabetes Clinics of 
the North Glasgow University National Health Service Trusts. North Glasgow University Hospitals 
National  Health  Service  Trust  ethics  committee  approved  the  study.  After  full  explanation  of 
experimental  procedures  aided  by  a  subject  information  sheet,  written  informed  consent  was 
obtained. Each subject was issued with details of the study as well as the investigators’ contact 
telephone numbers. The subject’s General Practitioner was informed of their involvement in the 
study. The inclusion and exclusion criteria for the study are outlined below:  
 
Inclusion criteria:  
BMI range 27-40 kg/m
2 
HbA1c > 7%, <11% (DCCT) at screening 
Previously treated with diet alone or oral monotherapy (i.e. metformin or sulphonylurea). Subjects 
on monotherapy had discontinued medication during the six-week run-in period 
 
Exclusion criteria:  
Subjects on warfarin treatment 
Subjects treated with insulin currently or in the previous 12 months 
Previous intolerance of metformin or sulphonylurea 
Presence of contra-indication to metformin therapy for example renal disease or congestive cardiac 
failure 
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2.2.2 Study protocol    
 
2.2.2.1 Study design 
The study had a randomised, double blind, glycaemia-controlled crossover design (Figure 2.1). 
Patients  on  monotherapy  discontinued  medication  during  a  six-week  run-in  period.  After  this 
period, patients were randomised to receive metformin (500mg three times daily) or gliclazide 
(80mg twice daily with a lunchtime placebo capsule to ensure blinding) for ten weeks, aiming for a 
similar reduction in HbA1c. Each drug had a two week dose titration as follows:  
 
Week 1: Gliclazide 80mg once daily with breakfast, metformin 500mg once daily with breakfast. 
 
Week 2: Gliclazide 80mg once daily with breakfast + dummy capsule at lunch, metformin 500mg 
twice daily with breakfast and lunch. 
 
Week 3 – 10: Gliclazide 80mg twice daily at breakfast and evening meal + dummy capsule at 
lunch, metformin 500mg three times daily with breakfast, lunch and evening meal. 
 
Subjects were asked to inform the investigators of any medication started or discontinued during 
the study period. No specific advice on lifestyle was given at the time of randomisation.  
 
Study randomisation 
Randomisation  and  tablet  supply  was  co-ordinated  by  the  hospital  pharmacy.  Metformin  and 
gliclazide capsules of identical appearance were manufactured by the Western Infirmary pharmacy, 
Glasgow. A computerised
 randomisation list was made. Randomisation codes were put into
 sealed 
envelopes and stored by the pharmacist of the Western Infirmary, Glasgow. Medication bottles 102 
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were numbered, and allocation
 was done in sequence. Unblinding was performed at the end of the
 
study period. 
 
Subject visits 
The  study  required  subjects  to  attend  the  Clinical  Investigation  and  Research  Unit  (CIRU), 
Division of Cardiovascular Sciences, Western Infirmary, University of Glasgow on a total of nine 
occasions: 
 
Week 0 - Screening visit 
Week 1 - Start of phase 1 
Week 5 - Interim visit 
Week 10 - End of phase 1 (with biopsy) 
Week 12 - Stitch removal 
Week 16 - Start of phase 2 
Week 21 - Interim visit 
Week 26 - End of phase 2 (with biopsy) 
Week 28 - Stitch removal 
 
Patients were contacted by telephone at two weeks and attended the CIRU for a brief assessment at 
five weeks during each phase to check on any side effects and to assess glycaemic control. Any 
patient with significant osmotic symptoms or a fasting blood glucose of >15mM would have been 
withdrawn from the study. Patients were then required to attend the CIRU at 0830hrs at the end of 
the ten week study phase having fasted from midnight (and having abstained from alcohol, caffeine 
and moderate/heavy exercise in the preceding 72 hours) for clinical measures, adipose biopsy and 
blood sampling for biochemical analysis. Taxis were available to transfer volunteers to and from 103 
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the CIRU. Snacks were provided at the CIRU when the study protocol was completed. Following a 
six-week washout phase, the groups were crossed over (Figure 2.1).  
6 weeks 10 weeks 10 weeks 6 weeks
washout
metformin 500mg TDS metformin 500mg TDS
gliclazide 80mg BD gliclazide 80mg BD
Clinical measures
Blood sampling
Clinical measures
Blood sampling
 
Figure 2.1: Crossover design 
 
2.2.2.2 Clinical and morphometric measurements 
 
2.2.2.2.1 Body mass index 
Body weight was measured using
 analogue scales (Seca, Germany) to within 1kg in light clothing 
without shoes.
 The weighing scales were calibrated regularly. Height was measured barefoot using 
a stadiometer to within 0.5
 cm. BMI was calculated as follows: weight (kg)/height(m)
2.  
 
2.2.2.2.2 Blood pressure 
Blood pressure recordings were taken by a semiautomatic sphygmomanometer (Dinamap Critikon, 
Johnson and Johnson Professional Products Ltd,
 Bracknell, UK) at screening and the end of each 104 
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ten  week  phase.  Readings  were  taken  supine  after  thirty  minutes  rest.  The  average  of  3 
measurements was calculated.  
 
2.2.2.3 Clinical procedures 
 
2.2.2.3.1 Buttock biopsy 
Subjects were invited to attend the CIRU at 0830, having fasted from midnight. With the subject 
lying prone, one buttock was exposed and the area sterilised with 10% (v/v) iodine. A strict aseptic 
technique was employed. 1% lignocaine hydrochloride was then instilled subcutaneously to cover 
an area of 6cm x 4cm. Once the area was anaesthetised, an elliptical incision was made in the 
buttock and a 3cm x 0.75 cm segment of skin and a diamond shaped segment of adipose tissue was 
removed. A 2g portion of adipose tissue was cut from the margin of the specimen, snap frozen in 
liquid nitrogen and stored at –70
oC. Four skin stitches were then inserted to close the wound. The 
volunteer  was  then  given  a  light  meal  and  asked  to  refrain  from  exertion  for  five days while 
keeping the wound clean. Ten days later the stitches were removed. 
 
2.2.2.3.2 Analysis of routine blood samples  
Fasting  venous  blood  samples  for  urea,  creatinine,  electrolytes,  total  cholesterol,  triglycerides, 
HDL-cholesterol,  LDL-cholesterol,  glucose,  liver  function  tests  and  HbA1C  were  collected  
between  0830hrs  and  0930hrs  from  the  antecubital  fossa  and  placed  immediately  into  the 
appropriate containers. Patients were in a recombinant position for at least ten minutes prior to the 
procedure. The samples were then analysed as routine samples in the Biochemistry Department, 
Gartnavel General Hospital, Glasgow.  
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2.2.2.3.3 Analysis of non-routine blood samples 
Venous blood was collected between 0830hrs and 0930hrs into EDTA-containing tubes, centrifuged 
(500 x g, 4
oC) and plasma removed into microcentrifuge tubes and stored at -70
oC until analysis. 
Total  adiponectin  was  determined
  using  ELISA  (R&D  Systems,  Abingdon,  UK).  Plasma 
concentrations of ADMA and related arginine metabolites were measured using an optimized and 
fully validated HPLC method, based on that previously described (Teerlink 2005), with certain 
modifications  as  recently  described  (Blackwell  et  al  2007).  All  assays  were  performed  at  the 
Biochemistry  department  at  Glasgow  Royal  Infirmary  under  the  direction  of  Professor  Naveed 
Sattar.  
 
2.2.2.3.4 Pulse wave velocity (PWV) 
A relatively simple and direct measure of arterial stiffness, PWV is determined by measurement of 
the time taken for the pulse wave to traverse the distance between two fixed measuring points. The 
PWV is therefore derived as: 
 
distance [m] / time [s], in m/s.  
 
There are a number of potential confounding factors to be considered when measuring the PWV. 
The measurement required is of the velocity of the forward wave, and reflected waves may interfere 
with the accuracy of the calculation. Measurements must therefore be taken from the foot of the 
waveform (the upstroke of the pressure wave), which is generated entirely by the forward wave. 
Another  potential  problem  is  the  accuracy  of  measurement  of  the  distance  between  measuring 
points. Out of necessity, the measurement (using standard techniques) is an approximation of the 
actual distance, as the actual length of the artery cannot be measured. This particular problem is 
addressed with new techniques for the measurement of PWV, using magnetic resonance imaging 106 
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(MRI)  (Mohiaddin  et  al  1993  and  MacGowan  et  al  2002).  Such  techniques  may  become  less 
constrained by time, expense and portability in the future and therefore more widely useable. A 
simple and well-established method of measurement of the PWV is to use a semi-automated device 
for  analysis  of  the  pressure  waveforms  at  the  two  measurement  sites  (Asmar  et  al  1995).  The 
upstroke of the wave is identified at each of these sites, and the time between the two upstroke 
points is measured. Once the distance between measuring points has been identified and entered, the 
velocity of the pulse wave is calculable by the software.  
 
An advantage of this method of PWV measurement over some of the available derived techniques 
(in which different pulse waves are measured at the same relative point in the cardiac cycle using 
ECG gating of data acquisition) is that the pressure waves measured at each point stem from the 
same  ventricular  systolic  contraction.  This  eliminates  potential  errors  arising  from  beat-to-beat 
variability of cardiac output and consequent variability of the pulse wave morphology. This directly 
observed method of PWV measurement has been used to demonstrate that an increase in PWV is 
observed in subjects with hypertension (Blacher et al 1991, Asmar et al 2001), polycystic ovary 
syndrome (Kelly et al 2002), diabetes (Lehmann et al 1992), atherosclerosis (Wada et al 1994), 
end-stage renal failure (London et al 2000) the elderly (Meaume et al 2001) and even acutely after 
smoking a single cigarette (Mahmud et al 2003).  
 
In this thesis pulse wave velocity was assessed by using SphygmoCor which uses the principle of 
applanation tonometry to record the pulse waveform at radial and carotid sites. This technique is 
non-invasive and extremely well tolerated. Total duration of the PWV protocol is around 20-30 
minutes and it was performed after each ten week phase of treatment in a temperature controlled 
room at 23
OC. A minimum of three readings were taken on each study day. After allowing the 
volunteer to rest prone for 15 minutes, a highly-sensitive TY-306 pressure transducer (Fukuda Co, 107 
 
107 
 
Tokyo, Japan) was applied lightly to the radial artery, enough to flatten the arterial wall but not to 
occlude blood flow. A stable pressure flow waveform was sampled for 10 seconds. Brachial artery 
blood pressure was measured concurrently by a semi-automated oscillometric device. An aortic 
waveform was then generated using validated transfer functions. By combining measurement of 
waveforms from carotid and femoral sites in conjunction with ECG input and a measurement of the 
distance between the two sites, pulse wave velocity can also be calculated. PWV was calculated by 
an automated device from the measurement of the pulse transit time and the distance between the 
two recordings sites at the carotid and femoral arteries [PWV = distance(m)/transit time(s)] 
 
2.2.2.4 Laboratory procedures  
 
2.2.2.4.1 Wire myography 
 
2.2.2.4.1.1 Introduction 
A  technique  for  the  investigation  of  the  properties  of  small  arteries  with  diameters  down  to 
approximately 100 µm was first suggested in 1972 by Bevan and Osher (Bevan and Osher 1972). 
This technique was developed by Mulvany and Halpern, with the method for investigation of a 
single vessel of diameter 100 – 1000 µm being published in 1977 (Mulvany and Halpern 1977). 
Over subsequent years this technique has been developed to allow investigation of initially two, and 
then four vessels simultaneously. This technique allows small vessels to be mounted as cylinder or 
ring preparations, using a relatively atraumatic technique to preserve vascular endothelial functional 
integrity. The technique allows measurement of isometric responses (Mulvany 1999, Angus 2000) 
and is termed Mulvany-Halpern (wire) myography.  
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2.2.2.4.1.2 Preparation of arteries  
A  single  investigator,  Angela  Spiers,  was  blinded  to  treatment  allocation,
  and  undertook  all 
myography studies. After the gluteal biopsy was dissected it was placed immediately in biopsy 
collection buffer (PSS) prewarmed to 37
oC and transported to the laboratory. In the myography 
laboratory, resistance arteries were dissected from the biopsy. Where possible, four segments of 
artery, (200-400 µm diameter and 2mm in length) were mounted as ring preparations on two 40 
µm  stainless  steel  wires  in  a  four-channel  small  vessel  myograph.    (Danish  MyoTechnology, 
Aarhus, Denmark). One wire was attached to an isometric force transducer and the other to a 
movable micrometer. The vessels were then bathed twice in a physiological salt solution, KPSS 
(PSS  solution  with  KCL  substituted  for  NaCl  on  an  equimolar  basis).  The  temperature  was 
maintained at 37
 oC, and pH maintained at 7.4, with a gas mixture of 5% (v/v) CO2 and 95%(v/v) 
O2 being bubbled throughout the experiment.  
 
2.2.2.4.1.3 Normalization of vessels  
Following  a  rest  period  of  30  minutes,  each  artery  was  stretched  at  one  minute  intervals  to 
determine the resting tension-internal circumference (L) relationship. The La Place equation P=T/r 
(P is the effective pressure, T is the wall tension and r is the internal radius), was used to determine 
L100. This is the calculated internal diameter of the vessel would have in vivo when relaxed and 
subjected to a transmural pressure of 100mmHg (13.3Kpa). To achieve optimal contraction, each 
vessel was then set to the normalised internal diameter L1 = 0.9L100.  
 
2.2.2.4.1.4 Wire myography protocol 
Small vessel myography is now an established technique used
 in the measurement of small vessel 
contractility  and  relaxation,
  particularly  in  response  to  vasoactive  agents.  The  measurement
  of 
insulin-mediated vasorelaxation by assessing its effect on
 NE-induced vasoconstriction has been 109 
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described  previously  by
  our  own  and  other  groups.
  Following  the  normalisation  procedure 
described above, the vessels were maintained in physiological salt solution (PSS) at 37
oC for a 
further  60  minutes.  The  vessels  were  then  exposed  twice  to  KPSS  (PSS  solution  with  KCL 
substituted for NaCl on an equimolar basis). Vessels were subsequently incubated in PSS for 30 
min (washout) before a cumulative concentration response curve (CRC) to norepinephrine (NE) 
from 10
-9 M to 3x10
-5 M was obtained.  After a further 30 min washout, a plateau contraction was 
obtained with 10
-5µM NE before a CRC to acetylcholine (ACh) from 10
-9 M to 3 x 10
-5 M was 
performed. In this manner, a quantitative assessment of endothelium-dependent vasodilation can be 
obtained.  Studies  in  our  laboratory  have  previously  shown  that  insulin  causes  relaxation  of 
resistance arteries, and that this is attenuated in vessels from insulin resistant subjects (Kelly et al 
2002). Accordingly, CRC to NE was repeated following incubation with insulin (1nM, 1h). Finally 
vessels  were  pre-incubated  with  insulin  as  before  with  the  addition  of  1mM  L-NMMA  to  all 
vessels. A final concentration curve to NE was then obtained. 
 
2.2.2.4.1.5 Wire myography analyses 
In this thesis, one parameter was used to compare myography data between phases. Responses are 
expressed as a vessel contraction response, the change in active effective pressure (kPa), calculated 
as change in isometric tension from resting divided by the normalised internal radius, pD2 (which is 
the negative logEC50 of the concentration of agonist (norepinephrine) required to produce 50% of 
the maximal contractile response for 1uM norepinephrine). 
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2.2.2.4.2 Cell culture 
 
2.2.4.2.1 Preparation of HAEC media 
HAECs  were  cultured  in  large  vessel  endothelial  cell  growth  medium  supplemented  with 
amphotericin B, gentamicin and an endothelial cell supplement (containing foetal bovine serum, 
heparin,  human  epidermal  growth  factor,  human  basic  fibroblast  growth  factor,  and 
hydrocortisone), supplied by TCS Cellworks (Boltolph Claydon, Buckinghamshire, UK). Media 
was prepared by mixing the components together and equilibrating at 37°C, 95% air and 5% CO2 in 
a humidified incubator for a minimum of 40 minutes. The final serum concentration of the media 
was 2% (v/v) and the glucose concentration was 5mM. 
 
2.2.4.2.2 Growth of HAECs 
Cryopreserved  HAECs  (approximately  500,000  cells  per  vial)  from  either  TCS  Cellworks  or 
Promocell (Heidelberg, Germany) were rapidly thawed at 37
oC and seeded into 10 x 25cm
2 flasks 
containing 4ml/flask of prepared medium. The media was changed after 24 hours, and every 48 
hours thereafter. The cells were maintained at 37°C, 95% air and 5% CO2 in a humidified incubator 
and passaged at 70% confluence. 
 
2.2.4.2.3 Passage of HAECs 
Media was discarded and replaced with 4ml/flask 0.05% (w/v) Trypsin-EDTA (InvitrogenTM). 
Flasks were returned to the humidified incubator for 1 minute, and subsequently lightly tapped to 
aid cell detachment. Complete medium (4ml) was added to the flasks and the resultant suspension 
was transferred to 50 ml centrifuge tubes. The cell suspension was centrifuged for 5min at 157g 
and  the  supernatant  discarded.  The  cells  were  resuspended  in  medium  and  distributed  equally 
between the desired number of plates or flasks. On average the cells from one confluent 75cm
2 111 
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flask were seeded into 5 x 10cm dishes. The medium was replaced 24 hours after trypsinisation, 
and every 48 hours thereafter. HAEC were utilised for experiments between passages 3 and 6. In no 
instances were cells used after passage 6. 
 
2.2.4.2.4 Quiescence of HAECs 
Cells  were  quiesced  for  3-6  hours  prior  to  experiments.  Medium  containing  no  endothelial 
supplement, gentamicin or amphotericin B was used during this time. 
 
2.2.4.2.5 Measurement of nitric oxide production in HAECs 
 
2.2.4.2.5.1 Detection of nitric oxide  
NO production was measured in cell culture media as follows. The detection of NO using the 
Sievers 280A Nitric Oxide Analyser is based on the reaction of NO  with dissolved oxygen to form 
nitrite (NO2
-) and nitrate (NO3
-) in liquid, with nitrite being the predominant product in cell culture 
systems. The Sievers 280A analyser determines the amount of NO produced from the amount of 
nitrite present in the liquid sample injected into the purge vessel. Under the reducing conditions in 
the purge vessel (see Figure 2) NO2
- is reduced to form NO. The reducing agent was prepared by 
dissolving 60mg of sodium iodide in 2ml of deionised water. This was added to 4ml of nitrogen 
flushed acetic acid in the purge vessel and nitrogen gas was bubbled through to purge the NO 
present from solution.  
 
I
- + NO2
- + 2H
+          NO + ½ I2 + H2O 
 
Figure 2.2 Nitrite is reduced to form Nitric oxide  112 
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The chemical reaction between sodium iodide and acetic acid results in reducing conditions that 
cause the reduction of nitrite (NO2
-) to NO in the liquid sample injected into the meter’s purge 
vessel.  
 
A photomultiplier measures any chemiluminescence that has resulted from the reaction of ozone 
with the NO produced in the purge vessel and produces a signal. This signal is converted to an 
electrical potential and displayed in mV by the NO analyser. The electrical potential displayed is 
related to the amount of nitrite present in the original liquid sample injected into the purge vessel. 
On each day of sample analysis a standard curve was prepared. A standard solution of 100mM 
NaNO2 stock was prepared using deionised water and serial dilutions were made to give 10nM, 
100nM, 1µM and 10µM standards. A calibration curve was generated from the amount of NO 
produced from the reduction of nitrite present in the standard solutions. HAEC culture medium of 
unknown nitrite concentration was analysed against this standard curve by computer analysis and 
the amount of NO present determined (in nM). 
 
2.2.4.2.5.2 Preparation of adenoviruses and infection of human endothelial cells 
Control  and  Dominant  negative  AMPK  adenovirus  (Ad.α1-DN)
  were  a  generous  gift  from  Dr 
Fabienne  Foufelle,  Paris,  France  and  were  propagated  and  purified  as  described  previously 
(Morrow  et  al  2003).    Human  endothelial  cells  were  infected  with  10  pfu/cell  adenovirus  in 
complete medium and the cells cultured for
 48 h prior to experimentation.  
 
2.2.4.2.5.3 Sample preparation for NO analysis 
HAECs  cultured  in  12-well  plates  were  quiesced  (section  2.2.4.2.4),  the  media  subsequently 
removed and cells incubated in 0.5 ml/well KRH buffer in a 37°C water bath for 1h. The medium 
was then removed and replaced with fresh KRH buffer (0.5 ml/well) in the presence of various 113 
 
113 
 
concentrations of test substances (metformin, phenformin and rosiglitazone). An 80µL sample was 
taken to ascertain a basal level of NO in the cell media. After incubation for various durations with 
metformin, phenformin or rosiglitazone, 80µL samples of media were removed and the amount of 
NO determined. The appropriate control experiments were performed in the presence of the eNOS 
inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME, 0.1 mM for 1 hour), calcium ionophore 
(A23187, 3 µM for 15 minutes) and insulin (1µM for 15 minutes). The dose of L-NAME used in 
all experiments is similar to the physiological plasma concentration of L-arginine (Goumas et al 
2001).  The  dose  and  duration  of  A23187  and  insulin  stimulation  was  based  on  previous 
investigations in our laboratory (Morrow et al 2003). Data is presented as L-NAME-sensitive NO 
synthesis as a percentage difference in NO between the basal and stimulated HAEC media.  
 
2.2.4.2.6 General methods 
 
2.2.4.2.6.1 HAEC lysate preparation 
HAECs cultured in 100mm dishes were quiesced for 3 - 4 hours at 37°C, 95% (v/v) air, 5% (v/v) 
CO2, in serum free medium. The medium was replaced with 5ml KRH buffer and cells placed in a 
37°C incubator for 1hour. The medium was replaced with 5 ml of fresh
 KRH buffer containing 
metformin, phenformin or rosiglitazone and incubated for various
 durations at 37°C. The medium 
was replaced with 0.5 ml of lysis buffer (see section 2.1.7). The cell extract was then scraped off 
and transferred to a microcentrifuge tube. Extracts were
 vortex-mixed and centrifuged (17530g, 
4°C, 3 minutes). The supernatants were then stored at -20°C prior to use. 
 
2.2.4.2.6.2 Adipose tissue lysate preparation 
From the gluteal adipose sample approximately 2g was snap frozen in liquid nitrogen and stored in 
–80
oC.  When all samples had been collected the samples were thawed for batch analysis. Adipose 114 
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lysates  were  prepared  as  follows.  0.5ml  of  lysis  buffer  (section  2.1.7.)  was  added  to  each 
microcentrifuge  tube  and  then  the  tissue  was  homogenised  by  20  passes  with  a  Dounce 
homogeniser.  Homogenates  were  then  centrifuged  at  805g at 4
oC for 5 minutes. The resulting 
infranatant was aspirated and stored at –80
o prior to use. The resultant supernatant and pellet was 
discarded.  
 
2.2.4.2.6.3 Gel electrophoresis 
Endothelial  cell  lysates  were  resolved  on  sodium  dodecyl  sulphate  (SDS)/polyacrylamide  gel 
electrophoresis (SDS-PAGE), carried out using the Bio-Rad mini-protean II system. The resolving 
gel consisted of approximately 10% acrylamide (percentage can vary depending on the molecular 
mass of the protein under study), 375mM Tris - HCl (pH 8.8), 0.1% (w/v) SDS, polymerised with 
0.1% (w/v) ammonium persulphate and 0.05% (v/v) TEMED. The stacking gel consisted of 5% 
acrylamide,  125mM  Tris  -  HCl  (pH  6.8),  0.1%  (w/v)  SDS,  polymerised  with  0.1%  (w/v) 
ammonium persulphate and 0.05% (v/v) TEMED. Lysate samples were mixed with 4 x sample 
buffer, and heated at 95°C for 5 minutes. Samples were loaded into the wells in the stacking gel. 
Broad range pre-stained molecular weight markers (15µl, New England Biolabs) were added to a 
minimum of one well. Gels were immersed in electrode buffer and proteins were resolved using a 
potential  difference  of  80V  through  the  gel.  Once  the protein samples had passed through the 
stacking gel a constant voltage of 100V - 150V was applied (generally 120V). 
 
2.2.4.2.6.4 Immunoblotting 
After gel electrophoresis, proteins were transferred to nitrocellulose using the Bio-Rad trans-blot 
apparatus. Nitrocellulose and Whatmann 3MM filter paper was cut to size using scissors and a ruler 
and then equilibrated in transfer buffer. The gel was laid on the nitrocellulose and sandwiched 115 
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between 2 sheets of filter paper and 2 sponges. This was placed in a transfer cassette and transfer of 
proteins was carried out at 400mA for 2 hours or 40mA overnight in a transfer tank.  
 
2.2.4.2.6.5 Immunodetection of proteins 
Nitrocellulose membrane was incubated with TBST containing 5% (w/v) non-fat milk powder, for 
1 hour at room temperature to block non-specific binding sites. The membrane was washed 3 times 
over 15 minutes with TBST before the primary antibody was added. The concentration of primary 
antibody  was  determined  by  the  manufacturer’s  data  sheet  and  was  diluted  to  the  required 
concentration in TBST containing either milk powder or BSA. The nitrocellulose was incubated 
with shaking with the antibody as determined by manufacturer data sheet but typically this was at 
4°C overnight. After the incubation with primary antibody was completed, the nitrocellulose was 
washed 3 times with TBST and the nitrocellulose incubated with secondary antibody for at least 1 
hour. The secondary antibody used were species specific and HRP-linked raised to the (tail) Fc-
region  of  the  primary  antibody  IgG  molecule,  and  were  used  at  a  1:2000  dilution  in  TBST 
containing  5%  (w/v)  non-fat  milk  powder.  After  incubation  with  the  secondary  antibody  was 
completed,  the  nitrocellulose  was  again  washed  3  times  with  TBST  and  twice  with  TBS. 
Immunolabelled proteins were visualised using the ECL (enhanced chemico-luminescence, section 
2.1.7) system. Solution 1 (2ml) was added to solution 2 (2ml), mixed, and incubated with the 
nitrocellulose  for  1  minute.  The  nitrocellulose  was  exposed  to  film  in  an  X-ray  cassette  and 
developed using a Kodak X-Omat S film processor. The films were then underwent densitometric 
analysis using NIH image software (Scion Image).  
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2.2.4.2.6.6 Immunoprecipitation of AMPK from lysates 
AMPK was immunoprecipitated from endothelial cell and adipose tissue lysates using isoform-
specific anti-AMPK antibodies. AMPKα1 and α2 subunit) antibodies (2µg / lysate) was pre-bound 
to 10µl per sample of 25% (w/v) protein G Sepharose in IP buffer (section 2.1.7) by incubation for 
1 h at 4 °C on a roller mixer. The mixture was then centrifuged (17530g 1min; 4 °C) and the bead 
were washed with 5 x 1 ml of IP buffer prior to the addition of the lysate (100µg). Beads and lysate 
were incubated together for 2 hours at 4°C. Beads were again washed 2 times in IP buffer and 2 
times with high salt IP buffer (containing 1M NaCl ) then a final wash with HEPES-Brij assay 
buffer. All washes were at 4°C. The final pellet was then resuspended in HEPES-Brij assay buffer 
to be assayed for AMPK activity. 
 
2.2.4.2.6.7 Preparation of Bradford Reagent and protein assays 
Protein  concentration  of  lysates  was  determined  by  the  method  of  Bradford  (Bradford  1976). 
Bradford reagent was prepared (5% [v/v] ethanol, 5.5% [v/v] phosphoric acid, 40mg/l Coomassie 
G), filtered and stored protected from light. To determine the protein concentration in lysate sample 
a 5µl aliquot of each sample was added to 95µl of sterile water and 1ml of a protein assay reagent. 
After mixing and equilibration, the absorbance was read in a spectrophotometer at a wavelength of 
595nm measured against a reference sample containing 1ml protein assay reagent and 100µl dH2O. 
A  standard  curve  of  2-6µg/ml  bovine  serum  albumin  (BSA)  was  prepared  and  the  protein 
concentration of lysates determined by comparing values to the standard curve. This was adapted 
from the method of Bradford (Bradford 1976). 
 
2.2.4.2.6.8 AMPK assays  
Cell lysates were prepared as described in section 2.2.4.2.6.1 and 2.2.4.2.6.2. AMPK activity was 
determined  as  follows.  AMPK  immunoprecipitations  were  carried  out  using  100µg  of  protein 117 
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lysate, 2µg of anti α1 AMPK antibody, and protein G sepharose beads (see section 2.2.4.2.6.6). 
Reaction mixtures (20µl) containing 5µl HEPES-Brij assay buffer, 5µl 1mM AMP in HEPES-Brij 
buffer, 5µl of 1mM SAMS peptide in HEPES-Brij buffer and 5 µl of the immunoprecipitated lysate 
(pellet) resuspended in HEPES-Brij assay buffer were prepared on ice. The reaction initiated by the 
addition of 5µl of [γ-
32P] ATP solution (1mM [γ-
32P] ATP with a specific activity in the range 
250,000 to 500,000 cpm/pmol, 25mM MgCl2). Assays were performed in triplicate including blank 
reactions  prepared  by substituting HEPES-Brij buffer for substrate peptide. After incubation at 
30°C  for  10min, 15µl of the reaction mixture was removed and spotted onto 1cm
2 squares of 
Whatmann P-81 phosphocellulose paper, and the paper dropped into 1% (v/v) phosphoric acid. The 
P-81 paper squares were washed twice with phosphoric acid and then rinsed with water and dried. 
The incorporation of 
32P into the substrate peptide was determined by immersion in 5 ml toluene-
based scintillation fluid (Ecoscint™) and liquid scintillation counting. Units of AMPK activity 
were expressed as nmol of [γ-
32P] incorporated into substrate peptide per min at 30 °C. In the case 
of adipose tissue AMPK assays experiments were performed in 4 batches of 10 lysates with AMPK 
activity determined as multiples of a protein of previously documented AMPK activity.  
 
2.2.2.5 Statistical analysis  
Analysis was performed using the Minitab statistical package. All data are expressed as standard 
error of the mean unless stated otherwise. Equivalent values from each study phase were compared 
using paired student t tests. In all cases, p<0.05 was taken as signifying conventional levels of 
statistical significance. Power calculations based on previous wire myography studies suggest that 
16 patients will be required to demonstrate a 10% change in pD2 (change of sensitivity of ACh 
dose-response curve) with 90% power (p<0.05, two-tailed). We planned to recruit 20 patients to 
allow for potential drop-out and technical difficulties with myography protocols. The crossover 118 
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study design allows us to use paired t-tests for comparison of the primary outcome measures, 
namely ex vivo resistance artery endothelial function (pD2 for ACh curves). 
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Chapter 3 
 
Studies on vascular function and plasma asymmetric dimethylarginine (ADMA) concentrations 
after metformin and gliclazide therapy in patients with Type 2 diabetes. 
 
3.1 Introduction 
Metformin is a widely used and useful hypoglycaemic agent. In the United Kingdom Prospective 
Diabetes Study (UKPDS, 1998), metformin reduced the incidence of myocardial infarction by 39% 
in comparison with conventional treatment. In addition, when the metformin group was compared 
with  a  group  treated  with  sulphonylurea  or  insulin,  there  was  a  significant  reduction  in  the 
incidence  of  stroke.  These  results  are  supported  by  a  recent  cross-sectional  study  in  which 
mortality rates were significantly reduced in patients on metformin monotherapy compared with 
sulphonylurea monotherapy (Johnson et al 2002).  
 
Despite these impressive effects, the mechanism of this vascular protective action of metformin 
remains unclear and the question that remains largely unanswered from UKPDS is why metformin 
has  beneficial  cardiovascular  effects  in  overweight  diabetic  patients?  In  some  animal  models, 
metformin appears to have a vascular action. In spontaneously hypertensive rats, metformin reduced 
blood  pressure  possibly  via  modulation  of  adrenergic  tone  (Peuler  et  al  1999).  In  addition,  in 
streptozocin-induced  diabetic  rats,  metformin  lowers  blood  pressure  and  improves  vascular 
endothelial  function  (Katakam  et  al  2000).  In  man,  metformin  does  not  alter  BP  although  BP 
responses to intravenous infusions of norepinephrine and angiotensin II were blunted
 supporting the 
concept  that  metformin  might  modulate  vascular  responsiveness  (McAuley  et  al  1997). 
Furthermore, vascular studies using metformin in T2DM have yielded conflicting data with one 
study  demonstrating  a  modest  improvement  while  another  reporting  no  change  in  vascular 120 
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endothelial function after 3 and 4 months respectively of metformin therapy versus placebo (Mather 
et al 2001, Natali et al 2004). In this chapter, we study of the effect of metformin versus gliclazide 
on  vascular  function  in  subjects  with  T2DM  using  a  randomised,  double-blind,  glycaemia 
controlled crossover design.  
 
Recent work on the cellular mechanism of metformin action has led to the suggestion that it could 
potentially  have  beneficial  vascular  actions,  possibly  by  indirect  or  by  direct  stimulation  of 
endothelial nitric oxide synthase (eNOS) activity (Davis et al 2006). This chapter investigates a 
potential mediator of metformin’s vascular action; ADMA. One way in which this metformin might 
exert  beneficial  effects  is  by  the  reduction  of  asymmetrical  dimethylarginine  (ADMA) 
concentrations. ADMA, a guanidino-substituted analogue of L-arginine, is a potent endogenous 
competitive  inhibitor  of  endothelial  nitric  oxide  (NO)  synthase  (Palm  et  al  2007).  ADMA  is 
produced  by  methylation  of  protein  bound  L-arginine  which  is  catalysed  by  protein  arginine 
methyltransferases (Palm et al 2007). The predominant mode of elimination of ADMA occurs via 
enzymatic  degradation  by  dimethylarginine  dimethylaminohydrolase  (DDAH)  to  citrulline  and 
dimethylamine  (Achan  et  al  2003).  Increased  levels  of  ADMA  reduce  NO  formation  and  are 
associated with endothelial dysfunction. Plasma levels of ADMA have been found to be increased 
in  hypercholesterolaemia  (Boger  et  al  1998),  hypertriglyceridaemia  (Lundman  et  al  2001), 
hyperhomocyst(e)inemia (Stuhlinger et al 2003), diabetes mellitus (Abbasi et al 2001), gestational 
diabetes (Mittlemayer et al 2002) and, most recently, polycystic ovary syndrome (Heutling et al 
2008).  There  is  a  close  relationship  between  concentrations  of  ADMA  and  insulin  resistance 
(Stuhlinger et al 2002). Indeed, in several prospective studies, ADMA has been noted to be an 
independent  predictor  of  cardiovascular  events  (Mittlemayer  et  al  2002,  Valkonen  et  al  2001, 
Krzyzanowska et al 2007). Metformin was reported to decrease the plasma ADMA concentrations 
in poorly controlled subjects with Type 2 diabetes in an open labelled, uncontrolled study without a 121 
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placebo arm; the fall in ADMA concentration was associated with improved fasting plasma glucose, 
although  the  study  failed  to  demonstrate  a  relationship  between  the  decrease  in  ADMA 
concentrations  and  improvement  in  glycaemic  control  (Asagami  et  al  2002).  Importantly,  no 
assessment of vascular function was made in this study. Furthermore, in a recent interesting study, a 
subgroup  of  women  with  PCOS  who  received  metformin  demonstrated  reductions  in  ADMA 
concentration independent of a reduction in BMI and fasting blood glucose (Heutling et al 2008). 
There  was  a  marginal  improvement  in  carotid  intima  media  thickness  in  favour  of  metformin 
therapy.  However,  once  again, this was also an uncontrolled study involving a small subset of 
patients without the benefit of a placebo or control arm and it is clear that more data would be 
beneficial to help confirm any metformin-induced reduction in ADMA concentration and, if so, 
whether  such  a  change  would  be  in  association  with  beneficial  effects  on  vascular  function  in 
overweight subjects with Type 2 diabetes. 
 
I  hypothesized  therefore  that  a  short  duration  of  metformin  therapy  would  improve  vascular 
endothelial function in association with a change in the circulating concentration of ADMA in 
comparison with gliclazide therapy.  
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3.2 Aims of this chapter 
This chapter was initiated to extend the observations discussed above and addressed the following 
issues.      
i.  Does  metformin  confer  benefit  in  vascular  function  when  compared  with 
gliclazide therapy?  
ii.  Are the effects of metformin on ADMA reproducible in a randomised controlled 
double-blind crossover trial? 
iii.  Does metformin have a beneficial effect on ADMA concentrations in subjects 
with Type 2 diabetes independent of changes in glycaemic control? 
 
Accordingly, this chapter compares the effect of metformin and gliclazide on plasma ADMA and 
vascular function in subjects with Type 2 diabetes using a randomised, double-blind, glycaemia 
controlled crossover design. 
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3.3 Results 
 
3.3.1 Clinical characteristics at recruitment 
At the time of recruitment; 12 subjects were on metformin monotherapy, 6 were diet controlled and 
2 were on gliclazide monotherapy. 19 subjects were on statin therapy. 17 subjects were on ACE 
inhibitor therapy. No subjects dropped out of the study. There were no reports of changes to drug 
therapy during the study period. The clinical characteristics of the 20 subjects at recruitment are 
summarised in Table 3.1. The mean (SD) age of study participants was 56.5 (3.9) years; mean (SD) 
BMI was 31.4 (4.3) kg/m
2. The mean (SD) HbA1c at recruitment was 8.3 (1.2) %. The mean (SD) 
creatinine  was  105.3  (18.8)  µmol/l.  The  mean  (SD)  duration  of  diabetes  was  3.5  (2.6)  years 
(minimum 6 months).  
 
Table 3.1: Clinical characteristics at recruitment 
 
 
 
 
 
 
 
Parameter    Mean 
 
SD 
 
Age    56.5yrs  3.9 
HbA1c    8.3%  1.2 
Creat 
 
BMI 
 
105.3 
 
31.4kg/m2 
18.8 
 
4.3 
Duration of diabetes    3.5yrs  2.6 124 
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3.3.2 Body mass index and blood pressure 
Mean BMI was not different after each period of therapy (p=0.80), (Table 3.2). There was also no 
significant  difference  in  either  systolic  blood  pressure  (p=0.906)  or  diastolic  blood  pressure 
(p=0.193, Table 3.2). 
 
Table 3.2: Clinical measures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Raw outcomes by treatment  Treatment Effect 
Outcome   
Metformin  Gliclazide 
   
Estimate  95% CI  p-value 
BMI (Kg/m
2)    31.0 (4.3)  31.0 (4.5)      -0.1  (-0.5, 0.4)  p=0.80 
SBP (mmHg)    137.2 (19.7)  137.0 (21.0)      -0.3  (-4.3, 3.8)  p=0.91 
DBP (mmHg)    72.3 (9.5)  75.0 (11.8)      2.8  (-1.2, 6.7)  p=0.19 125 
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3.3.3 Metabolic parameters 
Gliclazide therapy was more effective at lowering HbA1c than metformin [7.8% +/- 1.74 versus 
8.3% +/- 1.7, p<0.001]. This was complemented by significantly lower fasting blood glucose with 
gliclazide versus metformin therapy [10.3mM +/- 3.2 versus 12.1mM +/-, p=0.005]. Furthermore, 
average LDL cholesterol concentration was significantly lower after gliclazide therapy compared 
with metformin therapy [2.42 +/-0.74 versus 2.79 +/- 0.74, p=0.022].  There was, however, no 
significant difference in total cholesterol, HDL cholesterol or triglyceride between the two stages of 
treatment (Table 3.3).  
 
Table 3.3: Metabolic parameters  
Raw outcomes by treatment  Treatment Effect 
Outcome   
Metformin  Gliclazide 
   
Estimate  95% CI  p-value 
HbA1c (%)    8.34 (1.70)  7.82 (1.74)      0.53  (0.29, 0.76)  p<0.001 
Glucose (3.5-5.5) mM    12.1 (4.7)  10.3 (3.2)      1.8  (0.7, 2.9)  p=0.005 
Insulin (U/L)    15.6 (13.8)  14.3 (6.0)      1.3  (-4.9, 7.5)  p=0.69 
Cholesterol (mmol/l)    5.16 (1.16)  4.75 (1.59)      0.40  (-0.02, 0.78)  p=0.054 
HDL-C (mmol/l)    1.25 (0.24)  1.20 (0.24)      0.05  (-0.01, 0.11)  p=0.13 
LDL-C (mmol/l)    2.79 (0.74)  2.42 (0.73)      0.40  (0.09, 0.70)  p=0.022 
Triglycerides (mmol/l)    2.78 (3.76)  2.94 (4.80)      -0.16  (-0.70, 0.38)  p=0.58 126 
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3.3.4 ADMA and related metabolites 
ADMA was lower following metformin therapy [0.48µmol/l +/- 0.08 versus 0.50µmol/l +/- 0.07, 
p=0.019]. The raw data plot (Figure 3.1) demonstrates that 13 out of the 20 subjects had lower 
values  of  ADMA  concentrations  after  metformin,  five  had  lower  ADMA  concentrations  after 
gliclazide, and two subjects showed no difference. There was no significant difference in SDMA or 
arginine concentrations between the two treatment groups (Table 3.4). Moreover, there was no 
difference in the arginine/ADMA ratio [127.1 +/- 24.4 versus 129.6 +/- 23.94, p=0.74]. 
 
3.3.5 Pulse wave velocity 
A satisfactory number of acceptable tracings in both periods of treatment could not be obtained for 
four subjects and these data were discarded. Mean PWV for the remaining 16 subjects was not 
different after each period of therapy (p=0.40, Table 3.4).  Finally, there was also no correlation 
between metformin to gliclazide differences in ADMA and PWV, respectively (r=0.069, p=0.80), 
(Figure 3.2). 
 
Table 3.4:  PWV, ADMA and related metabolites 
 
Raw outcomes by treatment  Treatment Effect 
Outcome   
Metformin  Gliclazide 
   
Estimate  95% CI  p-value 
PWV (m/s)     7.89 (1.64)     8.12 (1.49)      -0.22  (-0.73, 0.28)  p=0.40 
ADMA (µmol/l)    0.48 (0.08)  0.50 (0.07)      -0.02  (-0.01, -0.04)  p=0.019 
SDMA (µmol/l)    0.41 (0.08)  0.42 (0.09)      -0.01  (-0.04, 0.01)  p=0.36 
HARG (µmol/l)    2.09 (0.72)  2.18 (0.62)      -0.09  (-0.34, 0.15)  p=0.46 
ARG (µmol/l)    61.6 (17.0)  65.6 (16.7)      -4.0  (-10.2, 2.2)  p=0.22 127 
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Figure 3.1: Comparison of ADMA concentrations for individual subjects (n=20) after gliclazide 
and metformin.   
 
 
 
 
 
 
The raw data plot demonstrating that 13 out of the 20 subjects had lower values of 
ADMA concentrations after metformin, five had lower ADMA concentrations after 
gliclazide, and two subjects showed no difference. Red arrows indicate those patients 
randomised to gliclazide first and blue arrows indicate those patients randomised to 
metformin first. 128 
 
128 
 
Figure 3.2: Correlation of metformin to gliclazide differences in ADMA and PWV.  
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3.3.6 Wire myography 
In total, forty biopsies (twenty subjects x 2) were performed. Twenty two biopsies successfully 
harvested vessels of a suitable diameter. Eighteen subjects had at least one successful biopsy with 
four subjects having full paired myography data. 33 vessels were successfully harvested from the 
11 subjects in the metformin phase versus 29 vessels from 7 subjects in the gliclazide phase. Four 
vessels were not successfully isolated in all cases so responses have been analysed in a paired and 
unpaired manner.  
 
3.3.6.1  Comparison  of  the  effect  of  metformin  and  gliclazide  on  norepinephrine-induced 
vasoconstriction. 
For this analysis, results were obtained from 18 subjects,
 with 4 subjects having data from both 
metformin  and  gliclazide  phases.  Each  subject  had  data  from  between  one  and  four  arteries
 
available for analysis, the mean of which was used as the CRC
 for that volunteer. Vessels from 
both groups
 displayed the characteristic sigmoid relationship to increasing
 concentrations of NE. 
There was no evidence of tachyphylaxis
 in response to NE in vessels used as controls for time of 
study, which were exposed to NE. To compare NE-induced vasoconstriction
 during metformin and 
gliclazide phases, data were analyzed
 as paired [i.e. subjects with completed myography studies 
from
 both phases: (n = 4)]
 or unpaired (i.e. including data from subjects with only one
 successful 
biopsy; n = 18). After paired analysis, there was a borderline statistically
 significant difference in 
the pD2 between phases [mean pD2 during metformin, 6.72 ± 0.17;
 pD2 during gliclazide, 6.35 ± 
0.22 (P = 0.05)]. There was, however, no statistical difference in the pD2 between phases [mean 
pD2  during  metformin,  6.49  ±  0.16;
  pD2  during  gliclazide,  6.16  ±  0.14 (P = 0.12)] following 
unpaired analysis. 
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3.3.6.2 Acetylcholine-mediated (enodothelial-dependent) vasodilation 
Both  groups  also  exhibited  similar  endothelium-dependent
  relaxation  to  Ach:  unpaired  data, 
maximum relaxation, metformin 64.9 ± 5.0% (n = 8)
 vs. gliclazide 69.6 ± 7.2% (n = 7); (P = 0.59). 
Paired data were only available for one subject. 
 
3.3.6.3 Insulin-mediated attenuation of NE-induced vasoconstriction  
 
3.3.6.3.1 Metformin phase 
Figure  3.2  demonstrates  the  effect  of  preincubation
  of  vessels  with  insulin  on  NE-mediated 
vasoconstriction  during
  the  metformin  phase.  Vessels  were  preincubated  with  insulin  [1
  nM]. 
Insulin-mediated  attenuation
  of  NE-induced  vasoconstriction  (a  right
  shift  in  the  CRC)  or  in 
maximal
 tension developed in response to NE was not demonstrated: pD2 control, 6.48 ± 0.13;
 pD2 
insulin, 6.48 ± 0.15 (P = 0.99); maximum contraction,
 97 ± 1.5% (P = 0.10 vs. control).
  
 
3.3.6.3.2 Gliclazide phase 
 
Figure  3.3  demonstrates  the  effect  of  preincubation
  of  vessels  with  insulin  on  NE-mediated 
vasoconstriction  during
  the  gliclazide  phase.  Vessels  were  preincubated  with  insulin  [1
  nM]. 
Insulin-mediated  attenuation
  of  NE-induced  vasoconstriction  (a  right
  shift  in  the  CRC)  or  in 
maximal
 tension developed in response to NE was not demonstrated: pD2 control, 6.14 ± 0.12;
 pD2 
insulin, 6.14 ± 0.13 (P = 0.94); maximum contraction:
 95 ± 1.5% (P = 0.19 vs. control). 
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Figure 3.3: NE-induced vasoconstriction in Metformin phase  
 
 
The effect of pre-incubation with insulin 1nM on NE induced vasoconstriction in human resistance 
vessels dissected during the metformin phase was examined (n=11). Insulin-mediated attenuation
 of 
NE-induced vasoconstriction (a right
 shift in the CRC) or in maximal
 tension developed in response 
to NE was not demonstrated. Error bars represent standard errors.  
 
 
 
 
 
 
 
 
 132 
 
132 
 
Figure 3.4: NE-induced vasoconstriction in Gliclazide phase 
 
 
The effect of pre-incubation with insulin 1nM on NE induced vasoconstriction in human resistance 
vessels dissected during the gliclazide phase was examined (n=7). Insulin-mediated attenuation
 of 
NE-induced  vasoconstriction  (a  right
  shift  in  the  CRC)  or  in  maximal
  tension  developed  in 
response to NE was not demonstrated. Error bars represent standard errors.  
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3.3.6.3.3 Comparison of insulin action during metformin and gliclazide phases 
To  compare  insulin-mediated  relaxation  of  NE-induced  vasoconstriction
  during  metformin  and 
gliclazide  phases  (Figure  3.4)  data  were  analyzed
  as  paired  [i.e.  subjects  with  completed 
myography studies from
 both phases: 1 nM insulin (n = 4) or unpaired (i.e. including data from 
subjects with only one
 successful biopsy; n = 18). pD2 and maximum contraction were compared 
between phases. On analysis of paired
 data, there was no significant difference in any of these 
variables
 at 1 nM insulin [pD2: metformin, 6.68 ± 0.2; gliclazide,
 6.39 ± 0.21 (P = 0.42); maximal 
contraction: metformin,
 99.5 ± 1.3%; gliclazide, 96.9 ± 1.2% (P = 0.26)]. On analysis of unpaired
 
data, there was no significant difference in any of these variables
 at 1 nM insulin [pD2: metformin, 
6.48 ± 0.13; gliclazide,
 6.12 ± 0.13 (P = 0.07); maximal contraction: metformin,
 97.3 ± 1.5%; 
gliclazide, 95.9 ± 1.4% (P = 0.49)]. 
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Figure 3.5: Comparison of metformin and gliclazide phases 
 
Insulin action, measured as pD2 in isolated human vessels, was compared between metformin and 
gliclazide phases (n=18). On analysis of unpaired
 data, there was no significant difference in pD2 
and maximum contraction between phases at 1 nM insulin. Error bar represent standard errors. 
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3.4 Discussion 
This  chapter  compared  the  effects  of  metformin  versus  gliclazide  on  large  artery  stiffness, 
resistance artery function and circulating concentrations of ADMA using a randomised, double-
blind crossover design in subjects with Type 2 diabetes. One of the main aims was to confirm or 
refute a beneficial effect of metformin on circulating ADMA concentrations in view of recent 
supportive data to this effect from uncontrolled trials. It was also hypothesised that ADMA might 
not only be a predictive marker but also a causative risk factor for cardiovascular disease and thus 
any  metformin-induced  reduction  in  ADMA  concentration  would  be  accompanied  by  an 
improvement in vascular function. The data demonstrate that metformin does indeed lower ADMA 
compared with gliclazide despite better glycaemia changes with the latter, supporting a glucose-
independent mechanism for this metformin effect.  That said, the reduction in ADMA was modest 
and  the  observed  magnitude  of  difference  contrasts  with  reports  of  much  larger  reductions  in 
ADMA concentration in uncontrolled studies of metformin therapy in women with PCOS as well 
as poorly controlled subjects with Type 2 diabetes, where the drug was added to diet control or 
sulphonylurea therapy (Abbasi et al 2001, Heutling et al 2008). Finally, the data shows that the 
change in ADMA concentration was not associated with any difference in large artery stiffness as 
measured by pulse wave velocity or resistance artery function as measured by wire myography.  
 
A  major  stimulus  for  this  study  was  the  notion  that  metformin  therapy  confers  cardiovascular 
benefit in overweight diabetic subjects when compared with sulphonylurea therapy or insulin.  It 
was  hypothesised  that  this  would  be  reflected  in  a  change  in  pulse  wave  velocity,  an  arterial 
stiffness measure which also has a vascular function component. Abnormal large artery function 
plays an important role in the development of cardiovascular disease. In the normal arterial system, 
there is a steep gradient of increasing arterial stiffness moving outward from the heart. In a young 
adult, pulse wave velocity (PWV), a close correlate of arterial wall stiffness, is only 4 to 6 m/s in 136 
 
136 
 
the highly compliant proximal aorta and increases to 8 to 10 m/s in the stiffer peripheral muscular 
arteries (Yasmin et al 2004). Carotid-femoral PWV (cfPWV) is a measure of aortic distensibility. It 
is known to predict all-cause and cardiovascular mortality in patients with end-stage renal failure, 
hypertension, diabetes and the elderly, independently of known confounding factors (Blacher et al 
1999, Laurent et al 2001, Meaume et al 2001, Cruickshank et al 2002). It was hypothesised that 
metformin therapy would lead to reduced PWV in subjects with Type 2 diabetes when compared 
with gliclazide therapy.  
 
Traditionally,  information  about  the  properties  of  small  arteries  had  to  be  inferred  from 
haemodynamic studies or visual examination of vessels of readily accessible vascular beds. Within 
the last decade techniques have become available that allow routine in vitro investigation of small 
arteries. One technique popularised through the work of Mulvany is wire myography (Mulvany et al 
1990). This involves the harvesting of small resistance arteries from adipose tissue (the buttock) and 
their mounting over two fine wires within small chambers filled with physiological salts solution 
(PSS). This allows ex vivo investigation of arterial tissue. Various agents may be added to the 
chambers  to  investigate  vascular  responses  and  these  are  measured  using  computer  software 
specially calibrated to detect small changes in vessel tone.  
 
The hypothesis tested was that metformin has similar beneficial effects on different parts of the 
vasculature; aortic compliance measured by cfPWV and endothelial function by wire myography of 
resistance  arteries.  The  results  here  have  demonstrated  that  in  subjects  with  Type  2  diabetes, 
insulin-mediated  attenuation
  of  NE-induced  vasoconstriction  (a  right
  shift  in  the  CRC)  is  not 
demonstrated. The data are insufficiently powered to detect any small changes in vascular function 
in association with this dose and duration of treatment. With this is mind, it is particularly important 
to consider the implication of the missing data set in the wire myography data; eighteen subjects had 137 
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at  least  one  successful  biopsy  with  myography  data  with  only  four  subjects  having  paired 
myography results. An absence of vessels of suitable diameter was the reason for failure to obtain 
vessels from biopsies with no myography data with the vessel yield in this study being lower than 
other wire myography studies completed by our group.    
 
The study also failed to show a significant benefit in pulse wave velocity and I need to consider 
why. In the present study subjects were not randomised to the maximum dose of each drug and the 
duration of treatment was relatively short at 10 weeks.  Whether a longer duration of each treatment 
in  higher  dose  would  have been associated with a larger change in ADMA concentration with 
measurable improvements in vascular function in favour of metformin is unknown and could be the 
subject of further study. Additionally, it is important to consider whether some of the other changes 
noted may have accounted for the variable alteration in vascular function that we noted. Recently it 
has been demonstrated that weight loss in morbidly obese patients can decrease circulating ADMA 
concentrations (Krzyanowska et al 2004). There was no significant difference in weight after each 
therapy  excluding  this  as  a  confounding factor. While metformin was associated with a fall in 
ADMA, the gliclazide arm was associated with improved glycaemic control as assessed by fasting 
blood glucose and haemoglobin A1c. The study design aimed to match glycaemic control at the end 
of each phase but this, in the event, proved not to be possible.  Associated with these changes was a 
small improvement in plasma LDL cholesterol. Thus, it is reasonable to speculate that confounding 
effects related to better short term glycaemia and LDL-cholesterol improvements with gliclazide 
may have attenuated any metformin-induced change in ADMA being associated with an associated 
beneficial  improvement  in  vascular  function.  Nevertheless,  despite  these  changes,  the  data  still 
recorded a significant reduction in ADMA with metformin, which adds some confidence to the 
validity of this latter observation.  This finding is important since increasing evidence indicates that 138 
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higher levels of ADMA are predictive of cardiovascular events independently of other risk factors 
(Krzyzanowska et al 2007, Asagami et al 2002, Heutling et al 2008).  
 
In conclusion, this chapter provides the strongest evidence thus far to support a beneficial effect of 
metformin therapy on circulating ADMA concentrations in patients with type 2 diabetes, although 
we could not confirm whether this improvement confers benefit on vascular function in subjects 
with  type  2  diabetes.    Future  studies  of  metformin  at  higher  doses  are  required  to  determine 
whether ADMA lowering by metformin improves vascular function and more importantly, whether 
such a reduction helps explain the vascular end-point benefits of this treatment in prospective 
clinical trials.  
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Chapter 4 
 
Studies on adipose AMP-activated protein kinase and plasma adiponectin after metformin and 
gliclazide therapy in patients with Type 2 diabetes. 
 
4.1 Introduction  
Activation of AMPK triggers catabolic pathways that produce energy, while turning off anabolic 
pathways that consume energy thereby maintaining cellular energy stores. For example, AMPK 
inhibits lipid and triglyceride synthesis in both liver and adipose tissue and stimulates skeletal 
muscle glucose uptake, glycolysis and fatty acid oxidation (Towler and Hardie 2007). Stimulation 
of fatty acid oxidation occurs when AMPK directly phosphorylates and inactivates the downstream 
target,  acetyl-coA  carboxylase  (ACC).  ACC  synthesizes  malonyl-CoA  which  inhibits  the  rate-
controlling step of fatty oxidation involving the transfer of fatty acids into the mitochondria by the 
enzyme carnitine palmitoyltransferase 1 (CPT1) (Trumble et al 1995, Ruderman et al 1999). The 
ability of AMPK to induce lipid oxidation and thus the amount of fat deposited in skeletal muscle 
and liver is considered an important feature of AMPK activation. Therefore it may be that AMPK 
plays an important role in controlling the whole body energy homoeostasis including the regulation 
of plasma glucose levels and body weight. The control of AMPK activity provides an attractive 
target for therapeutic intervention in metabolic disorders such as T2DM. 
 
AMPK is thought have important role in adipose tissue by inhibiting lipolysis and lipogenesis. 
Indeed, AMPK has been implicated in the regulation of lipolysis through direct phosphorylation of 
hormone-sensitive  lipase  (Garton  et  al  1989).  Lipolysis  and  lipogenesis  are  inhibited  in  rat 
adipocytes when using the AMPK activator AICAR, (Sullivan et al 1994). It is also suggested that 
when  the  regulation  of  lipid  metabolism  by  AMPK  is  absent,  then  weight  gain  and  insulin 
resistance prevail. Indeed when AMPK α2 knockout mice were fed with a high-fat diet they have 140 
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been shown to exhibit increased body weight, increased adiposity and a degree of insulin resistance 
when compared with wild-type mice (Viollet et al 2003, Jorgensen et al 2004, Villena et al 2004). 
It has also been recently shown that glucocorticoids inhibit AMPK activity in adipose tissue of 
insulin resistant patients with Cushing’s syndrome (Kola et al 2008). Moreover, metformin has 
been found to prevent the glucocorticoid effects on ex vivo cultured human adipocytes (Christ-
Crain et al 2008). The effect of insulin sensitizers such as metformin or the thiazolidinediones on 
AMPK activity in human adipose tissue has not yet been investigated. Further work is required to 
examine whether metformin exerts its beneficial metabolic effects in patients with T2DM in part by 
increasing AMPK activity in human adipose. 
 
Plasma levels of adiponectin negatively correlate to insulin resistance, obesity and cardiovascular 
disease. Interestingly, studies of the Pima Indian population in the USA have shown that in normal 
healthy  individuals  the  concentration  of  adiponectin  can  be  used  to  predict  the  likelihood  of 
developing T2DM later in life, with lower levels resulting in increased risk (Lindsay et al 2002). 
The effects of the adiponectin are partly accounted for by adiponectin induced AMPK activation 
which results in stimulation skeletal muscle fatty acid oxidation and glucose uptake (Tomas et al 
2002, Yamauchi et al 2002). Furthermore, activation of AMPK by adiponectin suppresses hepatic 
gluconeogenesis. (Yamauchi et al 2002). Adiponectin has also been demonstrated to increase nitric 
oxide production (Hattori et al 2003), by a pathway proposed to involve the direct phosphorylation 
of eNOS by AMP-activated protein kinase (AMPK), and also by a parallel pathway involving PI3K 
and PKB activation by AMPK (Chen et al 2003, Tan et al 2004, Ouchi et al 2004, Chen et al 
2005).  Furthermore,  adiponectin  has  been  shown  to  reduce  infarct  size  and  improved  left 
ventricular function and coronary blood flow following ischaemia and reperfusion of isolated rat 
hearts by a mechanism involving AMPK and NO release (Gonon et al 2008). Moreover, AMPK 
may be necessary for adiponectin to exert its cardio protective effect as ischaemia and reperfusion 141 
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caused a larger myocardial infarct and enhanced myocardial apoptosis in adiponectin knockout 
mice when compared with wild type mice (Shibata et al 2005). Adiponectin knockout mice have 
been shown to have progressive cardiac remodelling in a pressure-overloaded condition due to 
reduced AMPK signalling and increased insulin resistance when compared to wild type mice (Liao 
et al 2005). Therefore, AMPK appears to be important in mediating both the metabolic and the 
vascular effects of adiponectin but as yet the exact signalling mechanisms have not been clarified.  
 
Whilst  adiponectin  would  appear  to  have  a  preventative  role  in  atherosclerosis,  its  role  as  a 
predictive marker of vascular risk is less clear (Chen, Tsai et al 2005, Lindsay et al 2005, Schulze 
et  al  2005,  Sattar  et  al  2006,  Frystyk  et  al  2007).  Indeed,  the  addition  of  metformin  to 
sulphonylurea  therapy  has  been  shown  to  have  no  effect  on  circulating  concentrations  of 
adiponectin in subjects with Type 2 diabetes (Phillips et al 2003).  Data concerning the effects of 
sulphonylureas on adiponectin is less robust with some evidence of an increase in adiponectin 
concentration  in  both  rat  adipocytes  (Kanda  et  al  2008)  and  subjects  with  Type  2  diabetes 
(Drzewoski et al 2006). It is nevertheless tempting to hypothesise that any increase in adipose 
AMPK may be mediated by an increase in plasma adiponectin concentration  
 
Metformin has been previously shown to increase AMPK activity in hepatocytes (Zhou et al 2001) 
and  human  muscle  of  subjects  with  Type  2  diabetes  (Musi  et  al  2002),  potentially  leading  to 
improvements in both insulin sensitivity and glycaemia. In hepatocytes, AMPK activation leads to 
increased fatty acid oxidation and attenuated gluconeogenesis, fatty acid and cholesterol synthesis 
(Zhou et al 2001). In muscle, AMPK activation promotes fatty acid oxidation and glucose transport 
(Musi et al 2002). Conversely, in rat adipocytes AMPK activation has been proposed to attenuate 
both  lipolysis  and  fatty  acid  synthesis  (Sullivan  et  al  1994).  Indeed  incubation  of  3T3-L1 
adipocytes with AICAR, a pharmacological activator of AMPK, has been demonstrated to attenuate 142 
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insulin-stimulated glucose uptake, the opposite of what has been observed in skeletal muscle (Salt 
et al 2000).
 Moreover, metformin has been shown to stimulate AMPK activity, decrease lipolysis 
and inhibit fatty acid synthesis in 3T3L1 adipocytes (An et al 2007). Metformin and AICAR have 
been shown to stimulate AMPK activity but reduce adiponectin protein expression also in 3T3L1 
adipocytes (Huypens et al 2005). Previous work on AMPK has concentrated on rat adipocytes with 
work  on  human  adipocytes  or  human  adipose  tissue  confined  to  studies  of  AMPK  activity  in 
adipose tissue of subjects with corticosteroid excess and the prevention of corticosteroid-induced 
effects on AMPK in human adipocytes with metformin.  
 
If  metformin  counteracts  insulin  action  in  adipose  tissue  via  this  mechanism,  this  may  partly 
explain the common clinical observation of reduced fat mass on this drug (usually ascribed to 
appetite reduction secondary to gastrointestinal side-effects). Indeed, in many ways, metformin’s 
action parallels that of aerobic exercise, helping to divert calories away from storage tissues into 
skeletal muscle. It is possible that AMPK activation is a common mechanism utilised by both 
pharmacological and physiological interventions. Activation of AMPK in human adipose tissue 
would, therefore, be an attractive target for the treatment of T2DM and may explain some of 
metformin’s therapeutic effects.  
 
To test these hypotheses, it was vital that this thesis explored metformin’s action in human adipose 
tissue and on plasma adiponectin, an area thus far neglected in the literature.  
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4.2 Aims of this chapter 
This chapter was initiated to extend the observations discussed above and addressed the following 
issues.  
 
i.  Does metformin increase AMPK activity in adipose tissue of subjects with Type 
2 diabetes? 
ii.  Is any increase in AMPK activity associated with a change in circulating levels 
of adiponectin? 
 
Accordingly, this chapter compares the effect of metformin and gliclazide on adipose AMPK and 
plasma  adiponectin  levels  in  subjects  with  Type  2  diabetes  using  a  randomised,  double-blind, 
glycaemia controlled crossover design. 
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4.3 Results 
 
4.3.1 Adipose AMPK activity 
There was a significant increase in AMPK activity expressed as a multiple of an internal standard of 
known  AMPK  activity  (K)  with  metformin  therapy  when  compared  with  gliclazide  therapy 
[0.085+/-0.047 versus 0.044+/-0.035, p=0.002], (Table 4.1, Figure 4.1).  
 
Table 4.1: Adipose and AMPK 
Raw outcomes by treatment  Treatment Effect 
Outcome   
Metformin  Gliclazide 
   
Estimate  95% CI  p-value 
AMPK    0.085 (0.047)  0.044 (0.035)      -0.041  (-0.063, -0.019)  p=0.002 
             145 
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Figure 4.1: Gliclazide adipose AMPK activity expressed as a % of metformin treated adipose 
AMPK activity. There was a significant increase in AMPK activity expressed as a multiple of an 
internal  standard  of  known  AMPK  activity  (K)  with  metformin  therapy  when  compared  with 
gliclazide therapy (n=20). 
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4.3.2 Adipose AMPK protein expression 
There  was  no  significant  difference  in  protein  expression between the two phases of treatment 
activity (n=19, p=0.98). (See figure 4.2 where experiment was performed by Dr Ian Salt, University 
of Glasgow)  
 
Figure 4.2: Gliclazide adipose AMPK protein expression expressed as a % of metformin treated 
adipose  AMPK  protein  expression.  There  was  no  significant  difference  in  protein  expression 
between the two phases of treatment activity (n=19 due to insufficient lysate in one sample). 
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4.3.3 Serum total adiponectin concentration  
There was no significant difference in total adiponectin levels after each phase of therapy [4193 +/-
2696 versus 4648ng/ml +/- 3291ng/ml, p=0.054]. See Table 4.2, Figure 4.3. 
 
Table 4.2: Serum total adiponectin concentration 
 
 
 
 
 
 
 
 
 
 
Figure  4.3:  Gliclazide  plasma  adiponectin  concentration  expressed  as  a  %  of  metformin 
adiponectin concentration. There was no significant difference in total adiponectin levels after 
each phase of therapy (n=20).  
 
 
 
Raw outcomes by treatment  Treatment Effect 
Outcome   
Metformin  Gliclazide 
   
Estimate  95% CI  p-value 
Adiponectin    4648 (3291)  4193 (2696)      456  (22, 889)  p=0.054 
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4.4 Discussion 
This chapter compared the effects of metformin versus gliclazide on adipose AMPK activity and 
plasma adiponectin using a randomised, double-blind crossover design in subjects with Type 2 
diabetes.  The  main  aim  was  to  confirm  or  refute  a  beneficial  effect  of  metformin  on  adipose 
AMPK activity. It was also hypothesised that any increase in AMPK activity may be associated 
with  an  increase  in  plasma  adiponectin.    The  data  demonstrates  that  metformin  does  indeed 
increase adipose AMPK compared with gliclazide. The increase in adipose AMPK activity was not 
associated with an increase in AMPK protein expression. This finding suggests that the change in 
AMPK activity is an increase in the specific activity of AMPK rather than simply a difference in 
the total amount in AMPK between phases. The study design aimed to match glycaemic control 
(see 3.2.3) at the end of each phase but this, in the event, proved not to be possible. Metformin 
increased AMPK activity when compared with gliclazide despite better glycaemia changes with the 
latter,  supporting  a glucose-independent mechanism for this metformin effect. Associated with 
these  changes  was  a  small  improvement  in  plasma  LDL  cholesterol  (see  3.2.3).  Somewhat 
surprisingly, there was no significant difference in BMI (see 3.2.2) after each treatment although 
measurement of skin fold thickness or more sophisticated measurement of body composition may 
have provided a more specific marker of fat mass. Finally, the data show that the change in adipose 
AMPK activity was not associated with any difference in plasma adiponectin.  
 
In animal studies activation of AMPK has been proposed to attenuate lipolysis, fatty acid synthesis 
and insulin-stimulated glucose uptake in adipocytes (Towler and Hardie 2007). These data support 
the notion that metformin action parallels that of aerobic exercise, helping to divert calories away 
from storage tissues into skeletal muscle and it is possible that AMPK activation is a common 
mechanism utilised by both pharmacological and physiological interventions. This may explain 
some of the beneficial effects of metformin in patients with Type 2 diabetes. 149 
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It is important to consider the limitations of the data presented here. Firstly, while a robust and 
significant  difference  in  AMPK  activity  with  metformin  when  compared  with  gliclazide  is 
demonstrated it is important to note that the effect of gliclazide on AMPK activity has not been 
widely  studied.  The  principal  mechanism  of  action  of  the  sulphonylurea  class  of  drugs  is  to 
improve insulin secretion by the beta cells of the endocrine pancreas, and data concerning the 
effects of sulphonylurea on AMPK are limited. Indeed, glimepiride treatment has been shown to 
have no effect on AMPK activity in cultured myocytes as expressed by AMPK phosphorylation 
while gliclazide has no effect (up to 1 hour incubation) in 3T3-LI adipocytes on AMPK activity as 
assessed by kinase assay (Inukai et al 2005, P J Logan, personal communication). Secondly, there 
are  no  functional  data  examining  downstream  targets  of  AMPK,  which  is  now  the  subject  of 
further work out with the scope of this thesis. Indeed, in retrospect it may have been of interest to 
measure plasma FFA concentrations although these results may again have been confounded by the 
imperfect  matching  for  glycaemia.  Finally,  while  the  vast  majority  of  the  tissue  biopsy  will 
constitute human adipose only approximately 50% of the cells are adipocytes and therefore it is 
impossible to quantify whether any presence of blood or macrophages could confound the results.  
 
Despite the chapter demonstrating a change in adipose AMPK it failed to demonstrate a change in 
plasma adiponectin.  This is agreement with a previous study which demonstrated the addition of 
metformin to sulphonylurea therapy has been shown to have no effect on circulating concentrations 
of adiponectin in subjects with Type 2 diabetes (Phillips et al 2003).  The impact of metformin on 
plasma adiponectin may also be difficult to interpret in this chapter as there is some evidence 
supporting an increase in adiponectin concentration with gliclazide (Kanda et al 2008, Drzewoski 
et al 2006). It is also important to consider the limitations of the plasma adiponectin assay which is 
a  crude  measurement  of  only  total  adiponectin  using  ELISA.  The  exact  physiological  role  of 
adiponectin is incompletely understood but it is known that adiponectin exists in 3 or more different 150 
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higher order complexes: high molecular weight form), low molecular weight form and trimeric 
form. Adiponectin has also been shown to operate at a molecular level by increasing nitric oxide 
production (Hattori et al 2003) by pathways proposed to involve AMPK. Phosphorylation of eNOS 
by AMP-activated protein kinase (AMPK) has been proposed but the exact signalling mechanisms 
have not been clarified (Chen et al 2003, Tan et al 2004, Ouchi et al 2004, Chen et al 2005). It is 
therefore clear that further work is required to determine whether there is a relationship between 
AMPK and adiponectin in the action of metformin. 
 
Interestingly, it has been recently shown that glucocorticoids inhibit AMPK activity in adipose 
tissue of insulin resistant patients with Cushing’s (Kola et al 2008). Moreover, metformin has been 
found to prevent the glucocorticoid effects on ex vivo cultured human adipocytes (Christ-Crain et 
al 2008). The work in this thesis extends these observations by demonstrating that metformin is 
capable of activating AMPK in adipose tissue in patients who also have insulin resistance. 
 
In conclusion, this chapter provides the strongest evidence thus far to support a beneficial effect of 
metformin therapy on adipose AMPK concentrations in patients with type 2 diabetes, although 
there was no demonstrable change in plasma adiponectin concentration. Further work elucidating 
the molecular mechanisms by which metformin activate AMPK in adipose tissue may identify 
novel and tissue specific therapeutic targets in subjects with Type 2 diabetes.  
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Chapter 5 
 
Studies  on  biguanide  effects  on  AMP-activated  protein  kinase  and  nitric  oxide  synthesis  in 
human aortic endothelial cells.  
 
5.1 Introduction 
 
Recent clinical studies have shown that the effects of metformin may go beyond improving HbA1c 
and may include reductions in cardiovascular end points in T2DM. There is a growing body of 
evidence to suggest that the biguanide class of anti-diabetic drugs improve endothelial function. 
The mechanism of metformin action in target tissues that results in altered glucose homeostasis 
and potentiation of vascular endothelial function remains uncertain. Perhaps the most intriguing 
development  in  elucidating  metformin’s  cellular  mechanism  of  action  in  recent  years  is  the 
proposed involvement of AMPK. The metabolic and cardio-protective effects of metformin may be 
attributable to the activation of AMPK and its downstream pathways.  
 
AMPK  has  an  important  role  in  the  release  of  NO  from  the  vascular  endothelium.  AICAR 
stimulates eNOS Ser1177 phosphorylation and NO production in human aortic endothelial cells 
(HAECs)  (Morrow  et  al  2003).  Indeed,  AMPK  activation  has  been  demonstrated  to  stimulate 
muscle glucose uptake in a NO-dependent manner and NO production has been proposed to be 
largely responsible for insulin-independent glucose uptake during exercise (Chen et al 2000, Fryer 
et al 2000, Hawley et al 2002). AMPK also has a role in angiogenesis. Vascular endothelial growth 
factor (VEGF) is a key regulator of angiogenesis and stimulates differentiation, survival, migration, 
proliferation and vascular permeability (Ferrara et al 2003). VEGF rapidly stimulates endothelial 
NO synthesis and does so in an AMPK dependent manner (Reihill et al 2007).  152 
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It  has  recently  been  reported  that  metformin  stimulates  NO  synthesis  in  an  AMPK-dependent 
manner in BAECs (Zou et al 2004). This is in contrast to data that suggests that the incubation of 
BAECs with phenformin activates AMPK without altering Ser1177 phosphorylation (Mount et al 
2005). Further work has demonstrated that metformin acts to phosphorylate AMPK and ACC in 
HUVECs (Hattori et al 2006). However in HAECs, metformin failed to show any effect on AMPK 
activity within 2 hours (Morrow et al 2003). The reasons for these conflicting data remain elusive 
but may be explained by species- and tissue-specific factors. Moreover, the neutral results with 
metformin may reflect the reduced lipophilicity compared with phenformin, such that phenformin 
rapidly accumulates in cells and subsequently has a more rapid effect on metabolism compared with 
metformin.  Therefore, a longer incubation period with or higher concentration of metformin may 
be required to stimulate AMPK and NO synthesis in HAECs.  Furthermore, the neutral results with 
metformin may also be explained by the possibility of cells either not expressing OCT-1 or carrying 
reduced function polymorphisms of OCT-1. 
 
Exactly how metformin improves insulin action, lowers body weight, improves the lipid profile, 
improves  endothelial  function  and  reduces  the  incidence  of  myocardial  infarction  remains 
incompletely understood. Further work is required to examine if biguanides mediate these effects by 
stimulating AMPK in vascular endothelial cells and in this chapter I investigate the effect of both 
metformin and phenformin in HAECs. 
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5.2 Aims of this chapter 
 
This chapter was initiated to extend the observations discussed above and addressed the following 
issues.  
i.  Does  metformin  or  phenformin  stimulate  nitric  oxide  production  in  cultured 
HAECs?  
ii.  Does metformin or phenformin stimulate eNOS phosphorylation at Ser1177 in 
cultured HAECs?  
iii.  Does  metformin  or  phenformin  rapidly  stimulate  eNOS  phosphorylation  at 
Ser1177 and NO synthesis in an AMPK-dependent manner?  
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5.3 Results  
5.3.1 Effect of A23187, insulin and L-NAME on nitric oxide (NO) production in HAECs. 
In HAECs, both insulin and A23187 independently stimulated NO production when compared to 
control (Figure 5.1). This effect was inhibited by pre-treatment with L-NAME.  
 
Figure 5.1 Stimulation of NO synthesis by A23187 and insulin in HAECs. 
Cells were incubated in KRH buffer in the presence or absence of L-NAME (black bars) for 1 
hour. Cells were stimulated with insulin (1µM) or A23187 (3µM) for 15 minutes. After the times 
indicated, media was removed and assayed for NO2
- content as described in methods. The data 
shown  represents  the  mean  %  basal  ±  SEM  NO  synthesis  from  3  independent  experiments 
performed in sextuplicate. * p<0.05 relative to insulin or A23187 in the absence of L-NAME. 
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5.3.2 Effect of Metformin and Phenformin on nitric oxide (NO) production. 
This chapter examined the ability of the anti-diabetic biguanide drug metformin and its derivative, 
phenformin to modulate NO production in HAECs. Stimulation of HAECs with metformin (200 
µM) had no effect on the rate of NO synthesis after incubation for either 60 or 120 minutes (Figure 
5.2). Stimulation of HAECs with phenformin (200 µM) stimulated the rate of NO synthesis within 
60 minutes and reached a maximum 3.6-fold increase at 120 minutes (Figure 5.3).  Under identical 
conditions,  stimulation  of  NO  by  phenformin  was  dose  dependent  (Figure  5.4)  such  that  NO 
synthesis was significantly stimulated by 200 µM phenformin reaching a maximum 2.0-fold at 60 
minutes. 
 
5.3.3 Effect of Metformin and Phenformin on AMPK activity 
Phosphorylation of eNOS at Ser1177 has been reported to be mediated by several protein kinases, 
including  AMPK.  We  next  examined  the  ability  of  metformin  to  modulate  AMPK  activity  in 
HAECs as assessed by incorporation of 
32P from of [γ-
32P] ATP into the AMPK substrate peptide 
SAMS. Stimulation of HAECs with metformin (200 µM) had no effect on AMPK activity after 
incubation for 60 or 120 minutes (Figure 5.2). Stimulation of HAECs with phenformin (200 µM) 
stimulated AMPK activity within 60 minutes and reached a maximum 3.3-fold increase at 120 
minutes (Figure 5.3). Under identical conditions, stimulation of AMPK activity was also dose-
dependent,  such  that  20  µM  phenformin  significantly  stimulated  AMPK  activity,  reaching  a 
maximum 3.1-fold increase (Figure 5.4).  
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Figure 5.2 Metformin fails to stimulate AMPK and NO synthesis in HAECs.   
HAEC AMPK activity and the rate of L-NAME-sensitive NO2
- synthesis in media were determined 
after incubation in 200 µmol/l metformin for the indicated durations. Data shown represents the 
mean % basal ± S.E. NO synthesis or AMPK activity from 3 independent experiments. * p<0.05 
relative to value in absence of metformin.  
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Figure  5.3  Phenformin  stimulates  AMPK  and  NO  synthesis  in  HAEC  in  a  time-dependent 
manner.   
HAEC AMPK activity and the rate of L-NAME-sensitive NO2
- synthesis in media were determined 
after incubation in 200 µM phenformin for the indicated durations. Data shown represents the 
mean % basal ± S.E. NO synthesis or AMPK activity from 3 independent experiments. * p<0.05 
relative to value in absence of phenformin.  
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Figure  5.4  Phenformin  stimulates  AMPK  and  NO  synthesis  in  HAEC  in  a  dose-dependent 
manner.   
HAEC AMPK activity and the rate of L-NAME-sensitive NO2
- synthesis in media were determined 
after incubation for the indicated concentrations of phenformin for 1 hour. Data shown represents 
the mean % basal ± S.E. NO synthesis or AMPK activity from 3 independent experiments. * 
p<0.05 relative to value in absence of phenformin.  
 
 
 
 
 
 
 
 
 159 
 
159 
 
5.3.4 Effect on Phenformin on phosphorylation of ACC. 
To  further  characterise  the  effect  of  biguanides  on  HAEC  AMPK  activity  I  determined  the 
phosphorylation status of ACC, which is phosphorylated by AMPK at Ser80 in ACC1 and Ser 220 
in  ACC2  (human  sequence).    Using  an  antibody  that  recognises  both  phosphorylated  species, 
phenformin  (200  µM)  significantly  stimulated  phosphorylation  of  ACC  in  a  time-dependent 
manner (Figure 5.5).  
 
Figure 5.5  Phenformin stimulates phosphorylation of ACC in HAECs. 
HAEC lysates, prepared from cells incubated with phenformin (200 µM) for 60 minutes and 120 
minutes were resolved by SDS PAGE, transferred to nitrocellulose and probed with the antibodies 
indicated.    Representative  immunoblots  are  shown,  repeated  with  similar  results  on  3  different 
samples of lysates.   
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5.3.5 Effect of phenformin phosphorylation of eNOS at Ser1177 and Thr495 in HAECs.  
Phosphorylation  of  eNOS  has  been  demonstrated  to  be  an  important  determinant  of  NO 
production.  In particular, phosphorylation at Ser1177 and dephosphorylation of Thr495 has been 
demonstrated to increase eNOS activity (Lin et al 2003). I therefore determined the effects of 
phenformin on eNOS phosphorylation at these sites in HAECs using phosphorylation site-specific 
antibodies.  Stimulation  of  HAECs  with  200  µM  phenformin  significantly  stimulated 
phosphorylation  of  eNOS  at  Ser1177  (Figure  5.6).    In  contrast,  stimulation  of  HAECs  with 
phenformin was without any significant effect on phosphorylation of eNOS at Thr495 (Figure 5.6).   
 
Figure 5.6  Effect of phenformin on eNOS phosphorylation at Ser1177 and Thr495 in HAECs. 
HAEC lysates, prepared from cells incubated with phenformin (200 µM) for 60 min and 120 min 
were  resolved  by  SDS  PAGE,  transferred  to  nitrocellulose  and  probed  with  the  antibodies 
indicated.  Representative  immunoblots  are  shown,  repeated  with  similar  results  on  3  different 
samples of lysates.  
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5.3.6  Effect  of  the  use  of  adenovirus  expressing  dominant  negative  AMPK  on  phenformin 
stimulated AMPK activation and NO stimulation  
To determine whether AMPK activation was required for phenformin-stimulated NO synthesis, 
HAECs were infected with control (Ad.Null) adenoviruses or adenoviruses expressing dominant 
negative AMPK (Ad.alpha1DN) prior to incubation with phenformin (200 µM) for 1h and NO 
production  assessed.  HAECs  infected  with  Ad.alpha1DN  exhibited  significantly  attenuated 
phenformin stimulated NO production at 1 hour compared to control virus-infected cells (Figure 
5.4).  Insulin  has  previously  been  demonstrated  to  stimulate  NO  synthesis  by  PKB-mediated 
phosphorylation and activation of eNOS, independent of AMPK.  Infection of HAECs had no 
effect on insulin-stimulated (1µM, 15min) NO synthesis indicating that the effect of infection with 
Ad.alpha1DN did not result in the non-specific downregulation of NO synthesis in an AMPK-
independent manner. The effect of infection with Ad.alpha1DN on phosphorylation of eNOS or 
ACC was not examined. 
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Figure 5.7  Phenformin-stimulated NO synthesis is AMPK-dependent. 
The rate of L-NAME-sensitive NO2
- synthesis was determined in media of HAECs infected with 
Ad.Null or Ad.α1DN (10 Pfu/cell) after incubation in the presence or absence of phenformin (200 
µM, 1h) or insulin (1 µM, 15min). Data shown represents the mean % basal ± S.E. NO synthesis 
from 4 independent experiments performed in sextuplicate. * p<0.05 relative to value in Ad.Null-
infected cells. # p<0.05 relative to vehicle-treated cells.  
 
 
 
 
 
 
 
 
 
 
 
 163 
 
163 
 
5.3.4 Discussion 
The  central  finding  of  this chapter is that phenformin rapidly stimulates NO production in an 
AMPK-dependent manner in HAECs.  The stimulation of AMPK by phenformin is associated with 
increased phosphorylation of eNOS-Ser1177. The stimulation of NO production is attenuated by 
infection of HAECs with Ad.alpha1DN. These data support the hypothesis that biguanides increase 
NO production by an AMPK-dependent mechanism. As AMPK has previously been demonstrated 
to stimulate NO synthesis via phosphorylation of eNOS at Ser1177, the complete inhibition of 
phenformin-stimulated  NO  production  by  infection  with  Ad.alpha1DN  suggests  that  AMPK-
mediated phosphorylation and activation of eNOS underlies phenformin-stimulated NO synthesis.  
 
A number of studies have demonstrated that biguanides have the capacity to improve endothelial 
function in non-diabetic subjects and subjects with T2DM. The beneficial effects of biguanides 
have been reported to be independent of glycaemia inferring a direct effect on vascular tissues.  
The endothelial effects of biguanides may be relatively rapid and stimulation of AMPK activity 
and NO synthesis by phenformin was achieved at concentration of 200µM.  It is difficult to explain 
the neutral results with metformin. Phenformin is a more lipophilic and potent biguanide which 
was removed from clinical practice due to the incidence of lactic acidosis and is often used in in 
vitro  experimentation  as  the  biguanide  of  choice.  It  is  possible  that  metformin,  being  less 
lipophilic,  was  unable to reach a sufficiently high intracellular concentration to exhibit effects 
during the short course of my experiments.  
 
It  has  recently  been  reported  that  metformin  stimulates  NO  synthesis  in  an  AMPK-dependent 
manner in BAECs and has been demonstrated to phosphorylate AMPK and ACC in HUVECs (Zou 
et al 2004, Hattori et al 2006).  In the current study, I was unable to show any effect with metformin 
within 2 hours on either AMPK activity or NO production, in agreement with our laboratory’s 164 
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previous findings (Morrow et al 2003).  In contrast, the related biguanide, phenformin, robustly 
stimulated  AMPK  activity,  ACC  phosphorylation,  eNOS  Ser1177  phosphorylation  and  NO 
production in HAECs. Furthermore, infection of HAECs with Ad.alpha1DN indicates that AMPK 
activation is required for phenformin-stimulated NO synthesis.  It has been previously demonstrated 
that attenuation of AMPK signalling in this way does not alter NO synthesis in response to stimuli 
such as insulin. Indeed, insulin has previously been demonstrated to stimulate NO synthesis by 
PKB-mediated  phosphorylation  and  activation  of  eNOS,  independent  of  AMPK  (Morrow  et  al 
2003).  Infection  of  HAECs  had  no  effect  on  insulin-stimulated  (1µM,  10  min)  NO  synthesis 
indicating that Ad.alpha1DN solely attenuates AMPK-dependent stimulation of NO synthesis and 
does  not  result  in  the  non-specific  downregulation  of  NO  synthesis  in  an  AMPK-independent 
manner. 
 
In contrast to the current study, incubation of BAECs with phenformin was recently reported to 
activate AMPK without altering Ser1177 phosphorylation (Mount et al 2005).  The reasons for 
these conflicting data remain elusive, but may reflect species-specific differences with respect to 
phenformin  action.    The  neutral  results  with  metformin  may  reflect  the  reduced  lipophilicity 
compared with phenformin, such that phenformin rapidly accumulates in cells and subsequently has 
a more rapid effect on metabolism compared with metformin.  Furthermore, the neutral results with 
metformin  may  also  be  explained  by  the  possibility  of  certain  cells  carrying  reduced  function 
polymorphisms of OCT-1. 
 
It is also important to consider if a longer incubation period or a higher concentration of metformin 
may be required to stimulate AMPK and NO synthesis in HAECs.  The plasma concentrations of 
metformin in patients treated with the drug are estimated to be 10–20 µM (Bailey et al 1996). It is 
important to consider that in many experiments involving cultured cells the doses used to activate 165 
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metformin are consistently higher in a range between 1 and 10 mM (Yang et al 2006, Zhang et al 
2007). This can be explained in part by the fact that OCT-1 predominantly expressed in the liver 
and is not expressed in many cultured cells. Indeed, 25% of the total dose of metformin is found in 
the liver 10 minutes after intravenous administration to wild type mice compared with <1% with 
OCT-1 knockout mice (Wang et al 2002). Higher doses of metformin are not used in patients with 
T2DM due to gastrointestinal side effects and also because of the risk of lactic acidosis, both of 
which might be caused by the ability of the compound to act as an inhibitor of the respiratory chain 
at  high  concentrations  (Owen  et  al  2000).  Further  work  is  required  to  determine  the  time  and 
concentration of metformin which will result in the maximal beneficial effects of AMPK activation 
without the development of gastrointestinal side effects and lactic acidosis. Indeed, it has been 
shown  that  an  increase  in  the  phosphorylation  of  ACC  is  evident  when  the  degree  of 
phosphorylation and activation of AMPK is very small (Hawley et al 2002). This suggests that to 
obtain beneficial therapeutic effects of metformin, maximal activation of AMPK may therefore not 
be necessary. However, with that in mind it may now be possible to develop a new generation of 
drugs  that  are  more  precisely  targeted  at  AMPK.  If  new  drugs  could  activate  AMPK  at  lower 
concentrations they may have fewer unwanted side effects.  
 
Taken  together  with  these  previous  studies,  this  thesis  postulates  that  phenformin  is  able  to 
stimulate endothelial NO synthesis in an AMPK-dependent manner, but species- and tissue-specific 
factors may underlie the seemingly conflicting data concerning the effects of metformin obtained to 
date.  
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Chapter 6 
 
Studies on thiazolidinedione effects on AMP-activated protein kinase and nitric oxide synthesis 
in human aortic endothelial cells.  
 
6.1 Introduction 
 
There is a growing body of evidence to suggest that the TZD class of anti-diabetic drugs improve 
endothelial function, as assessed by endothelium-dependent vasodilatation in patients with T2DM 
or  insulin  resistance  (Pitrosch  et  al  2004,  Natali  et  al  2004,  Semple  et  al  2006).    The 
hypoglycaemic effects of TZDs are mediated by the transcription factor PPARgamma, but recent 
work suggests that the improvement of endothelial function by TZDs is independent of the effect 
on glycaemia (Satoh et al 2003, Pritosch et al 2004, Semple et al 2006). Therefore, the mechanism 
of action by which TZDs improve vascular endothelial function remains uncertain.   
 
Recent  studies  have  suggested  that  prolonged  exposure  to  TZDs  directly  improves  NO 
bioavailability in endothelial cells and increases phosphorylation of eNOS at Ser1177 (Calnek et al 
2003, Cho et al 2004, Polikandriotis et al 2005, Kim et al 2006).  Several protein kinases have 
been  demonstrated  to  phosphorylate  eNOS  Ser1177  in  endothelial  cells,  including  PKB  and 
AMPK, but the protein kinase and signalling mechanism responsible for phosphorylation of eNOS 
in response to TZDs is as yet undetermined (Fulton et al 1999, Dimmeler et al 1999, Chen et al 
1999, Fryer et al 2002, Morrow et al 2003).  As TZDs have been demonstrated to rapidly and 
chronically activate AMPK in muscle, liver and adipose, it is possible that activation of AMPK 
may mediate eNOS phosphorylation and NO synthesis in response to TZDs in endothelial cells 
(Fryer et al 2002, Saha et al 2004, Konrad et al 2005, Lebrasseur et al 2006).   167 
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6.2 Aims of this chapter 
This chapter was initiated to extend the observations discussed above and addressed the following 
issues.  
i.  Does rosiglitazone stimulate nitric oxide production in HAECs?  
ii.  Does rosiglitazone stimulate eNOS phosphorylation at Ser1177 in HAECs?  
iii.  Does rosiglitazone rapidly stimulate eNOS phosphorylation at Ser1177 and NO 
synthesis  in  an  AMPK-dependent  manner  and/or  PPAR  gamma-independent 
manner? 
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6.3 Results 
6.3.1 Effect of Rosiglitazone on nitric oxide (NO) production 
Stimulation of HAECs with rosiglitazone (200 µM) stimulated the rate of NO synthesis within 30 
minutes and reached a maximum 2.1 fold increase at 60 min (Fig. 6.1a).  The increase in the rate of 
NO  synthesis  was  sustained  for  24h.  Under  identical  conditions,  Stimulation  of  NO  by 
rosiglitazone was dose dependent (Fig. 6.1b) such that NO synthesis was significantly stimulated 
by 2 µM rosiglitazone and was stimulated maximally by 20 µM rosiglitazone (2.1 fold). 
 
6.3.2 Effect of Rosiglitazone on AMPK activity 
Stimulation of HAECs with rosiglitazone (200 µM) maximally stimulated AMPK activity 3.5 fold 
within  30  minutes  and  activation  was  sustained  for  24  hours  (Figure  6.1a).  Under  identical 
conditions, stimulation of AMPK activity was also dose-dependent, such that 2 µM rosiglitazone 
significantly stimulated AMPK activity, reaching a maximum 2.4 fold increase in AMPK activity 
at 200 µM (Figure 6.1b). 
 
6.3.3 Effect of a PPARgamma inhibitor on Rosiglitazone stimulated NO production and AMPK 
activity 
The principal therapeutic actions of the TZDs are thought to be alterations in gene expression 
mediated by PPARgamma. Preincubation of HAECs with the PPARgamma inhibitor, GW9662 (5 
µM)  was  without  effect  on  rosiglitazone-stimulated  AMPK  activity  and  NO  synthesis  (Figure 
6.1b).  
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Figure 6.1 Rosiglitazone stimulates AMPK and NO synthesis in HAECs.   
HAEC AMPK activity and the rate of L-NAME-sensitive NO2
- synthesis in media were determined 
after incubation A) in 200 µM rosiglitazone for the indicated durations and B) for the indicated 
concentrations of rosiglitazone for 1h after preincubation with GW9662 (G, 5 µM) for a further 1h. 
Data  shown  represents  the  mean  %  basal  ±  S.E.  NO  synthesis  or  AMPK  activity  from  3 
independent experiments. * p<0.05 relative to value in absence of rosiglitazone.  
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6.3.4 Effect on Rosiglitazone on phosphorylation of AMPK 
Activation of AMPK requires phosphorylation at Thr172 by an AMPK kinase. Using a phospho-
Thr172-specific  anti-AMPK  antibody,  it  was  observed  that  that  rosiglitazone  also  stimulates 
phosphorylation  of  AMPK  at  Thr172  in  a  time  and  concentration-dependent  manner  (Figures 
6.1c); in close agreement with the AMPK assay data (Figures 6.1a & 6.1b).   
 
Figure 6.1 Rosiglitazone stimulates AMPK and NO synthesis in HAECs.   
C) Under identical conditions, AMPK Thr172 phosphorylation was determined in HAEC lysates.  
Representative immunoblots are shown from 3 independent experiments. 
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6.3.5  Effect  of  the  use  of  adenovirus  expressing  dominant  negative  AMPK  on  Rosiglitazone 
stimulated AMPK activation and NO stimulation  
To determine whether AMPK activation was required for rosiglitazone-stimulated NO synthesis, 
HAECs were infected with control (Ad.Null) adenoviruses or adenoviruses expressing dominant 
negative AMPK (Ad.alpha1DN) prior to incubation with rosiglitazone (200 µM) for 1 hours or 24 
hours and NO production assessed.  HAECs infected with Ad.alpha1DN exhibited significantly 
attenuated  rosiglitazone  (1  hour)  stimulated  NO  production  (Fig.  6.2a)  compared  with  control 
virus-infected  cells.    In  HAECs  incubated  with  rosiglitazone  for  24  hours  there  was  a  non-
significant reduction in NO synthesis in cells infected with Ad.alpha1DN compared with control 
virus-infected cells.  Insulin has previously been demonstrated to stimulate NO synthesis by PKB-
mediated phosphorylation and activation of eNOS, independent of AMPK.  Infection of HAECs 
had  no  effect  on  insulin-stimulated  (1µM,  15min)  NO  synthesis  indicating  that  the  effect  of 
infection with Ad.alpha1DN did not result in the non-specific downregulation of NO synthesis in 
an  AMPK-independent  manner  (Fig.  6.2a).  Infection  with  Ad.alpha1DN  markedly  attenuated 
rosiglitazone-stimulated AMPK activity, as assessed by ACC phosphorylation and was without 
effect on eNOS expression (Fig. 6.2b) 
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Figure 6.2. Rosiglitazone-stimulated NO synthesis is AMPK-dependent. 
A) The rate of L-NAME-sensitive NO2
- synthesis was determined in media of HAECs infected 
with Ad.Null or Ad.α1DN after incubation in the presence or absence of rosiglitazone (RSG, 200 
µM, 1h or 24h) or insulin (1 µM, 15min). Data shown represents the mean % basal ± S.E. NO 
synthesis from 4 independent experiments. * p<0.05 relative to value in Ad.Null-infected cells. # 
p<0.05 relative to vehicle-treated cells.  
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Figure 6.2. Rosiglitazone-stimulated NO synthesis is AMPK-dependent. 
B) Under identical conditions, ACC phosphorylation and eNOS expression were determined in 
HAEC lysates.  Representative immunoblots are shown from 3 independent experiments. 
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6.3.6 Effect on Rosiglitazone on eNOS phosphorylation 
Phosphorylation  of  eNOS  has  been  demonstrated  to  be  an  important  determinant  of  NO 
production.  In particular, phosphorylation at Ser1177 has been demonstrated to increase eNOS 
activity. I therefore determined the effects of thiazolidinediones on eNOS phosphorylation at these 
sites  in  HAECs  using  phosphorylation  site-specific  antibodies.  Incubation  of  HAECs  with 
rosiglitazone  (20µM)  stimulated  phosphorylation  of  eNOS  at  Ser1177  (Fig.  6.3).  Furthermore, 
rosiglitazone-stimulated  eNOS  Ser1177  phosphorylation  was  completely  inhibited  in  HAECs 
infected with Ad.alpha1DN compared to cells infected with control Ad.null viruses.  In the same 
lysates,  infection  with  Ad.alpha1DN  abrogated  rosiglitazone-stimulated  AMPK  activity,  as 
assessed by ACC phosphorylation (Fig. 6.3).   
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Figure 6.3. Rosiglitazone-stimulated eNOS Ser1177 phosphorylation is AMPK-dependent. 
Phosphorylation of eNOS Ser1177 and ACC was determined in lysates prepared from HAECs 
infected  with  Ad.Null  or  Ad.α1DN  after  incubation  with  rosiglitazone  (20  µM)  for  1h.  
Representative immunoblots are shown, repeated with similar results on 3 different samples of 
lysates. 
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6.4 Discussion 
The central finding of this chapter is that rosiglitazone rapidly stimulates NO production and eNOS 
Ser1177 phosphorylation in an AMPK-dependent manner in HAECs.  The stimulation of AMPK by 
rosiglitazone is associated with increased phosphorylation of eNOS-Ser1177.  The stimulation of 
NO production and phosphorylation of eNOS at Ser1177 is attenuated by infection of HAECs with 
Ad.alpha1DN. These data support the hypothesis that thiazolidinediones increase NO production by 
an AMPK-dependent mechanism. As AMPK has previously been demonstrated to stimulate NO 
synthesis  via  phosphorylation  of  eNOS  at  Ser1177,  the  complete  inhibition  of  rosiglitazone-
stimulated  eNOS  Ser1177  phosphorylation  by  infection  with  Ad.alpha1DN  provides  strong 
evidence that AMPK-mediated phosphorylation and activation of eNOS underlies rosiglitazone-
stimulated NO synthesis.  
 
Previous  studies  have  demonstrated  that  incubation  of  human  umbilical  vein  endothelial  cells 
(HUVECs) with rosiglitazone for 48h stimulated NO synthesis and phosphorylation of eNOS at 
Ser1177 (Cho et al 2004).  Similarly, troglitazone has been reported to stimulate NO synthesis 
within 3h and eNOS phosphorylation at the equivalent site (Ser1179) in bovine aortic endothelial 
cells  (BAECs),  (Polikandriotis  et  al  2005).    In  this  chapter,  I  show  for  the  first  time  that 
rosiglitazone  stimulates  NO  synthesis  and  eNOS  Ser1177  phosphorylation  in  HAECs,  in 
agreement  with  the  previous  studies  in  HUVECs  &  BAECs.    Furthermore,  I  demonstrate  a 
mechanism by which the rapid stimulation of NO synthesis and eNOS Ser1177 phosphorylation is 
achieved. 
 
In  HUVECs,  rosiglitazone-stimulated  NO  synthesis  and  eNOS  Ser1177  phosphorylation  were 
reported  to  be  completely  inhibited  in  the  presence  of  the  PPARgamma  inhibitor,  GW9662 
(Polikandriotis et al 2005).  In BAECs, however, troglitazone-stimulated NO synthesis and eNOS 177 
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Ser1179 phosphorylation was only partially inhibited in the presence of the PPARgamma inhibitor, 
BADGE (Cho et al 2004). In contrast, I demonstrated that rosiglitazone-stimulated NO synthesis 
was  unaffected  by  the  PPARgamma  inhibitor,  GW9662.  The  likely  reason  for  the  differences 
observed  between  the  findings  of  this  chapter  and  those  conducted  previously  may  reflect  the 
different cell types utilized, but is more likely to be a result of the markedly different durations of 
rosiglitazone stimulation.  I incubated cells with rosiglitazone for 1-2 hours, whereas Polikandroitis 
and  colleagues  stimulated  HUVECs  with  rosiglitazone  for  24  hours  and  Cho  and  co-workers 
stimulated with troglitazone for up to 24 hours (Cho et al 2004, Polikandriotis et al 2005).   
 
As the principal effect of PPARgamma is the regulation of gene transcription, it seems likely that 
the  acute  effects  observed  in  the  current  study  are  too  rapid  to  be  the  result  of  PPARgamma-
mediated  alterations  in  gene  transcription.    I  cannot,  however,  rule  out  the  later  (12-24  hours) 
effects of rosiglitazone and other thiazolidinediones being the result of altered gene transcription.  
 
A  number  of  studies  have  demonstrated  that  thiazolidinediones  have  the  capacity  to  improve 
endothelial function in non-diabetic subjects and subjects with type 2 diabetes. Despite the TZD 
related improvements in vascular biology and endothelial function described above, it is important 
to note that metformin remains the only oral hypoglycaemic drug to demonstrate good evidence for 
cardiovascular  protection  in  a  randomised  trial.  Indeed,  in  both  the  large  scale  clinical  trials 
involving thiazolidinediones, PROactive and RECORD, pioglitazone and rosiglitazone failed to 
confer cardiovascular protection in patient with T2DM. It is therefore clear that the molecular 
mechanisms  by  which  rosiglitazone  and  other  thiazolidinediones  have  their  effects  on  the 
cardiovascular system are complex.  
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The beneficial effects of TZDs have been reported to be independent of glycaemia, inferring a 
direct effect on vascular tissues (Satoh et al 2003, Pitrosch et al 2004).  The endothelial effects of 
TZDs  may  be  relatively  rapid;  indeed  rosiglitazone  has  been  reported  to  improve  endothelial 
function within 24 hours in healthy human subjects and it is increasingly clear that the TZDs have 
non-genomic, PPARgamma-independent effects (Hetzel et al 2005).  Furthermore, stimulation of 
NO synthesis and AMPK activity by rosiglitazone was achieved at concentrations as low as 2 µM.   
These  concentrations  are  close  to  those  achieved  clinically;  healthy  subjects  given  8  mg  of 
rosiglitazone have been demonstrated to exhibit a peak plasma rosiglitazone concentration of 0.7 - 
0.8 µM after 1 hour (Kim et al 2004).  The findings of this final chapter of results provide evidence 
for  an  AMPK-dependent  mechanism  by  which  TZDs  rapidly  contribute  to  increase  NO 
bioavailability.  This mechanism may underlie the rapid effects of TZDs on endothelial function 
that are independent of PPARgamma-mediated alterations in gene transcription.  
 
The work in this final chapter has been complemented and significantly extended by work carried 
out by my laboratory colleagues.  
 
I demonstrated that preincubation of HAECs with GW9662 had no effect was on rosiglitazone-
stimulated AMPK activity and NO synthesis, suggesting that this was a PPARgamma independent 
effect of rosiglitazone. Importantly, this observation has been extended with data confirming that 
preincubation  of  HAECs  with  GW9662  prevents  rosiglitazone  stimulated  expression  of  CD36 
mRNA, indicating that GW9662 does effectively inhibit PPARgamma-mediated transcription in 
HAECs under these conditions. This finding adds weight to the suggestion that that PPARgamma 
is  not  an  upstream  component  of  rapid  thiazolidinedione-stimulated,  AMPK-dependent  NO 
synthesis (Boyle et al 2008).   
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Two upstream AMPK kinases have been isolated to date, LKB1 and Ca
2+/calmodulin-dependent 
kinase kinase (CaMKK), (Hawley et al 2003, Woods et al 2003, Hawley et al 2005).   
 
It has been proposed that LKB1 activity is constitutive, such that AMP binding to AMPK inhibits 
dephosphorylation at Thr172 permitting phosphorylation and activation by LKB1 (Woods et al 
2003). Further work by laboratory colleagues has determined that LKB1 activity is necessary for 
rosiglitazone-stimulated  AMPK  activity.    HeLa  cells  do  not  express  endogenous  LKB1,  and 
therefore  the effect of rosiglitazone on AMPK activity and AMPK Thr172 phosphorylation in 
HeLa cells stably expressing wild type (LKB1-WT) or kinase inactive mutant (LKB1-KD) LKB1 
was  investigated  (Sapkota  et  al  2002).    Rosiglitazone  stimulated  AMPK  activity  and  AMPK 
Thr172 phosphorylation in cells expressing LKB1-WT, but no effect of rosiglitazone was apparent 
in  HeLa  cells  expressing  LKB1-KD  (Boyle  et  al  2008).    Moreover,  Rosiglitazone  had  no 
significant effect on LKB1 activity as assessed by its ability to activate recombinant AMPK kinase 
domain.  These  data  provides  evidence  that  rosiglitazone  stimulates  AMPK  activity  utilizing  a 
LKB1-dependent mechanism and is in agreement with previous studies showing no changes in 
LKB1 activity with phenformin, AICAR, muscle contraction and extreme ischemia in a variety of 
tissues (Lizcano et al 2004, Sakamoto et al 2004, Altarejos et al 2005).  
 
It is now apparent that CaMKK can act as an alternate upstream kinase to LKB1 that activates 
AMPK  in  a  Ca
2+-dependent  and  AMP-independent  manner  (Hawley  et  al  2005,  Woods  et  al 
2005). It has been demonstrated that HAECs express CaMKK and that CaMKK mediates VEGF-
stimulated AMPK activation in HAECs (Reihill et al 2007). Further work has demonstrated that 
preincubation  of  cells  with  the  CaMKK  inhibitor  STO-609  has  no  significant  effect  on 
rosiglitazone-stimulated AMPK activity, AMPK Thr172 phosphorylation or phosphorylation of the 
AMPK  substrate,  acetyl  CoA  carboxylase  (ACC),  yet  completely  inhibits  VEGF-stimulated 180 
 
180 
 
AMPK activity (Boyle et al 2008). This observation suggests that CaMKK is not an upstream 
kinase responsible for AMPK activation in response to rosiglitazone.   
 
It has also been determined that other thiazolidinediones activate AMPK in HAEC’s.  Stimulation 
of HAECs with troglitazone or pioglitazone (20 µM) for one hour stimulated AMPK activity, 
AMPK Thr172 phosphorylation and ACC phosphorylation and preincubation with GW9662 was 
without effect (Boyle et al 2008). This observation suggests that activation of AMPK is a common 
mechanism utilized by thiazolidinediones. 
 
Finally,  endothelial  NO  synthesis  has  been  demonstrated  to  inhibit  monocyte  adhesion  to  the 
endothelium, an early, key step in atherogenesis.  A previous study has demonstrated a modest 
reduction in TNF-α-stimulated adhesion of U937 cells to HAECs in response to incubation with 
pioglitazone for 24h (Kurebayashi et al 2005). Further work in our laboratory demonstrated that 
acute (1 hour) stimulation with rosiglitazone was sufficient to reduce TNF-α-stimulated adhesion 
of U937 cells to HAECs in an L-NAME-sensitive manner (Boyle et al 2008).  These data suggest 
that AMPK-mediated rosiglitazone-stimulated NO synthesis has rapid functional effects.  
 
In summary, the findings of this chapter provide evidence for an AMPK-dependent mechanism by 
which thiazolidinediones rapidly contribute to increased NO bioavailability.  This mechanism may 
underlie the rapid effects of thiazolidinediones on endothelial function that are independent of 
PPARgamma-mediated alterations in gene transcription.  
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Chapter 7 Discussion 
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7.1 Background  
Cardiovascular  risk  assessment  in  patients  with  T2DM  shows  that  even  when  traditional 
cardiovascular risk factors (smoking, hypertension and hypercholesterolaemia) are corrected for, 
insulin resistance remains an independent risk factor for vascular disease (Laakso 1999). Moreover, 
despite aggressive treatment of the individual risk factors, death from T2DM remains unacceptably 
high (Ford 2005). Insulin sensitizers such as the biguanides and thiazolidinediones are widely used 
in the treatment of T2DM but the site and precise mode of their action remain uncertain. The 
prevalence  of  T2DM  is  reaching  epidemic  proportions  and  there  is  a  growing  need  for  new 
therapeutic  targets.  AMPK  is  a  novel  therapeutic  target  because  it  has  been  demonstrated  to 
mediate, at least in part, the effects of a number of physiological and pharmacological factors that 
exert beneficial effects on metabolism and the vasculature. Thus, the development of specific tissue 
specific AMPK activators is an attractive prospect for the future.  
 
7.2 Aims  
The aims of this thesis were as follows: 
 
i.  To  determine  if  metformin  improves  vascular  endothelial  function  in 
association with a lower circulating concentration of ADMA.  
ii.  To determine if metformin exerts beneficial metabolic effects in patients with 
T2DM in association with altered AMPK activity in human adipose. 
iii.  To  determine  if  insulin  sensitizers  such  as  metformin  and  the 
thiazolidinediones,  acting  directly  on  vascular  endothelial  cells,  increase  NO 
production by increasing AMPK activity thus accounting for beneficial effects 
on endothelial function and, in metformin’s, case cardiovascular outcome. 
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7.3 Metformin fails to improve vascular function but is associated with a small fall in circulating 
concentrations of ADMA when compared with Gliclazide therapy. 
I hypothesized that a short duration of metformin therapy would improve vascular function in 
association with lower circulating concentrations of ADMA in comparison with gliclazide therapy. 
To  test  this  hypothesis  I  compared  the  effects  of  metformin  versus  gliclazide  on  large  artery 
stiffness, resistance artery function and circulating concentrations of ADMA using a randomised, 
double-blind crossover design in subjects with Type 2 diabetes. One of the main aims was to 
confirm or refute a beneficial effect of metformin on circulating ADMA concentrations in view of 
recent supportive data to this effect from uncontrolled trials. It was also hypothesised that ADMA 
might not only be a predictive marker but also a causative risk factor for cardiovascular disease and 
thus  any  metformin-induced  reduction  in  ADMA  concentration  would  be  accompanied  by  an 
improvement  in  vascular  function.  The  data  demonstrates  that  metformin  does  indeed  lower 
ADMA compared with gliclazide despite better glycaemia changes with the latter, supporting a 
glucose-independent mechanism for this metformin effect. Finally, the data show that the change 
in  ADMA  concentration  was  not  associated  with  any  difference  in  large  artery  stiffness  as 
measured by pulse wave velocity or resistance artery function as measured by wire myography.  
 
There are certain limitations to this work. The reduction in ADMA was modest and the observed 
magnitude of difference contrasts with reports of much larger reductions in ADMA concentration 
in uncontrolled studies of metformin therapy in women with PCOS as well as poorly controlled 
subjects with Type 2 diabetes, where the drug was added to diet control or sulphonylurea therapy 
(Abbasi et al 2001, Heutling et al 2008). Thus, while of interest, the difference in ADMA could be 
deemed as biologically insignificant and clinically irrelevant. It is also particularly important to 
consider the implication of the missing data set in the wire myography data; eighteen subjects had 
at  least  one  successful  biopsy  with  myography  data  with  only  four  subjects  having  paired 184 
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myography results. An absence of vessels of suitable diameter was the reason for failure to obtain 
vessels from biopsies with no myography data although the vessel yield in this study is consistent 
with other wire myography studies completed by our group and others. The data are therefore 
insufficiently powered to detect any small changes in vascular function in association with this 
dose and duration of treatment. The data also failed to show that metformin conferred a benefit in 
pulse wave velocity and it was important to consider why. In the present study subjects were not 
randomised to the maximum dose of each drug and the duration of treatment was relatively short at 
10 weeks.  Whether a longer duration of each treatment in higher dose would have been associated 
with a larger change in ADMA concentration with measurable improvements in vascular function 
in favour of metformin is unknown and could be the subject of further study. The study design 
aimed to match glycaemic control at the end of each phase but this, in the event, proved not to be 
possible. Associated with these changes was a small improvement in plasma LDL cholesterol. 
Thus, it is reasonable to speculate that confounding effects related to better short term glycaemia 
and LDL-cholesterol improvements with gliclazide may have attenuated any metformin-induced 
change in ADMA being associated with an associated beneficial improvement in vascular function. 
Finally, the decision at the design stage to not make baseline measurements of both PWV and 
ADMA concentration at the beginning of each phase may have made strict interpretation of the 
results more difficult. From this we could truly know if metformin treatment lowered ADMA 
concentration as it is impossible to distinguish if the final results represent an effect of gliclazide to 
raise ADMA concentration or PWV.  The protocol for each patient was already fairly rigorous and 
therefore  an  assessment  of  resistance  artery  endothelial  function  would  have  been  difficult  to 
justify (two additional buttock biopsies). Future studies of metformin at higher doses for a longer 
duration  are  required  to  determine  whether  ADMA  lowering  by  metformin  improves  vascular 
function  and  more  importantly,  whether  such  a reduction helps explain the vascular end-point 
benefits of this treatment in prospective clinical trials.  185 
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7.4 Metformin increases AMPK activity in adipose tissue in patients with T2DM when compared 
with Gliclazide therapy. 
I hypothesized that a short duration of metformin therapy exerts beneficial metabolic effects in 
patients with T2DM in association with increased AMPK activity in human adipose and that this 
may be associated with changes in circulating levels of plasma adiponectin concentration. To test 
these  hypotheses,  this  thesis explored metformin’s action in human adipose tissue and plasma 
adiponectin,  an  area  thus  far  neglected  in  the  literature.  This  chapter  compared  the  effects  of 
metformin  versus  gliclazide  on  adipose  AMPK  activity  and  plasma  adiponectin  using  a 
randomised, double-blind crossover design in subjects with Type 2 diabetes. The main aim was to 
confirm  or  refute  a  beneficial  effect  of  metformin  on  adipose  AMPK  activity.  It  was  also 
hypothesised that any increase in AMPK activity may be associated with an increase in plasma 
adiponectin concentration.  The data demonstrate that metformin does indeed increase adipose 
AMPK compared with gliclazide. The increase in adipose AMPK activity was not associated with 
an increase in AMPK protein expression. This finding suggests that the change in AMPK activity 
is an increase in the specific activity of AMPK rather than simply a difference in the total amount 
in AMPK between phases. The study design aimed to match glycaemic control at the end of each 
phase but this, in the event, proved not to be possible. Metformin increased AMPK activity when 
compared with gliclazide despite better glycaemia changes with the latter, supporting a glucose-
independent  mechanism  for  this  metformin  effect.  Associated  with  these  changes  was  a small 
improvement  in plasma LDL cholesterol with gliclazide. Somewhat surprisingly, there was no 
significant difference in BMI after each treatment although measurement of skin fold thickness or 
more sophisticated measurement of body composition may have provided a more specific marker 
of fat mass. Finally, the data show that the change in adipose AMPK activity was not associated 
with any difference in plasma adiponectin. 186 
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There  are  certain  limitations  to  this  work. Firstly, while a robust and significant difference in 
AMPK activity with metformin when compared with gliclazide is demonstrated it is important to 
note that the effect of gliclazide on AMPK activity has not been widely studied. The principal 
mechanism of action of the sulphonylurea class of drugs is to improve insulin secretion by the beta 
cells of the endocrine pancreas, and the data concerning the effects of sulphonylurea on AMPK are 
limited. Indeed, glimepiride treatment has been shown to have no effect on AMPK activity in 
cultured myocytes as expressed by AMPK phosphorylaton while gliclazide has no effect (up to 1 
hour incubation) in 3T3-LI adipocytes on AMPK activity as assessed by kinase assay (Inukai et al 
2005, P J Logan, personal communication). Secondly, there is also no functional data examining 
downstream targets of AMPK. Without evidence of downstream effects any beneficial metabolic 
effects associated with increased AMPK activity with metformin therapy can only be implied. 
Finally,  while  the  vast  majority  of  the  tissue  biopsy  will  constitute  human  adipose  only 
approximately 50% of the cells are adipocytes and therefore it is impossible to quantify whether 
any presence of blood or macrophages could confound the results and that the increase in AMPK 
activity is in the circulating plasma or in vascular cells. Finally, again the decision at the design 
stage to not make baseline measurements of plasma adiponectin at the beginning of each phase 
may have made strict interpretation of the results more difficult. From this we could truly know if 
metformin treatment increased plasma adiponectin as it is impossible to distinguish if the final 
results represent an effect of gliclazide to increase adiponectin concentration.  It is also important 
to consider the limitations of the plasma adiponectin assay which is a crude measurement of only 
total  adiponectin  using  ELISA.  The  exact  physiological  role  of  adiponectin  is  incompletely 
understood  and  further  work  is  required  to  determine  whether  there  is  a  relationship  between 
AMPK  and  adiponectin  in  the  action  of  metformin.  Further  work  elucidating  the  molecular 
mechanisms by which metformin activates AMPK in adipose tissue may identify novel and tissue 
specific therapeutic targets in subjects with Type 2 diabetes. 187 
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7.5 Phenformin, but not Metformin stimulates NO in an AMPK dependant manner. 
I hypothesized that biguanide therapy would stimulate NO production in an AMPK dependant 
manner in HAECs. Metformin failed to stimulate NO production or AMPK activity in HAECs. In 
contrast, phenformin rapidly stimulated NO production in an AMPK-dependent manner in HAECs.  
The stimulation of AMPK by phenformin is associated with increased phosphorylation of eNOS-
Ser1177.  The  stimulation  of  NO  production  is  attenuated  by  infection  of  HAECs  with 
Ad.alpha1DN. These data support the hypothesis that phenformin increases NO production by an 
AMPK-dependent  mechanism.  As  AMPK  has  previously  been  demonstrated  to  stimulate  NO 
synthesis via phosphorylation of eNOS at Ser1177, the inhibition of phenformin-stimulated NO 
production by infection with Ad.alpha1DN suggests that AMPK-mediated phosphorylation and 
activation of eNOS underlies phenformin-stimulated NO synthesis.  
 
There  are  certain  limitations  to  this  work.  In  retrospect,  the  hypothesis  that  AMPK-mediated 
phosphorylation and activation of eNOS underlies phenformin-stimulated NO synthesis could have 
been further strengthened if I had demonstrated that phosphorylation of eNOS at Ser1177 and ACC 
was attenuated by infection with Ad.alpha1DN. It is also important to consider the neutral data with 
metformin. It has recently been reported that metformin stimulates NO synthesis in an AMPK-
dependent manner in BAECs and has been demonstrated to phosphorylate AMPK and ACC in 
HUVECs (Zou et al 2004, Hattori et al 2006).  I was unable to show any effect of metformin within 
2 hours on either AMPK activity or NO production, in agreement with previous findings (Morrow 
et  al  2003).    Phenformin,  however,  robustly  stimulated  AMPK  activity,  ACC  phosphorylation, 
eNOS  Ser1177  phosphorylation  and  NO  production  in  HAECs.  The  contrasting  results  make 
interpretation of the findings with phenformin more difficult. Phenformin in a more lipophilic and 
potent biguanide which was removed from clinical practice due to the incidence of lactic acidosis 
and is often used in in vitro experimentation as the biguanide of choice. The dose of phenformin 188 
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most commonly used in the experiments described was 200µM, which is supra-physiological. It is 
possible that metformin, being less lipophilic, was unable to reach a sufficiently high intracellular 
concentration to exhibit effects during this short course of my experiments. It is also important to 
consider if a longer incubation period or a higher concentration of metformin may be required to 
stimulate AMPK and NO synthesis in HAECs.  The plasma concentrations of metformin in patients 
treated with the drug are estimated to be 10–20 µM (Bailey et al 1996). It is important to consider 
that in many experiments the doses used to activate metformin are consistently higher in a range 
between 1 and 10 mM (Yang et al 2006, Zhang et al 2007). Higher doses of metformin are not used 
in patients with T2DM due to gastrointestinal side effects and also because of the risk of lactic 
acidosis, both of which might be caused by the ability of the compound to act as an inhibitor of the 
respiratory chain at high concentrations (Owen et al 2000). Further work is required to determine 
the time and concentration of metformin which will result in the maximal beneficial effects of 
AMPK  activation  without  the  development  of  gastrointestinal  side  effects  and  lactic  acidosis. 
Furthermore, it is impossible to exclude if the neutral results with metformin may also be explained 
by the possibility of certain HAECs either not expressing OCT-1 which is expressed particularly in 
the liver or carrying reduced function polymorphisms of OCT-1 (Wang et al 2002). Finally, it is 
important to state that while phenformin has been shown to stimulate NO production and AMPK 
activity  in  HAECs,  further  work  is  required  to  confirm  if  this  would  translate  into  beneficial 
metabolic and vascular effects in patients with T2DM. 
 
7.6 Rosiglitazone stimulates NO in an AMPK dependent manner. 
I hypothesized that rosiglitazone therapy would stimulate NO production in an AMPK dependant 
manner  in  HAECs.  Rosiglitazone  rapidly  stimulates  NO  production  and  eNOS  Ser1177 
phosphorylation  in  an  AMPK-dependent  manner  in  HAECs.    The  stimulation  of  AMPK  by 
rosiglitazone is associated with increased phosphorylation of eNOS-Ser1177.  The stimulation of 189 
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NO production and phosphorylation of eNOS at Ser1177 is attenuated by infection of HAECs with 
Ad.alpha1DN. These data support the hypothesis that thiazolidinediones increase NO production by 
an AMPK-dependent mechanism. As AMPK has previously been demonstrated to stimulate NO 
synthesis  via  phosphorylation  of  eNOS  at  Ser1177,  the  complete  inhibition  of  rosiglitazone-
stimulated  eNOS  Ser1177  phosphorylation  by  infection  with  Ad.alpha1DN  provides  strong 
evidence that AMPK-mediated phosphorylation and activation of eNOS underlies rosiglitazone-
stimulated NO synthesis. Moreover, rosiglitazone-stimulated NO synthesis was unaffected by the 
PPARgamma inhibitor, GW9662.  
 
There are certain limitations to this work. I demonstrated that rosiglitazone-stimulated NO synthesis 
was unaffected by the PPARgamma inhibitor, GW9662. As the principal effect of PPARgamma is 
the regulation of gene transcription, it seems likely that the acute effects observed in the current 
study are too rapid to be the result of PPARgamma-mediated alterations in gene transcription. This 
is in disagreement with work in other cell lines. Indeed, in HUVECs, rosiglitazone-stimulated NO 
synthesis  and  eNOS  Ser1177  phosphorylation  were  reported  to  be  completely  inhibited  in  the 
presence of the PPARgamma inhibitor, GW9662 (Polikandriotis et al 2005).  Moreover, in BAECs, 
however,  troglitazone-stimulated  NO  synthesis  and  eNOS  Ser1179  phosphorylation  was  only 
partially inhibited in the presence of the PPARgamma inhibitor, BADGE (Cho et al 2004).  The 
likely reason for the differences observed between the findings in this thesis and those conducted 
previously  may  reflect  the  different  cell  types  utilized,  but is more likely to be a result of the 
markedly different durations of rosiglitazone stimulation.  I incubated cells with rosiglitazone for 1-
2 hours, whereas Polikandroitis and colleagues stimulated HUVECs with rosiglitazone for 24 hours 
and  Cho  and  co-workers  stimulated  with  troglitazone  for  up  to  24  hours  (Cho  et  al  2004, 
Polikandriotis  et  al  2005).    I  cannot,  however,  rule  out  the  later  (12-24  hours)  effects  of 
rosiglitazone and other thiazolidinediones being the result of altered gene transcription and it would 190 
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have been of value to compare the effect of GW9962 on NO production and AMPK activity at both 
the 1 and 24 hour time points. Finally, it is important to state that while rosiglitazone has been 
shown  to  stimulate  NO  production  and  AMPK  activity  in  HAECs,  further  work  is  required to 
confirm if this would translate into beneficial metabolic and vascular effects in patients with T2DM. 
It is also important to consider that despite the TZD related improvements in vascular biology and 
endothelial  function  described  above  metformin  remains  the  only  oral  hypoglycaemic  drug  to 
demonstrate good evidence for cardiovascular protection in a randomised trial. Indeed, in both the 
large scale clinical trials involving thiazolidinediones, PROactive and RECORD, pioglitazone and 
rosglitazone failed to confer cardiovascular protection in patients with T2DM. It is therefore clear 
that  the  molecular  mechanisms  by  which  rosiglitazone  and  other  thiazolidinediones  have  their 
effects on the cardiovascular system are complex.  
 
7.7 Future work and summary 
AMPK is an attractive goal for therapeutic intervention in T2DM. As demonstrated in the data 
presented in this thesis in both adipose tissue of patients with T2DM and cultured human vascular 
endothelial  cells,  two  of  the  most  commonly  used  treatments  for  diabetes,  biguanides  and 
thiazolidinediones, may well exert a proportion of their beneficial effects through the activation of 
AMPK. The generation of more specific and potent activators of AMPK, however, could have 
additional metabolic and vascular benefits for patients with T2DM.  
 
At this point in time, it is still uncertain whether direct activation of the AMPK pathway in patients 
with  T2DM  will  be  safe.  It  is  unknown  whether  directly  activating  AMPK  in  the  absence  of 
depleted energy stress or physiological stress would be detrimental. It is certain that the effects of 
AMPK  activation  in  other  organs  or  tissues  need  to  be  carefully  evaluated  as  the  widespread 
cellular  functions  of  AMPK  will  make  selective  targeting  challenging  for  the  pharmaceutical 191 
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industry. A greater understanding of specific AMPK signalling pathways and their regulation will 
be crucial for the development of such drug therapy.  
 
Three target tissues have caused concern in the literature to date; hypothalamus, pancreas and the 
heart. The hypothalamus plays a key role in the regulation of energy balance. It does so by using 
AMPK as a fuel gauge that can respond to both hormones, anorexia or an excess of food. (Schwartz 
et al 2000, Andersson et al 2004). Injection of leptin into rodents inhibits AMPK activity in the 
hypothalamus whereas administration of ghrelin stimulates AMPK activity (Andersson et al 2004). 
Moreover,  fasting  stimulates  AMPK  activity  whereas  hyperglycaemia  and  refeeding  inhibits 
AMPK activity in the hypothalamus (Minokowski et al 2004). Therefore, it appears that activating 
AMPK can stimulate food intake through its action in the hypothalamus. While this effect probably 
represents a physiological response in glucose homeostasis, the prospect of patients gaining weight 
through the pharmacological targeting of AMPK for the treatment of T2DM is unattractive and 
presents a significant challenge to the pharmaceutical industry. It is important to note, however, 
that this theoretical side effect of AMPK activators remains to be established.  
 
Another area of concern is AMPK’s role in the pancreas. It has been demonstrated that an increase 
in glucose levels represses AMPK activity in β cell lines (Salt et al 1998, Le Clerc et al 2004), 
whereas  when  AMPK  is  activated  by  AICAR,  insulin  release  in  response  to  high  glucose  is 
attenuated  (Zhang  et  al  1995).  Furthermore,  overexpression  of  a  constitutively  active  form  of 
AMPK results in a reduction in insulin release from β cell lines while overexpression of a dominant 
negative  form  of  AMPK  leads  to  an  increase  in  insulin  release  (Da  Silva  Xavier  et  al  2003). 
Moreover, when metformin is added to β cell lines, AMPK is activated and insulin secretion in 
response  to  insulin  is  attenuated  (Leclerc  et  al  2004).  The  activation  of  pancreatic  AMPK  is 
therefore  associated  with  decreased  insulin  secretion  which  could  have  a  negative  effect  on 192 
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glycaemic control in patients with T2DM. This effect may, however, be a protective effect during 
periods  of  hypoglycaemia,  where  AMPK  is  activated  and  insulin  secretion  falls  to  maintain 
euglycaemia.  Nevertheless,  the  effects  the  exact  role  of  AMPK  in  insulin  release  remains 
incompletely understood and further work is required before AMPK can targeted by drug therapy in 
patients with T2DM. 
 
Finally,  alterations  in  cardiac  AMPK  activity  are  associated  with  a  number  of  cardiovascular-
related  diseases  including  glycogen  storage  cardiomyopathy  (Arrad  et  al  2003)  and  Wolff–
Parkinson–White  syndrome  (Gollob  et  al  2001)  suggesting  that  the  manipulation  of  AMPK 
activity in cardiac tissue may not be without risks.  
 
All of these uncertainties will need to be clarified by further work defining the effects of AMPK 
activation  in  the  various  target  tissues  described  above.  An  ideal  AMPK  activator  would  be 
administrated by the oral route, activate AMPK at low concentration and be effective in specific 
target organs, such as the liver, skeletal muscle and adipose tissue but not the hypothalamus or 
pancreas. Tissue-specific pharmacological activation of AMPK is, therefore, essential and could 
potentially be achieved through isoform-specific activation or targeting of downstream substrates 
of AMPK. The first validation of the beneficial effects of a direct AMPK activator were recently 
reported (Cool et al 2006). The small molecule, compound A-769662 has been shown to directly 
activate AMPK both in vitro and in vivo. In cell culture studies A-769662 has been shown to 
reduce  fatty  acid  synthesis  in  primary  rat  hepatocytes  (Cool  et  al  2006).  Moreover,  acute 
intraperitoneal injection of A-769662 in Sprague–Dawley rats rapidly decreased hepatic malonyl 
CoA levels and stimulated fatty acid oxidation. Furthermore, treatment of ob/ob mice with A-
769662 for five days, again by injection, decreased plasma glucose and triglyceride concentrations, 
lowered hepatic triglyceride content and glucose production and reduce body weight.  These results 193 
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demonstrate that small-molecule-mediated activation of AMPK in vivo is feasible and, therefore 
may represent a promising approach for the treatment of patients with T2DM.  It is important to 
note that the compound A-769662 has poor oral bioavailability which at the present time limits its 
use  in  a  clinical  setting.  This  study  does  however  pave  the  way  for  the  development  of  an 
alternative small-molecule compound that if safe, potent, acted directly on AMPK and had good 
oral bioavailability, would be an attractive candidate to progress towards clinical study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 194 
 
194 
 
Bibliography  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 195 
 
195 
 
Abate N, Garg A, Peshock RM, Stray-Gundersen J, Adams-Huet B, Grundy SM: Relationship of 
generalized and regional adiposity to insulin sensitivity in men with NIDDM. Diabetes 45:1684-
1693, 1996.  
 
Abbasi F, Carantoni M, Chen YD, Reaven GM: Further evidence for a central role of adipose tissue 
in the antihyperglycemic effect of metformin. Diabetes Care 21:1301-1305, 1998. 
 
Abbasi  F,  Asagami  T,  Cooke  JP:  Plasma  concentrations  of  asymmetric  dimethylarginine  are 
increased in patients with type 2 diabetes mellitus. Diabetes 50:147 (suppl 2), 2001.  
 
Abe H, Yamada N, Kamata K, Kuwaki T, Shimada M, Osuga J, Shionoiri F, Yahagi N, Kadowaki 
T,  Tamemoto  H,  Ishibashi  S,  Yazaki  Y,  Makuuchi  M: Hypertension, hypertriglyceridemia, and 
impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. 
J.Clin.Invest. 101:1784-1788, 1998. 
 
Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R Vallance P: Asymmetric 
dimethylarginine  causes  hypertension  and  cardiac  dysfunction  in  humans  and  is  actively 
metabolized  by  dimethylarginine  dimethylaminohydrolase.  Arterioscler.Thromb.Vasc.Biol.  23: 
1455–1459, 2003. 
 
Alberti KGMM, Zimmet P, Shaw J: for the IDF Epidemiology Task Force Consensus Group: The 
metabolic syndrome – a new worldwide definition. Lancet 366:1059 -1062, 2005. 
 196 
 
196 
 
Altarejos  JY,  Taniguchi  M,  Clanachan  AS,  Lopaschuk  GD:  Myocardial  ischemia  differentially 
regulates LKB1 and an alternate 5'-AMP-activated protein kinase kinase. J.Biol.Chem. 280:183-
190, 2005. 
 
Altinova AE, Arslan M, Sepici-Dincel A, Akturk M, Altan N, Toruner FB: Uncomplicated type 1 
diabetes  is  associated  with  increased  asymmetric  dimethylarginine  concentrations. 
J.Clin.Endocrinol.Metab. 92:1881-1885, 2007. 
 
An  Z,  Wang  H,  Song  P,  Zhang  M,  Geng  X,  Zou  MH:  Nicotine-induced  activation  of  AMP-
activated protein kinase inhibits fatty acid synthase in 3T3L1 adipocytes: a role for oxidant stress. 
J.Biol.Chem. 282:26793-26801, 2007.  
 
Andersson U, Filipsson K, Abbott CR, Woods A, Smith K, Bloom SR, Carling D, Small CJ: AMP-
activated protein kinase plays a role in the control of food intake. J.Biol.Chem. 279:12005–12008, 
2004. 
 
Andreelli F, Foretz M, Knauf C, Cani PD, Perrin C, Iglesias MA, Pillot B, Bado A, Tronche F, 
Mithieux G, Vaulont S, Burcelin R, Viollet B: Liver adenosine monophosphate-activated kinase-
alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin 
and leptin but not insulin. Endocrinology 147:2432–2441, 2006. 
 
Andreozzi F, Laratta E, Procopio C, Hribal ML, Sciacqua A, Perticone M, Miele C, Perticone F, 
Sesti G: Interleukin-6 impairs the insulin signaling pathway, promoting production of nitric oxide in 
human umbilical vein endothelial cells. Mol. Cell Biol. 27:2372-2383, 2007. 
 197 
 
197 
 
Angus  JA, Wright CE: Techniques to study the pharmacodynamics of isolated large and small 
blood vessels. J.Pharmacol.Toxicol. Methods 44:395-407, 2000. 
 
Arad  M,  Benson  DW,  Perez-Atayde  AR,  McKenna  WJ,  Sparks  EA,  Kanter  RJ,  McGarry  K, 
Seidman JG, Seidman CE: Constitutively active AMP kinase mutations cause glycogen storage 
disease mimicking hypertrophic cardiomyopathy. J.Clin.Invest. 109:357–362, 2002. 
 
Arita  Y,  Kihara  S,  Ouchi  N,  Takahashi  M,  Maeda  K,  Miyagawa  J,  Hotta  K,  Shimomura  I, 
Nakamura  T,  Miyaoka  K,  Kuriyama  H,  Nishida  M,  Yamashita  S,  Okubo  K,  Matsubara  K, 
Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific 
protein, adiponectin, in obesity. Biochem.Biophys.Res.Commun. 257:79-83, 1999. 
 
Asagami T, Abbasi F, Stuelinger M, Lamendola C, McLaughlin T, Cooke JP, Reaven GM, Tsao 
PS: Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 
diabetes Metabolism 51:843-846, 2002. 
 
Asmar  R,  Benetos  A,  Topouchian  J,  Laurent  P,  Pannier  B,  Brisac  AM,  Target  R,  Levy  BI: 
Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and 
clinical application studies. Hypertension 26:485-490, 1995. 
 
Asmar R, Rudnichi A, Blacher J, London GM, Safar ME: Pulse pressure and aortic pulse wave are 
markers of cardiovascular risk in hypertensive populations. Am.J.Hypertens. 14:91-97, 2001. 
 
Bailey CJ, Mynett KJ, Page T: Importance of the intestine as a site of metformin-stimulated glucose 
utilization. Br.J.Pharmacol. 112:671-675, 1994. 198 
 
198 
 
 
Bailey CJ, Turner RC: Metformin. N.Engl. J. Med. 334, 574–579, 1996. 
 
Bailey CJ, Day C: Metformin: its botanical background. Practical Diabetes International 21:115–
117, 2004. 
 
Banerji M, Chaiken R, Gordon D, Lebowitz H: Does intra-abdominal adipose tissue in black men 
determine whether NIDDM is insulin resistant or insulin sensitive? Diabetes 44:141-146, 1995. 
 
Basu A, Basu R, Shah P, Vella A, Johnson CM, Nair KS, Jensen MD, Schwenk WF, Rizza RA: 
Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle 
glucose metabolism: evidence for a defect in hepatic glucokinase activity. Diabetes 49:272-283, 
2000. 
 
Behrendt D, Ganz P: Endothelial Function: From vascular biology to clinical applications. Am. 
J.Cardiol. 90(suppl):40-48, 2002  
 
Bevan JA, Osher JV: A direct method for recording tension changes in the wall of small blood 
vessels in vitro. Agents Actions 2:257-260, 1972. 
 
Bevan P: Insulin signalling. J. Cell Sci. 114:1429-1430, 2001. 
 
Birk JB, Wojtaszewski JF: Predominant alpha2/beta2/gamma3 AMPK activation during exercise in 
human skeletal muscle. J.Physiol. 577:1021–1032, 2006. 
 199 
 
199 
 
Blacher J, Asmar R, Djane S, London GM, Safar ME: Aortic pulse wave velocity as a marker of 
cardiovascular risk in hypertensive patients. Hypertension 33:1111-1117, 1999. 
 
Blackwell  S,  O'Reilly  DS,  Talwar  D:  Biological  variation  of  asymmetric  dimethylarginine  and 
related  arginine  metabolites  and  analytical  performance  goals  for  their  measurement  in  human 
plasma. Eur.J. Clin.Invest. 37:364-371, 2007. 
 
Boden G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-
10, 1997. 
 
Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP: 
Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in 
hypercholesterolemia. Circulation 98:1842–1847, 1998. 
 
Bohlen HG: Localization of vascular resistance changes during hypertension. Hypertension 8:181-
183, 1986.  
 
Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA: A leukocyte homologue of the IL-8 receptor 
CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-
deficient mice. J.Clin.Invest. 101:353-363, 1998. 
 
Bonetti PO, Lerman LO, Lerman A: Endothelial Dysfunction. A marker of atherosclerotic risk. 
Arterioscler.Thromb.Vasc.Biol. 23:168-175, 2003.  
 200 
 
200 
 
Bonow  RO,  Smaha  LA,  Smith  SC,  Mensah  GA,  Lenfant  C:  World  Heart  Day  2002:  the 
international  burden  of  cardiovascular  disease:  responding  to  the  emerging  global  epidemic. 
Circulation 106:1602-1605, 2002. 
 
Borge PD, Moibi J, Greene SR, Trucco M, Young RA, Gao Z Wolf BA: Insulin receptor signalling 
and sarco/endoplasmic reticulum calcium ATPase in beta cells. Diabetes 51 (Suppl) 3:427-433, 
2002. 
 
Boyle  JG,  Logan  PJ,  Ewart  MA,  Reihill  JA,  Ritchie  SA,  Connell  JM,  Cleland  SJ,  Salt  IP: 
Rosiglitazone stimulates nitric oxide synthesis in human aortic endothelial cells via AMP activated 
protein kinase. J.Biol.Chem. 283: 11210-11217, 2008. 
 
Bradford  MM:  A  rapid  and  sensitive  method  for  the  quantification  of  microgram  quantities  of 
protein utilizing the principle of protein-dye binding. Anal.Biochem. 72:248-254, 1976.  
 
Bramwell JA, Hill AV: Velocity of transmission of the pulse wave and elasticity of arteries. Lancet 
1:891-892, 1922. 
 
Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL: A mammalian 
protein targeted by G1-arresting rapamycin-receptor complex. Nature 369:756–758, 1994. 
 
Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, Roden M, Gnaiger E, Nohl H, 
Waldhäusl W, Fürnsinn C: Thiazolidinediones, like metformin, inhibit respiratory complex I: a 
common mechanism contributing to their antidiabetic actions? Diabetes 53:1052-1059, 2004. 
 201 
 
201 
 
Caballero AE, Delgado A, Aguilar-Salinas CA, Herrera AN, Castillo JL, Cabrera T, Gomez-Perez 
FJ,  Rull  JA:  The  differential  effects  of  metformin  on  markers  of  endothelial  activation  and 
inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical 
trial. J.Clin.Endocrinol.Metab. 89:3943-3948, 2004. 
 
Calnek D, Mazzella L, Roser S, Roman J, Hart CM: Peroxisome proliferator activated receptor 
gamma  ligands  increase  release  of  nitric  oxide  from  endothelial  cells. 
Arterioscler.Thromb.Vasc.Biol. 23:52-57, 2003. 
 
Calvert, JW, Gundewar S, Jha S, Greer JJ, Bestermann, WH, Tian R, Lefer DJ: Acute metformin 
therapy  confers  cardioprotection  against  myocardial  infarction  via  AMPK-eNOS-mediated 
signaling. Diabetes 57:696–705, 2008. 
 
Campbell P, Carlson M: Impact of obesity on insulin action in NIDDM. Diabetes 42:405-410, 
1993. 
 
Carling D: The AMP-activated protein kinase cascade: a unifying system for energy control. Trends 
Biochem.Sci. 29:18–24, 2004. 
 
Chan  JC,  Tomlinson  B,  Critchley  JA,  Cockram  CS,  Walden  RJ:  Metabolic  and  hemodynamic 
effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care 16:1035-
1038, 1993. 
 
Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ: Adiponectin stimulates production 
of nitric oxide in vascular endothelial cells. J.Biol.Chem. 278:45021-45026, 2003. 202 
 
202 
 
Chen MB, McAinch AJ, Macaulay SL, Castelli LA, O'Brien PE, Dixon JB, Cameron-Smith D, 
Kemp BE, Steinberg GR: Impaired activation of AMP-kinase and fatty acid oxidation by globular 
adiponectin in cultured human skeletal muscle of obese type 2 diabetics. J.Clin.Endocrinol.Metab. 
90:3665-3672, 2005. 
 
Chen MP, Tsai JC, Chung FM, Yang SS, Hsing LL, Shin SJ, Lee YJ: Hypoadiponectinemia is 
associated  with  ischemic  cerebrovascular  disease.  Arterioscler.Thromb.Vasc.Biol.  25:821-826, 
2005. 
 
Chen ZP, Mitchelhill KI, Michell BJ, Stapleton D, Rodriguez-Crespo I, Witters LA, Power DA, 
Ortiz de Montellano PR, Kemp BE: AMP-activated protein kinase phosphorylation of endothelial 
NO synthase. FEBS Lett. 1443: 285-289, 1999. 
 
Chen  ZP,  McConell  GK,  Michell  BJ,  Snow  RJ,  Canny  BJ,  Kemp  BE:  AMPK  signaling  in 
contracting  human  skeletal  muscle:  acetyl-CoA  carboxylase  and  NO  synthase  phosphorylation. 
Am.J.Physiol.Endocrinol.Metab. 279:1202-1206, 2000. 
 
Chinen I, Shimabukuro M, Yamakawa K, Higa N, Matsuzaki T, Noguchi K, Ueda S, Sakanashi M, 
Takasu  N:  Vascular  lipotoxicity: endothelial dysfunction via fatty-acid induced reactive oxygen 
species overproduction in obese Zucker diabetic fatty rats. Endocrinology 148:160-165, 2007. 
 
Cho DH, Choi YJ, Jo SA, Jo I: Nitric oxide production and regulation of endothelial nitric-oxide 
synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of 
peroxisome  proliferator-activated  receptor  (PPAR)  gamma-dependent  and  PPARgamma-
independent signalling pathways. J.Biol.Chem. 279: 2499-2506, 2004. 203 
 
203 
 
Chowienczyk PJ, Watts GF, Cockcroft JR, Ritter JM: Impaired endothelium dependent vasodilation 
of forearm resistance vessels in hypercholesterolaemia. Lancet 340:1430-1432, 1992. 
 
Christ-Crain M, Kola B, Lolli F, Fekete C, Seboek D, Wittmann G, Feltrin D, Igreja SC, Ajodha S, 
Harvey-White J, Kunos G, Müller B, Pralong F, Aubert G, Arnaldi G, Giacchetti G, Boscaro M, 
Grossman  AB,  Korbonits  M:  AMP-activated  protein  kinase  mediates  glucocorticoid-induced 
metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J. 22:1672-1683, 2008. 
 
Cleland  SJ,  Petrie  JR,  Small  M,  Elliott  HL,  Connell  JM:  Insulin  action  is  associated  with 
endothelial dysfunction in hypertension and type 2 diabetes. Hypertension 35: 500-507, 2000. 
 
Coggins M, Lindner J, Rattigan S, Jahn L, Fasy E, Kaul S, Barrett E: Physiologic hyperinsulinemia 
enhances human skeletal muscle perfusion by capillary recruitment. Diabetes 50:2682-2690, 2001. 
 
Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, 
Marco CC, McKee LJ, Bauer TL: Serum immunoreactive-leptin concentrations in normal-weight 
and obese humans. N.Engl.J.Med. 334:292-295, 1996. 
 
Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M, Dickinson R, Adler A, Gagne G, Iyengar 
R, Zhao G, Marsh K, Kym P, Jung P, Camp HS, Frevert E: Identification and characterization of a 
small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic 
syndrome. Cell metabolism 3:403–416, 2006. 
 
Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA: Inhibition of glycogen synthase 
kinase-3 by insulin mediated by protein kinase B. Nature 378:785-789, 1995. 204 
 
204 
 
Cruickshank  K,  Riste  L,  Anderson  SG,  Wright  JS,  Dunn  G,  Gosling  RG:  Aortic  pulse-wave 
velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of 
vascular function? Circulation 106:2085-2090, 2002. 
 
Currie CJ, Kraus D, Morgan CL, Gill L, Stott NC, Peters JR: NHS acute sector expenditure for 
diabetes: the present, future, and excess in-patient cost of care. Diabet.Med. 14:686-692, 1997. 
 
Da Silva Xavier G, Leclerc I, Varadi A, Tsuboi T, Moule SK, Rutter GA: Role for AMP-activated 
protein  kinase  in  glucose-stimulated  insulin  secretion  and  preproinsulin  gene  expression. 
Biochem.J. 371(Pt 3):761–774, 2003. 
 
Danielsson A, Ost A, Nystrom FH, Stralfors P: Attenuation of insulin-stimulated insulin receptor 
substrate-1  serine  307  phosphorylation  in  insulin  resistance  of  type  2  diabetes.  J.Biol.Chem. 
280:34389-34392, 2005. 
 
Daousi C, Casson IF, Gill GV, MacFarlane IA, Wilding JP, Pinkney JH: Prevalence of obesity in 
type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad.Med.J. 
82:280-284, 2006. 
 
Davies JK, Wells DJ, Liu K, Whitrow HR, Daniel TD, Grignani R, Lygate CA, Schneider  JE, Noel 
G, Watkins H, Carling D: Characterization of the role of γ 2 R531G mutation in AMP-activated 
protein kinase in cardiac hypertrophy and Wolff-Parkinson-White syndrome. Am.J.Physiol. Heart 
Circ.Physiol. 290:1942–1951, 2006. 
 205 
 
205 
 
Davis BJ, Xie Z, Viollet B, Zou MH: Activation of the AMP-activated kinase by antidiabetes drug 
metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock 
protein 90 and endothelial nitric oxide synthase. Diabetes 55:496-505, 2006. 
 
Davis MJ, Ferrer PN, Gore RW: Vascular anatomy and hydrostatic pressure profile in the hamster 
cheek pouch. Am.J.Physiol. 250:291-303, 1986. 
 
De Aguiar LG, Bahia LR, Villela N, Laflor C, Sicuro F, Wiernsperger N, Bottino D, Bouskela E: 
Metformin  improves  endothelial  vascular  reactivity  in  first-degree  relatives  of  type  2  diabetic 
patients  with  metabolic  syndrome  and  normal  glucose  tolerance.  Diabetes  Care  29:1083-1089, 
2006. 
 
De Jager J, Kooy A, Lehert P, Bets D, Wulffelé MG, Teerlink T, Scheffer PG, Schalkwijk CG, 
Donker  AJ,  Stehouwer  CD:  Effects  of  short-term  treatment  with  metformin  on  markers  of 
endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-
controlled trial. J.Intern.Med. 257:100-109, 2005. 
 
Defronzo  R,  Tobin  JD,  Anders  R:  Glucose  clamp  technique:  a  method  for  quantifying  insulin 
secretion and resistance. Am.J.Physiol. 237:214-223, 1979. 
 
Defronzo  RA,  Ferrannini  E,  Simonson  DC:  Fasting  hyperglycemia  in  non-insulin-dependent 
diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose 
uptake. Metabolism 38:387-395, 1989. 
 206 
 
206 
 
DeFronzo  RA,  Bonadonna  RC,  Ferrannini  E:  Pathogenesis  of  NIDDM.  A  balanced  overview. 
Diabetes Care 15:318-368, 1992. 
 
Defronzo RA, Ferrannini E, Keen H, Zimmet P: International Textbook of Diabetes Mellitus. Wiley 
Press Third Edition, Volume 2. 2004. 
 
Diamanti-Kandarakis  E,  Alexandraki  K,  Protogerou  A,  Piperi  C,  Papamichael  C,  Aessopos  A, 
Lekakis J, Mavrikakis M: Metformin administration improves endothelial function in women with 
polycystic ovary syndrome. Eur.J.Endocrinol. 152:749-756, 2005. 
 
Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM: Activation of nitric oxide 
synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399: 601-605, 1999. 
 
Dominguez  LJ,  Davidoff  AJ,  Srinivas  PR,  Standley  PR,  Walsh  MF,  Sowers  JR:  Effects  of 
metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rat vascular 
smooth muscle. Endocrinology 137:113-121, 1996. 
 
Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, 
Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, 
Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, 
Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators. 
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive 
Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled 
trial. Lancet 366:1279-1289, 2005. 
 207 
 
207 
 
Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, Slezak LA, Andersen DK, 
Hundal RS, Rothman DL, Petersen KF, Shulman GI: Effects of free fatty acids on glucose transport 
and IRS-1-associated phosphatidylinositol 3-kinase activity. J.Clin.Invest. 103:253-259, 1999 
 
Dresser  MJ,  Xiao  G,  Leabman  MK,  Gray  AT,  Giacomini  KM:  Interactions  of  n-
tetraalkylammonium  compounds  and  biguanides  with  a  human  renal  organic  cation  transporter 
(hOCT2). Pharm.Res. 19:1244–1247, 2002. 
 
Drzewoski J, Zurawska-Klis M: Effect of gliclazide modified release on adiponectin, interleukin-6, 
and  tumor  necrosis  factor-alpha  plasma  levels  in  individuals  with  type  2  diabetes  mellitus. 
Curr.Med.Res.Opin. 22:1921-1926, 2006. 
 
Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M, Vollenweider P, Pedrazzini T, Nicod 
P,  Thorens  B, Scherrer U: Insulin resistance, hyperlipidemia, and hypertension in mice lacking 
endothelial nitric oxide synthase. Circulation 104:342-345, 2001.  
 
El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X: Dimethylbiguanide inhibits 
cell  respiration  via  an  indirect  effect  targeted  onthe  respiratory  chain  complex  I.  J.Biol.Chem. 
275:223–228, 2000. 
 
European  Medicines  Agency:  EMEA  recommends  new  warnings  and  contraindications  for 
rosiglitazone. E.M.E.A./42232/2008.  
 
Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, Sanna V, Jebb SA, Perna F, 
Fontana S, Lechler RI, DePaoli AM, O'Rahilly S: Beneficial effects of leptin on obesity, T cell 208 
 
208 
 
hyporesponsiveness,  and  neuroendocrine/metabolic  dysfunction  of  human  congenital  leptin 
deficiency. J.Clin.Invest. 110:1093-1103, 2002. 
 
Feletou  M,  Vanhoutte  PM:  Endothelium-derived  hyperpolarizing  factor:  where  are  we  now? 
Arterioscler.Thromb.Vasc.Biol. 26:1215-1225, 2006. 
 
Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat.Med. 29:669-676, 
2003.  
 
Fisher FF, Trujillo ME, Hanif W, Barnett AH, McTernan PG, Scherer PE, Kumar S: Serum high 
molecular weight complex of adiponectin correlates better with glucose tolerance than total serum 
adiponectin in Indo-Asian males. Diabetologia 48:1084-1087, 2005. 
 
Ford ES: Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the 
metabolic syndrome: a summary of the evidence. Diabetes Care 28:1769-1778, 2005. 
 
Forstermann U, Munzel T: Endothelial nitric oxide synthase in vascular disease: from marvel to 
menace. Circulation 113:1708-1714, 2006. 
 
Fox CS, Coady S, Sorlie PD, D'Agostino RB, Sr., Pencina MJ, Vasan RS, Meigs JB, Levy D, 
Savage  PJ:  Increasing  cardiovascular  disease  burden  due  to  diabetes  mellitus:  the  Framingham 
Heart Study. Circulation 115:1544-1550, 2007. 
 209 
 
209 
 
Fryer LG, Hajduch E, Rencurel F, Salt IP, Hundal HS, Hardie DG, Carling D: Activation of glucose 
transport  by  AMP-activated  protein  kinase  via  stimulation  of  nitric  oxide  synthase.  Diabetes 
49:1978-1785, 2000. 
 
Fryer LG, Parbu-Patel A, Carling D: The Anti-diabetic drugs rosiglitazone and metformin stimulate 
AMP-activated protein kinase through distinct signaling pathways. J.Biol.Chem. 277:25226-25232, 
2002. 
 
Frystyk J, Berne C, Berglund L, Jensevik K, Flyvbjerg A, Zethelius B: Serum adiponectin is a 
predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. 
J.Clin.Endocrinol.Metab. 92:571-576, 2007. 
 
Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, 
Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. 
Nature 399: 597-601, 1999. 
 
Gao X, Pan D: TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. 
Genes Dev. 15:1383–1392, 2001. 
 
Garber  AJ,  Duncan  TG,  Goodman  AM,  Mills  DJ,  Rohlf  JL:  Efficacy  of  metformin  in  type  II 
diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am.J.Med. 103:491-7, 
1997. 
 
Garland JG, McPherson GA: Evidence that nitric oxide does not mediate the hyperpolarization and 
relaxation to acetylcholine in the rat small mesenteric artery. Br.J.Pharmacol. 105:429-435, 1992. 210 
 
210 
 
Garton AJ, Campbell DG, Carling D, Hardie DG, Colbran RJ, Yeaman SJ: Phosphorylation of 
bovine  hormone-sensitive  lipase  by  the  AMP-activated  protein  kinase.  A  possible  antilipolytic 
mechanism. Eur.J.Biochem. 179:249–254, 1989. 
 
Gerich JE: Oral hypoglycemic agents. N. Engl. J. Med. 321:1231-1245, 1989.  
 
Goldner MG, Knatterud GL, Prout TE: Effects of hypoglycemic agents on vascular complications in 
patients with adult-onset diabetes. 3. Clinical implications of UGDP results. JAMA 218:1400-1410, 
1971.  
 
Goldstein BJ, Scalia R: Adiponectin: A novel adipokine linking adipocytes and vascular function. 
J.Clin.Endocrinol.Metab. 89:2563-2568, 2004. 
 
Gollob  MH,  Seger  JJ,  Gollob  TN,  Tapscott  T,  Gonzales  O,  Bachinski  L,  Roberts,  R:  Novel 
PRKAG2  mutation  responsible  for  the  genetic  syndrome  of  ventricular  preexcitation  and 
conduction system disease with childhood onset and absence of cardiac hypertrophy. Circulation 
104:3030–3033, 2001. 
 
Gonon AT, Widegren U, Bulhak A, Salehzadeh F, Persson J, Sjöquist PO, Pernow J: Adiponectin 
protects against myocardial ischaemia-reperfusion injury via AMP-activated protein kinase, Akt, 
and nitric oxide: Cardiovasc.Res. 278:116-122, 2008. 
 
Gorus  FK,  Schuit  FC,  In't Veld PA, Gepts W, Pipeleers DG: Interaction of sulfonylureas with 
pancreatic beta-cells. A study with glyburide. Diabetes 37:1090-1095, 1988. 
 211 
 
211 
 
Goumas G, Tentolouris C, Tousoulis D, Stefanadis C, Toutouzas P: Therapeutic modification of the 
L-arginine-eNOS pathway in cardiovascular diseases. Atherosclerosis 154:255-267, 2001. 
 
Grundy SM, Pasternack R, Greenland P, Smith S, Fuster V: Assessment of cardiovascular risk by 
use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the 
American Heart Association and the American College of Cardiology. Circulation 100:1481-1492, 
1999.  
 
Grundy SM, Cleeman JI, Daniels SR Donato KA, MS, RD, Eckel RH, Franklin BA, PhD; Gordon 
DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F: Diagnosis and management of the 
metabolic  syndrome.  An  American  Heart  Association/National  Heart,  Lung  and  Blood  Institute 
Scientific Statement. Circulation 112:2735-2752, 2005. 
 
Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, Ramachandran A, Anaya-Cisneros 
M, Tian R, Lefer DJ: Activation of AMP-Activated Protein Kinase by Metformin Improves Left 
Ventricular Function and Survival in Heart Failure. Circ. Research 104:403-411, 2009. 
 
Halaas  JL:  Weight-reducing  effects  of  the  plasma  protein  encoded  by  the  obese  gene.  Science 
269:543–546, 1995. 
 
Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N.Engl.J.Med. 352:1685-
1695, 2005. 
 
Haque M: Role of the sympathetic nervous system and insulin in enhancing glucose uptake in 
peripheral tissues after intrahypothalamic injection of leptin in rats. Diabetes 48:1706–1712, 1999. 212 
 
212 
 
Hardie DG: The AMP-activated protein kinase cascade, the key sensor of cellular energy status. 
Endocrinology 144:5179–5183, 2003. 
 
Hardie DG: The AMP-activated protein kinase pathway: new players upstream and downstream. J. 
Cell Sci. 117:5479-5487, 2004.  
 
Harrison DG: Cellular and molecular mechanisms of endothelial cell dysfunction. J.Clin.Invest. 
100:2153-2157, 1997. 
 
Hartell NA, Archer HE, Bailey CJ: Insulin-stimulated endothelial nitric oxide release is calcium 
independent and mediated via protein kinase B. Biochem.Pharmacol. 69:781-790, 2005. 
 
Hattori Y, Suzuki M, Hattori S, Kasai K: Globular adiponectin upregulates nitric oxide production 
in vascular endothelial cells. Diabetologia 46:1543-1549, 2003. 
 
Hattori Y, Kasai K, Gross SS: NO suppresses while peroxynitrite sustains NF-kappaB: a paradigm 
to  rationalize  cytoprotective  and  cytotoxic  actions  attributed  to  NO.  Cardiovasc.Res.  63:31-40, 
2004. 
 
Hattori  Y,  Suzuki  K,  Hattori  S,  Kasai  K:  Metformin  inhibits  cytokine-induced  nuclear  factor 
kappaB  activation  via  AMP-activated  protein  kinase  activation  in  vascular  endothelial  cells. 
Hypertension 47:1183-1188, 2006. 
 213 
 
213 
 
Haupt  E,  Köberich  W,  Beyer  J,  Schöffling  K:  Pharmacodynamic  aspects  of  tolbutamide, 
glibenclamide, glibornuride and glisoxepide. I. Dose response relations and repeated administration 
in diabetic subjects. Diabetologia 7:449-454, 1971. 
 
Hawley SA, Gadalla AE, Olsen GS, Hardie DG: The antidiabetic drug metformin activates the 
AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 
51:2420-2425, 2002. 
 
Hawley  SA,  Boudeau  J,  Reid  JL,  Mustard,  KJ,  Udd  L,  Makela  TP,  Alessi  DR,  Hardie  DG: 
Complexes between the LKB1 tumor suppressor, STRAD α/β and MO25 α/β are upstream kinases 
in the AMP-activated protein kinase cascade. J. Biol. 2:28, 2003. 
 
Hawley  SA,  Pan  DA,  Mustard  KJ,  Ross  L,  Bain  J,  Edelman  AM,  Frenguelli BG, Hardie DG: 
Calmodulin-dependent  protein  kinase  kinase-beta  is  an  alternative  upstream  kinase  for  AMP-
activated protein kinase. Cell Metab. 2:9-19, 2005. 
 
Hetzel J, Balletshofer B, Rittig K, Walcher D, Kratzer W, Hombach V, Haring HU, Koenig W, 
Marx  N:  Rapid  effects  of  rosiglitazone  treatment  on  endothelial  function  and  inflammatory 
biomarkers. Arterioscler.Thromb.Vasc.Biol. 25:1804-1809, 2005. 
 
Heutling D, Schulz H, Nickel I, Kleinstein J, Kaltwasser P, Westphal S, Mittermayer F, Wolzt M, 
Krzyzanowska  K,  Randeva  H,  Schernthaner  G,  Lehnert  H:  Asymmetrical  dimethylarginine, 
inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after 
metformin treatment. J.Clin.Endocrinol.Metab. 93:82-90, 2008. 214 
 
214 
 
Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray 
JJ:  RECORD  Study  Group.  Rosiglitazone  evaluated  for  cardiovascular  outcomes--an  interim 
analysis. N.Engl.J.Med. 357:28-38, 2007. 
 
Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, 
McMurray JJ: RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral 
agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label 
trial. Lancet 373:2125-2135, 2009. 
 
Horike N, Sakoda H, Kushiyama A, Ono H, Fujishiro M, Kamata H, Nishiyama K, Uchijima Y, 
Kurihara  Y,  Kurihara  H,  Asano  T:  AMP-activated  protein  kinase  activation  increases 
phosphorylation of glycogen synthase kinase 3 beta and thereby reduces cAMP-responsive element 
transcriptional  activity  and  phosphoenolpyruvate  carboxykinase  C  gene  expression  in  the  liver. 
J.Biol.Chem. 283:33902-33910, 2008. 
 
Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: 
direct role in obesity-linked insulin resistance. Science 259:87-91, 1993. 
 
Hotamisligil  GS,  Arner  P,  Caro  JF,  Atkinson  RL,  Spiegelman  BM:  Increased  adipose  tissue 
expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J.Clin.Invest. 
95:2409-2415, 1995. 
 
Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, 
Ouchi  N,  Maeda  K,  Nishida  M,  Kihara  S,  Sakai  N,  Nakajima  T,  Hasegawa  K,  Muraguchi M, 
Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y: Plasma concentrations of a 215 
 
215 
 
novel,  adipose-specific  protein,  adiponectin,  in  type  2  diabetic  patients. 
Arterioscler.Thromb.Vasc.Biol. 20:1595-1599, 2000. 
 
Howlett, H.C.S., Bailey, C.J. Metformin: The Gold Standard. Wiley Press First Edition, 2007. 
 
Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K: Prevalence of the metabolic 
syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men 
and women. Arch.Intern.Med. 164:1066-1076, 2004. 
 
Hu S, Wang S, Fanelli B, Bell PA, Dunning BE, Geisse S, Schmitz R, Boettcher BR: Pancreatic 
beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison 
with sulfonylureas and repaglinide. J.Pharmacol.Exp.Ther. 293:444-452, 2000. 
 
Hubbard SR, Wei L, Ellis L, Hendrickson WA: Crystal structure of the tyrosine kinase domain of 
the human insulin receptor. Nature 372:746-754, 1994. 
 
Hubbard SR: Crystal structure of the activated insulin receptor tyrosine kinase in complex with 
peptide substrate and ATP analog. EMBO J. 16:5572-5581, 1997. 
 
Hundal HS, Ahmed A, Gumà A, Mitsumoto Y, Marette A, Rennie MJ, Klip A: Biochemical and 
immunocytochemical localization of the 'GLUT5 glucose transporter' in human skeletal muscle. 
Biochem J. 286:339-343, 1992. 
 216 
 
216 
 
Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann 
WC,  Petersen  KF,  Landau  BR,  Shulman  GI:  Mechanism  by  which  metformin  reduces  glucose 
production in type 2 diabetes. Diabetes 49:2063-2069, 2000. 
 
Hutber  CA,  Hardie  DG,  Winder  WW:  Electrical  stimulation  inactivates  muscle  acetyl-CoA 
carboxylase  and  increases  AMP-activated  protein  kinase.  Am.J.Physiol.Endocrinol.Metab. 
272:262–266, 1997. 
 
Huypens P, Quartier E, Pipeleers D, Van de Casteele M: Metformin reduces adiponectin protein 
expression and release in 3T3-L1 adipocytes involving activation of AMP activated protein kinase. 
Eur.J.Pharmacol. 518:90-95, 2005. 
 
Information Centre Quality Outcomes Framework Data 2005/06. Diabetes Indicators: accessible at 
http://www.ic.nhs.uk/servicesnew/qof06/spreadsheets/ICfolder_view, 2006. 
 
Inukai  K,  Watanabe  M,  Nakashima  Y,  Takata  N,  Isoyama  A,  Sawa  T,  Kurihara  S,  Awata  T, 
Katayama  S:  Glimepiride  enhances  intrinsic  peroxisome  proliferator-activated  receptor-gamma 
activity in 3T3-L1 adipocytes. Biochem.Biophys.Res.Commun. 328:484-490, 2005. 
 
Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287:360-
372, 2002. 
 
Ito N, Rubin GM: Gigas, a Drosophila homolog of tuberous sclerosis gene product-2, regulates the 
cell cycle. Cell 96:529–539, 1999. 
 217 
 
217 
 
Jadhav  S,  Ferrell  W,  Greer  IA,  Petrie  JR,  Cobbe  SM,  Sattar  N:  Effects  of  metformin  on 
microvascular function and exercise tolerance in women with angina and normal coronary arteries: 
a randomized, double-blind, placebo-controlled study. J.Am.Coll.Cardiol. 48:956-963, 2006. 
 
Johansen  K:  Efficacy  of  metformin  in  the  treatment  of  NIDDM.  Meta-analysis.  Diabetes  Care 
22:33-37, 1999. 
 
Johnson AB, Webster JM, Sum CF, Heseltine L, Argyraki M, Cooper BG, Taylor R: The impact of 
metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in 
overweight type II diabetic patients. Metabolism 42:1217-1222, 1993. 
 
Johnson JA, Majumdar SR, Simpson SH, Toth EL: Decreased mortality associated with the use of 
metformin compared with sulfonylurea monotherapy in type 2 diabetes Diabetes Care 25:2244-
2248, 2002. 
 
Jonker JW, Schinkel AH: Pharmacological and physiological functions of the polyspecific organic 
cation transporters, OCT1, 2, and 3 (SLC22A1- SLC22A3). J.Pharmacol.Exp.Therap. 308, 2–9, 
2004. 
 
Jorgensen SB, Viollet B, Andreelli F, Frosig C, Birk JB, Schjerling P, Vaulont S, Richter EA, 
Wojtaszewski JF: Knockout of the alpha2 but not alpha1 5′-AMP-activated protein kinase isoform 
abolishes  5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranosidebut  not  contraction-induced 
glucose uptake in skeletal muscle. J.Biol.Chem. 279:1070–1079, 2004. 
 
Kahn BB, Flier JS: Obesity and insulin resistance. J.Clin.Invest. 106:473–481, 2000. 218 
 
218 
 
 
Kahn BB, Alquier T, Carling D, Hardie, DG: AMP-activated protein kinase: ancient energy gauge 
provides clues to modern understanding of metabolism. Cell Metab. 1:15–25, 2005. 
 
Kanda Y, Matsuda M, Tawaramoto K, Kawasaki F, Hashiramoto M, Matsuki M, Kaku K: Effects 
of sulfonylurea drugs on adiponectin production from 3T3-L1 adipocytes: implication of different 
mechanism from pioglitazone. Diabetes Res.Clin.Pract. 8113-8118, 2008. 
 
Kang KT, Sullivan JC, Sasser JM, Imig JD, Pollock JS: Novel nitric oxide synthase -- dependent 
mechanism of vasorelaxation in small arteries from hypertensive rats. Hypertension 49:893-901, 
2007. 
 
Karttunen P, Uusitupa M, Lamminsivu U: The pharmacokinetics of metformin: a comparison of the 
properties of a rapid-release and a sustained-release preparation. Int.J.Clin.Pharmacol.Ther.Toxicol. 
21:31-36, 1983. 
 
Katakam PVG. Ujhelyi MR. Hoenig M. Miller AW: Metformin Improves Vascular Function in 
Insulin-Resistant Rats. Hypertension 35:108, 2000. 
 
Kelley DE, Simoneau JA: Impaired free fatty acid utilization by skeletal muscle in non-insulin-
dependent diabetes mellitus. J.Clin.Invest. 94:2349-2356, 1994 
 
Kelly  AS,  Thelen  AM,  Kaiser  DR,  Gonzalez-Campoy  JM,  Bank  AJ:  Rosiglitazone  improves 
endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in 
patients with type 2 diabetes mellitus. Vasc.Med. 12:311-318, 2007. 219 
 
219 
 
 
Kelly CJ, Speirs A, Gould GW, Petrie JR, Lyall H, Connell JM: Altered vascular function in young 
women with polycystic ovary syndrome. J.Clin.Endocrinol.Metab. 87:742-746, 2002. 
 
Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB: The expression of tumor 
necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to 
lipoprotein lipase. J.Clin.Invest. 95:2111-2119, 1995. 
 
Kido  Y,  Nakae  J,  Accili  D:  Clinical  review  125:  The  insulin  receptor  and  its  cellular  targets. 
J.Clin.Endocrinol.Metab. 86:972-979, 2001. 
 
Kim  F,  Gallis  B,  Corson  MA:  TNF-alpha  inhibits  flow  and  insulin  signaling  leading  to  NO 
production in aortic endothelial cells. Am.J.Physiol. Cell Physiol. 280:C1057-C1065, 2001. 
 
Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, Noh HL, Cho YR, Cline G, Kim YB, 
Kim JK: Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in 
vivo. Diabetes 53:1060-1067, 2004. 
 
Kim  KA,  Park  JY:  Simple  and  extractionless  high-performance  liquid  chromatographic 
determination of rosiglitazone in human plasma and application to pharmacokinetics in humans. 
Biomed.Chromatogr. 18:613-614, 2004. 
 
Kim  KY,  Cheon  HG:  Antiangiogenic  effect  of  rosiglitazone  is  mediated  via  peroxisome 
proliferator-activated-receptor gamma-activated maxi-K channel opening in human umbilical vein 
endothelial cells. J.Biol.Chem. 281: 13503-13512, 2006 220 
 
220 
 
 
Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, Inui K: Metformin is a superior 
substrate  for  renal  organic  cation  transporter  OCT2  rather  than  hepatic  OCT1.  Drug 
Metab.Pharmacokinet. 20:379-386, 2005. 
 
Kohn AD, Summers SA, Birnbaum MJ, Roth RA: Expression of a constitutively active Akt Ser/Thr 
kinase  in  3T3-L1  adipocytes  stimulates  glucose  uptake  and  glucose  transporter  4  translocation. 
J.Biol.Chem. 271:31372-31378, 1996. 
 
Koistinen HA, Galuska D, Chibalin AV, Yang J, Zierath JR, Holman GD, Wallberg-Henriksson H: 
5-amino-imidazole  carboxamide  riboside  increases  glucose  transport  and  cell-surface  GLUT4 
content in skeletal muscle from subjects with type 2 diabetes. Diabetes 52:1066–1072, 2003. 
 
Kojda G, Harrison D: Interactions between NO and reactive oxygen species: pathophysiological 
importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc.Res. 43:562-571, 
1999. 
 
Kola B, Christ-Crain M, Lolli F, Arnaldi G, Giacchetti G, Boscaro M, Grossman AB, Korbonits M: 
Changes  in  adenosine  5'-monophosphate-activated  protein  kinase  as  a  mechanism  of  visceral 
obesity in Cushing's syndrome. J.Clin.Endocrinol.Metab. 93:4969-4973, 2008.  
 
Konrad D, Rudich A, Bilan PJ, Patel N, Richardson C, Witters LA, Klip A: Troglitazone causes 
acute  mitochondrial  membrane  depolarisation  and  an  AMPK-mediated  increase  in  glucose 
phosphorylation in muscle cells. Diabetologia. 48: 954-966, 2005. 
 221 
 
221 
 
Korytkowski M, Thomas A, Reid L, Tedesco MB, Gooding WE, Gerich J: Glimepiride improves 
both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care 25:1607-1611, 
2002. 
 
Krishnamurthy M, Sahouria JJ, Desai R, Caguiat J: Buformin-induced lactic acidosis--a symptom 
of modern healthcare malady. J.Am. Geriatr. Soc. 52:1785, 2004. 
 
Krzyzanowska  K,  Mittermayer  F,  Kopp  HP,  Wolzt  M,  Schernthaner  G:  Weight  loss  reduces 
circulating  asymmetrical  dimethylarginine  concentrations  in  morbidly  obese  women. 
J.Clin.Endocrinol.Metab. 89:6277-6281, 2004. 
 
Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G: Asymmetric dimethylarginine predicts 
cardiovascular events in patients with type 2 diabetes. Diabetes Care 30:1834–1839, 2007.   
 
Kubota N, Tobe K, Terauchi Y, Eto K, Yamauchi T, Suzuki R, Tsubamoto Y, Komeda K, Nakano 
R,  Miki  H,  Satoh  S,  Sekihara  H,  Sciacchitano  S,  Lesniak  M,  Aizawa  S,  Nagai  R,  Kimura  S, 
Akanuma  Y,  Taylor  SI,  Kadowaki  T:  Disruption  of  insulin  receptor  substrate  2  causes  type  2 
diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. Diabetes 
49:1880-1889, 2000. 
 
Kurebayashi S, Xu X, Ishii S, Shiraishi M, Kouhara H, Kasayama S: A novel thiazolidinedione 
MCC-555 down-regulates tumor necrosis factor-alpha-induced expression of vascular cell adhesion 
molecule-1 in vascular endothelial cells. Atherosclerosis 182:71-77, 2005. 
 222 
 
222 
 
Laakso  M:  Hyperglycemia  and  cardiovascular  disease  in  type  2  diabetes.  Diabetes  48:937-942, 
1999. 
 
Lago RM, Singh PP, Nesto RW: Congestive heart failure and cardiovascular death in patients with 
prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical 
trials. Lancet 370:1129-36, 2007. 
 
Laurent S, Boutouyrie P, Asmar Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A: Aortic 
stiffness  is  an  independent  predictor  of  all-cause  and  cardiovascular  mortality  in  hypertensive 
patients. Hypertension 37:1236-1241, 2001. 
 
Le Gouill E, Jimenez M, Binnert C, Jayet PY, Thalmann S, Nicod P, Scherrer U, Vollenweider P: 
Endothelial  nitric  oxide  synthase  (eNOS)  knockout  mice  have  defective  mitochondrial  beta-
oxidation. Diabetes 56:2690-2696, 2007. 
 
Lebovitz  HE,  Banerji  MA:  Point:  visceral  adiposity  is  causally  related  to  insulin  resistance. 
Diabetes Care 28:2322-2325, 2005 
 
Lebrasseur  NK,  Kelly  M,  Tsao  TS,  Farmer  SR,  Saha  AK,  Ruderman  NB,  Tomas  E: 
Thiazolidinediones  can  rapidly  activate  AMP-activated  protein  kinase  in  mammalian  tissues. 
Am.J.Physiol.Endocrinol.Metab. 291: E175-E181, 2006. 
 
Leclerc I, Woltersdorf WW, da Silva Xavier G, Rowe RL, Cross SE, Korbutt GS, Rajotte RV, 
Smith  R,  Rutter  GA:  Metformin,  but  not  leptin,  regulates  AMP-activated  protein  kinase  in 223 
 
223 
 
pancreatic islets: impact on glucose-stimulated insulin secretion. Am.J.Physiol.Endocrinol.Metab. 
286:1023–1031, 2004. 
 
Lehmann ED, Gosling RG, Sonksen PH: Arterial wall compliance in diabetes. Diabet. Med. 9:114–
119, 1992. 
 
Lehmann  JM,  Moore  LB,  Smith-Oliver  TA,  Wilkison  WO,  Willson  TM,  Kliewer  SA.  An 
antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor 
gamma (PPAR gamma). J.Biol.Chem. 270:12953-12956, 1995. 
 
Lewis  GF,  Carpentier  A,  Adeli  K,  Adria  G:  Disordered  Fat  Storage  and  Mobilization  in  the 
Pathogenesis of Insulin Resistance and Type 2 Diabetes. Endocrine Reviews 23: 201-229, 2002. 
 
Liao Y, Takashima S, Maeda N, Ouchi N, Komamura K, Shimomura I, Hori M, Matsuzawa Y, 
Funahashi  T,  Kitakaze  M:  Exacerbation  of  heart  failure  in  adiponectin-deficient  mice  due  to 
impaired regulation of AMPK and glucose metabolism. Cardiovasc.Res. 67:705-713, 2005. 
  
Lillioja  S,  Mott  DM,  Spraul  M,  Ferraro  R,  Foley  JE,  Ravussin  E,  Knowler  WC,  Bennett  PH, 
Bogardus  C:  Insulin  resistance  and  insulin  secretory  dysfunction  as  precursors  of  non-insulin-
dependent diabetes mellitus. N.Engl.J.Med. 329:1988–1992, 1993 
 
Lin MI, Fulton D, Babbitt R, Fleming I, Busse R, Pritchard KA Jr, Sessa WC: Phosphorylation of 
threonine  497  in  endothelial  nitric-oxide  synthase  coordinates  the  coupling  of  L-arginine 
metabolism to efficient nitric oxide production. J.Biol.Chem. 278:44719-44726, 2003. 
 224 
 
224 
 
Lindsay  RS,  Funahashi  T,  Hanson  RL,  Matsuzawa  Y,  Tanaka  S,  Tataranni  PA,  Knowler  WC, 
Krakoff J: Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 
360:57-58, 2002. 
 
Lindsay RS, Resnick HE, Zhu J, Tun ML, Howard BV, Zhang Y, Yeh J, Best LG: Adiponectin and 
coronary heart disease: the Strong Heart Study. Arterioscler.Thromb.Vasc.Biol. 25:15-16, 2005. 
 
Liu J, Garcia-Cardena G, Sessa WC: Biosynthesis and palmitoylation of endothelial nitric oxide 
synthase:  mutagenesis  of  palmitoylation  sites,  cysteines  -15  and/or  -26,  argues  against 
depalmitoylation-induced translocation of the enzyme. Biochemistry 34:12333-12340, 1995. 
 
Lizcano JM, Goransson O, Toth R, Deak M, Morrice, NA, Boudeau J, Hawley SA, Udd L, Makela 
TP,  Hardie  DG,  Alessi  DR:  LKB1  is  a  master  kinase  that  activates  13  kinases  of  the  AMPK 
subfamily, including MARK/PAR-1. EMBO J. 23:833-843, 2004. 
 
Lochhead PA, Salt IP, Walker KS, Hardie DG, Sutherland C: 5-Aminoimidazole-4-carboxamide 
riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK 
and glucose-6-phosphatase. Diabetes 49:896-903, 2000.  
 
Lochhead  PA,  Coghlan  M.P,  Rice  SQJ,  Sutherland  C:  Inhibition  of  GSK3  selectively  reduces 
G6Pase and PEPCK gene expression. Diabetes 50:937-947, 2001. 
 
London GM, Marchais SJ, Safar ME, Genest AF, Guerin AP, Metivier F, Chedid K, London AM: 
Aortic and large artery compliance in end-stage renal failure. Kidney Int. 37:137–142, 1990. 
 225 
 
225 
 
Long  YC,  Zierath  JR:  AMP-activated  protein  kinase  signaling  in  metabolic  regulation. 
J.Clin.Invest. 116:1776-1783, 2006. 
 
Ludvik B, Nolan J, Baloga J, Sacks D, Olefsky J: Effect of obesity on insulin resistance in normal 
subjects and patients with NIDDM. Diabetes 44:1121-1125, 1995. 
Luiken,  JJ,  Coort  SL,  Willems  J,  Coumans  WA,  Bonen  A.,  van  der  Vusse  GJ,  Glatz,  JF: 
Contraction-induced fatty acid translocase/CD36 translocation in rat cardiac myocytes is mediated 
through AMP-activated protein kinase signaling. Diabetes 52:1627–1634, 2003. 
 
Lundman  P,  Eriksson  MJ,  Stuhlinger  M,  Cooke  JP,  Hamsten  A,  Tornvall  P:  Mild-to-moderate 
hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma 
concentrations of asymmetric dimethylarginine. J.Am.Coll.Cardiol. 38:111–116, 2001. 
 
Luo M, Langlais P, Yi Z, Lefort N, De Filippis EA, Hwang H, Christ-Roberts CY, Mandarino LJ: 
Phosphorylation of human insulin receptor substrate-1 at Serine 629 plays a positive role in insulin 
signaling. Endocrinology 148:4895-4905, 2007. 
 
Macgowan CK, Henkelman RM, Wood ML: Pulse-wave velocity measured in one heartbeat using 
MR tagging. Magn.Reson.Med. 48:115-121, 2002. 
 
MacKenzie IS, Wilkinson IB, Cockcroft JR: Assessment of arterial stiffness in clinical practice. 
Q.J.Med. 95:67-74, 2002. 
 226 
 
226 
 
Maguire SM, Nugent AG, McGurk C, Johnston GD, Nicholls DP: Abnormal vascular responses in 
human chronic cardiac failure are both endothelium dependent and endothelium independent. Heart 
80:141-145, 1998. 
 
Mahmud A, Feely J: Effect of Smoking on Arterial Stiffness and Pulse Pressure Amplification. 
Hypertension 41:183-187, 2003. 
 
Mahomed FA: The physiology and clinical use of the sphygmograph. Med. Times Gazette 1:62, 
1872 
 
Mather KJ, Verma S, Anderson TJ: Improved Endothelial Function with Metformin in Type 2 
Diabetes Mellitus. Journal of the American College of Cardiology 37: 1344-1350, 2001. 
 
Matthaei  S,  Reibold  JP,  Hamann  A,  Benecke  H,  Häring  HU,  Greten  H,  Klein  HH:  In  vivo 
metformin  treatment  ameliorates  insulin  resistance:  evidence  for  potentiation of insulin-induced 
translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat 
adipocytes. Endocrinology 133:304-311, 1993. 
 
McAuley D, McGurk C, Nugent AG, Hanratty C, Maguire S, Johnston GD: Forearm endothelium-
dependent  vascular  responses  and  the  potassium-ATP  channel.  British  Journal  of  Clinical 
Pharmacology 44: 292-294, 1997. 
 
McDonald DA, Taylor MG: The hydrodynamics of the arterial circulation. Progr.Biophys.Chem. 
9:697-716, 1959. 
 227 
 
227 
 
McLaughlin T, Stühlinger M, Lamendola C, Abbasi F, Bialek J, Reaven GM, Tsao PS: Plasma 
asymmetric dimethylarginine concentrations are elevated in obese insulin-resistant women and fall 
with weight loss. J.Clin.Endocrinol.Metab. 91:1896-1900, 2006. 
 
McManus EJ, Sakamoto K, Armit LJ, Ronaldson L, Shpiro N, Marquez R, Alessi DR: Role that 
phosphorylation of GSK3 plays in insulin and Wnt-signalling defined by knockin analysis. EMBO 
J. 24:1571-1583, 2005 
 
McNeil AM, Rosamund WD, Girman CJ, Golden SH, Schmidy MI, East HE, Ballantyne CM, Heiss 
G:  The  Metabolic  Syndrome  and  11-Year  Risk  of  Incident  Cardiovascular  Disease  in  the 
Atherosclerosis Risk in Communities Study. Diabetes Care 28:385-390, 2005 
 
Meaume S, Benetos A, Henry OF, Rudnichi A, Safar ME: Aortic pulse wave velocity predicts 
cardiovascular  mortality  in  subjects  >70  years  of  age.  Arterioscler.Thromb.Vasc.Biol.  21:2046-
2050, 2001. 
 
Meijssen S, Cabezas MC, Ballieux CG, Derksen RJ, Bilecen S, Erkelens DW: Insulin mediated 
inhibition of hormone sensitive lipase activity in vivo in relation to endogenous catecholamines in 
healthy subjects. J.Clin.Endocrinol.Metab. 86:4193-4197, 2001. 
 
Merril GF, Kurth EJ, Hardie DG, Winder WW: AICA riboside increases AMP-activated protein 
kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am.J.Physiol. 273: 1107–1112, 1997.  
 
Michel T, Feron O: Nitric oxide synthases: which, where, how, and why? J.Clin.Invest. 100:2146-
2152, 1997. 228 
 
228 
 
 
Miles JM, Jensen MD: Counterpoint: visceral adiposity is not causally related to insulin resistance. 
Diabetes Care 28:2326-2328, 2005. 
 
Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, Kahn BB: Leptin stimulates 
fatty-acid oxidation by activating AMP-activated protein kinase. Nature  415:339–343, 2002. 
 
Minokoshi  Y,  Alquier  T,  Furukawa  N,  Kim  YB,  Lee  A,  Xue  B,  Mu  J,  Foufelle  F,  Ferré  P, 
Birnbaum MJ, Stuck BJ, Kahn BB: AMP-kinase regulates food intake by responding to hormonal 
and nutrient signals in the hypothalamus. Nature 428:569-574, 2004. 
 
Misbin RI: The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes 
Care 27:1791-1793, 2004. 
 
Mithieux G, Rajas F, Zitoun C: Glucose utilization is suppressed in the gut of insulin-resistant high 
fat-fed rats and is restored by metformin. Biochem.Pharmacol. 72:1757-1762, 2006. 
 
Mittermayer F, Mayer BX, Meyer A, Winzer C, Pacini G, Wagner OF, Wolzt M, Kautzky-Willer 
A: Circulating concentrations of asymmetrical dimethyl-L-arginine are increased in women with 
previous gestational diabetes. Diabetologia 45:1372-1378, 2002. 
 
Mittermayer F, Krzyzanowska K, Exner M, Mlekusch W, Amighi J, Sabeti S, Minar E, Muller M, 
Wolzt  M,  Schillinger  M:  Asymmetric  dimethylarginine  predicts  major  adverse  cardiovascular 
events in patients with advanced peripheral artery disease. Arterioscler.Thromb.Vasc.Biol. 26:2536–
2540, 2006. 229 
 
229 
 
 
Mizuno TM, Kleopoulos SP, Bergen HT, Roberts JL, Priest CA, Mobbs CV: Hypothalamic pro-
opiomelanocortin mRNA is reduced by fasting and [corrected] in ob/ob and db/db mice, but is 
stimulated by leptin. Diabetes 47:294-297, 1998.  
 
Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW: 
Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. 
J.Clin.Endocrinol.Metab. 82:4196-4200, 1997. 
 
Mohiaddin  RH,  Firmin  DN,  Longmore  DB:  Age-related  changes  of  human  aortic  flow  wave 
velocity  measured  noninvasively  by  magnetic  resonance  imaging.  J.Appl.Physiol.  74:492-497, 
1993. 
 
Moncada S, Higgs A: The L-arginine -nitric oxide pathway. N.Engl.J.Med. 329:2002-2012, 1993. 
Montagnani M, Chen H, Barr VA, Quon MJ: Insulin-stimulated activation of eNOS is independent 
of Ca2+ but requires phosphorylation by Akt at Ser(1179). J.Biol.Chem. 276:30392-30398, 2001. 
 
Montagnani M, Golovchenko I, Kim I, Koh GY, Goalstone ML, Mundhekar AN, Johansen M, 
Kucik DF, Quon MJ, Draznin B: Inhibition of phosphatidylinositol 3-kinase enhances mitogenic 
actions of insulin in endothelial cells. J.Biol.Chem. 277:1794-1799, 2002. 
 
Montagnani M, Ravichandran LV, Chen H, Esposito DL, Quon MJ: Insulin receptor substrate-1 and 
phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide 
in endothelial cells. Mol.Endocrinol. 16:1931-1942, 2002. 
 230 
 
230 
 
Morrow VA, Foufelle F, Connell JM, Petrie JR, Gould GW, Salt IP: Direct activation of AMP-
activated  protein  kinase  stimulates  nitric  -oxide  synthesis  in  human  aortic  endothelial  cells. 
J.Biol.Chem. 278:31629-31639, 2003. 
 
Mount PF, Hill RE, Fraser SA, Levidiotis V, Katsis F, Kemp BE, Power DA: Acute renal ischemia 
rapidly activates the energy sensor AMPK but does not increase phosphorylation of eNOS-Ser1177. 
Am.J.Physiol.Renal.Physiol. 289:1103-1115, 2005. 
 
Mu J, Brozinick JT, Valladares O, Bucan M, Birnbaum MJ: A role for AMP-activated protein 
kinase  in  contraction-  and  hypoxia-regulated  glucose  transport  in  skeletal  muscle.  Mol.Cell. 
7:1085–1094, 2001. 
 
Mulvany  M:  Procedures  for  investigation  of  small  vessels  using  small  vessel  myograph.  J.P 
Trading, Aarhus, Denmark, 1999. 
 
Mulvany MJ, Halpern W: Contractile properties of small arterial resistance vessels in spontaneously 
hypertensive and normotensive rats. Circ.Res. 41:19-26, 1977. 
 
Mulvany MJ, Aalkjaer C: Structure and function of small arteries. Physiol.Rev. 70:921-961, 1990.  
 
Mulvany MJ: Small Artery Remodeling in Hypertension. Curr.Hypertens.Rep. 4:49-55, 2002. 
 
Munday MR, Campbell DG, Carling, D, Hardie DG: Identification by amino acid sequencing of 
three  major  regulatory  phosphorylation  sites  on  rat  acetyl-CoA  carboxylase.  Eur.J.Biochem. 
175:331–338, 1998. 231 
 
231 
 
 
Muniyappa R, Montagnani M, Koh KK, Quon MJ: Cardiovascular actions of insulin. Endocr.Rev. 
28:463-491, 2007. 
 
Muoio  DM,  Dohm  GL,  Fiedorek  FT,  Tapscott  EB,  Coleman  RA:  Leptin  directly  alters  lipid 
partitioning in skeletal muscle. Diabetes 46:1360–1363, 1997. 
 
Musi N, Fujii N, Hirshman MF, Ekberg I, Froberg S, Ljungqvist O, Thorell A, Goodyear LJ: AMP-
activated protein kinase (AMPK) is activated in muscle of subjects with type 2 diabetes during 
exercise. Diabetes 50:921–927, 2001. 
 
Musi, N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, Zhou G Williamson 
JM,  Ljunqvist  O,  Efendic  S,  Moller  DE,  Thorell  A,  Goodyear  LJ:  Metformin  increases  AMP-
activated  protein  kinase  activity  in  skeletal  muscle  of  subjects  with  type  2  diabetes.  Diabetes 
51:2074-2081, 2002. 
 
Natali A, Baldeweg S, Toschi E, Capaldo B, Barbaro D, Gastaldelli A, Yudkin JS, Ferrannini E: 
Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. 
Diabetes Care 27: 1349–1357, 2004. 
 
Nichols WW, Edwards DG: Arterial elastance and wave reflection augmentation of systolic blood 
pressure: deleterious effects and implications for therapy. J.Cardiovasc.Pharmacol.Ther. 6:5-21, 
2001. 
 232 
 
232 
 
Nichols WW, Singh BM: Augmentation index as a measure of peripheral vascular disease state. 
Curr.Opin.Cardiol. 17:543-551, 2002. 
 
Nieto-Vazquez I, Fernandez-Veledo S, de Alvaro C, Lorenzo M: Dual role of interleukin -6 in 
regulating insulin sensitivity in murine skeletal muscle. Diabetes 57:3211-3221, 2008. 
 
Nisoli E, Tonello C, Cardile A, Cozzi V, Bracale R, Tedesco L, Falcone S, Valerio A, Cantoni O, 
Clementi E, Moncada S, Carruba MO: Calorie restriction promotes mitochondrial biogenesis by 
inducing the expression of eNOS. Science 310:314-317, 2005. 
 
Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from 
cardiovascular causes. N.Engl.J.Med. 356, 2457-2471, 2007. 
 
O’Rourke M, Staessen J, Vlachopoulos C, Duprez D, Plante G: Clinical applications of arterial 
stiffness; definitions and reference values. Am.J.Hypertens. 15:426-444, 2002.  
 
O’Rourke MF: Mechanical principles in arterial disease. Hypertension 26:2-9, 2005. 
 
Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R: Effects of an engineered human anti-TNF-alpha 
antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 
45:881-885, 1996. 
 
Orio F Jr, Palomba S, Cascella T, De Simone B, Manguso F, Savastano S, Russo T, Tolino A, Zullo 
F,  Lombardi  G,  Azziz  R,  Colao  A:  Improvement  in  endothelial  structure  and  function  after 233 
 
233 
 
metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 
6-month study. J.Clin.Endocrinol.Metab. 90:6072-5076, 2005.  
 
Ouchi N, Kobayashi H, Kihara S, Kumada M, Sato K, Inoue T, Funahashi T, Walsh K: Adiponectin 
stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt 
signaling in endothelial cells. J.Biol.Chem. 279:1304-1309, 2004. 
 
Owen MR, Doran E, Halestrap AP: Evidence that metformin exerts its anti-diabetic effects through 
inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 348, 607–614, 2000. 
 
Palm  F,  Onozato  ML,  Luo  Z,  Wilcox  CS:  Dimethylarginine  dimethylaminohydrolase (DDAH): 
expression, regulation, and function in the cardiovascular and renal systems. Am.J.Physiol. Heart 
Circ.Physiol. 293:3227-3245, 2007. 
 
Paquot  N,  Castillo MJ, Lefebvre PJ, Scheen AJ: No increased insulin sensitivity after a single 
intravenous  administration  of  a  recombinant  human  tumor  necrosis  factor  receptor:  Fc  fusion 
protein in obese insulin-resistant patients. J.Clin.Endocrinol.Metab. 85:1316-1319, 2000. 
 
Perriello  G,  Misericordia  P,  Volpi  E,  Santucci  A,  Santucci  C,  Ferrannini  E,  Ventura  MM, 
Santeusanio  F,  Brunetti  P,  Bolli  GB:  Acute  antihyperglycemic  mechanisms  of  metformin  in 
NIDDM.  Evidence  for  suppression  of  lipid  oxidation  and  hepatic  glucose  production. Diabetes 
43:920-928, 1994. 
 
Petersen  KF,  Dufour  S,  Savage  DB,  Bilz  S,  Solomon  G,  Yonemitsu  S,  Cline  GW,  Befroy  D, 
Zemany L, Kahn BB, Papademetris X, Rothman DL, Shulman GI: The role of skeletal muscle 234 
 
234 
 
insulin  resistance  in  the  pathogenesis  of  the  metabolic  syndrome.  Proc.Natl.Acad.Sci.U.S.A. 
104:12587-12594, 2007. 
 
Peuler JD: Opposing adrenergic actions of intravenous metformin on arterial pressure in female 
spontaneously hypertensive rats. Cardiovascular Research 43: 237-247, 1999. 
 
Phillips SA, Ciaraldi TP, Kong AP, Bandukwala R, Aroda V, Carter L, Baxi S, Mudaliar SR, Henry 
RR:  Modulation  of  circulating  and  adipose  tissue  adiponectin  levels  by  antidiabetic  therapy. 
Diabetes 52:667-674, 2003. 
 
Pistrosch  F,  Passauer  J,  Fischer  S,  Fuecker  K,  Hanefeld  M,  Gross  P:  In  type  2  diabetes, 
rosiglitazone  therapy  for  insulin  resistance  ameliorates  endothelial  dysfunction  independent  of 
glucose control. Diabetes Care 27: 484–490, 2004. 
 
Ploug T, Galbo H, Richter EA: Increased muscle glucose uptake during contractions: no need for 
insulin. Am.J.Physiol. 247:726-731, 1984. 
 
Podor TJ, Jirik FR, Loskutoff DJ, Carson DA, Lotz M: Human endothelial cells produce IL-6. Lack 
of responses to exogenous IL-6. Ann.N.Y.Acad.Sci. 557:374-385, 1989. 
 
Polikandriotis JA, Mazzella LJ, Rupnow HL, Hart CM: Peroxisome proliferatoractivated receptor 
gamma  ligands  stimulate  endothelial  nitric  oxide  production  through  distinct  peroxisome 
proliferator-activated  receptor  gamma-dependent  mechanisms.  Arterioscler.Thromb.Vasc.Biol. 
25:1810-1816, 2005  
 235 
 
235 
 
Potter CJ, Huang H, Xu T: Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in 
regulating cell growth, cell proliferation, and organ size. Cell 105:357–368, 2001. 
 
Potter CJ, Pedraza LG, Xu T: Akt regulates growth by directly phopshorylating Tsc2. Nat.Cell Biol. 
4:658-665, 2002. 
 
Rajan AS, Aguilar-Bryan L, Nelson DA, Yaney GC, Hsu WH, Kunze DL, Boyd AE: Ion channels 
and insulin secretion. Diabetes Care 13:340-363, 1990. 
 
Raju TN: The Nobel chronicles. 1998: Robert Francis Furchgott (b 1911), Louis J Ignarro (b 1941), 
and Ferid Murad (b 1936). Lancet 356:346, 2000. 
 
Reihill  JA,  Ewart  MA,  Hardie  DG,  Salt  IP  AMP-activated  protein  kinase  mediates  VEGF-
stimulated endothelial NO production. Biochem.Biophys.Res.Commun. 354: 1084–1088, 2007. 
 
Riek U, Scholz R, Konarev P, Rufer A, Suter M, Nazabal A, Ringler P, Chami M, Muller SA, 
Neumann D, Forstner M, Hennig M, Zenobi R, Engel A, Svergun D, Schlattner U, Wallimann T: 
Structural properties of AMP-activated protein kinase: dimerization, molecular shape, and changes 
upon ligand binding. J.Biol.Chem. 283:18331–18343, 2008. 
 
Ross R: Atherosclerosis is an inflammatory disease. Am.Heart J. 138:S419-S420, 1999.  
 
Rotter V, Nagaev I, Smith U: Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes 
and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-
resistant subjects. J.Biol.Chem. 278:45777-45784, 2003. 236 
 
236 
 
 
Ruderman  NB,  Saha  AK,  Vavvas  D,  Witters,  LA:  Malonyl-CoA,  fuel  sensing,  and  insulin 
resistance. Am. J.Physiol.Endocrinol.Metab. 276:1-18, 1999.  
 
Russell  RR,  Bergeron  R,  Shulman  GI,  Young  LH:  Translocation  of  myocardial  GLUT-4  and 
increased glucose uptake through activation of AMPK by AICAR. Am.J.Physiol. 277: 643–649, 
1999. 
 
Russell RR, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, Giordano FJ, Mu J, Birnbaum MJ, 
Young, LH: AMP-activated protein kinase mediates ischemic glucose uptake and prevents post 
ischemic cardiac dysfunction, apoptosis, and injury. J.Clin.Invest. 114: 495–503, 2004. 
 
Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D: Metformin monotherapy 
for type 2 diabetes mellitus. Cochrane Database Systematic Reviews, CD002966, 2005.  
 
Saha AK, Avilucea PR, Ye JM, Assifi MM, Kraegen EW, Ruderman NB: Pioglitazone treatment 
activates  AMP-activated  protein  kinase  in  rat  liver  and  adipose  tissue  in  vivo. 
Biochem.Biophys.Res.Commun. 314: 580-585, 2004. 
 
Sakamoto K, Goransson O, Hardie DG, Alessi DR: Activity of LKB1 and AMPK-related kinases in 
skeletal muscle: effects of contraction, phenformin, and AICAR. Am.J.Physiol.Endocrinol.Metab. 
287:310-317, 2004. 
 237 
 
237 
 
Sakamoto K, McCarthy A, Smith D, Green KA, Hardie DG, Ashworth A, Alessi DR. Deficiency of 
LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO 
J. 24:1810-1820, 2005. 
 
Salt IP, Johnson G, Ashcroft SJ, Hardie DG: AMP-activated protein kinase is activated by low 
glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release. Biochem.J. 
335 (Pt 3):533-539, 1998. 
 
Salt  IP,  Connell  JM,  Gould  GW:  5-aminoimidazole-4-carboxamide  ribonucleoside  (AICAR) 
inhibits insulin-stimulated glucose transport in 3T3-L1 adipocytes. Diabetes 49:1649-1656, 2000. 
 
Salt IP, Morrow VA, Brandie FM, Connell JM, Petrie JR: High glucose inhibits insulin stimulated 
nitric oxide production without reducing endothelial nitric-oxide synthase Ser1177 phosphorylation 
in human aortic endothelial cells. J.Biol.Chem. 278:18791-18797, 2003. 
 
Saltiel AR, Kahn CR: Insulin signalling and the regulation of glucose and lipid metabolism. Nature 
414:799-806, 2001. 
 
Saltiel AR, Pessin JE: Insulin signalling pathways in time and space. Trends. Cell. Biol. 12:65-71, 
2002. 
 
Sanders MJ, Grondin PO, Hegarty BD, Snowden MA, Carling D: Investigating the mechanism for 
AMP activation of the AMP-activated protein kinase cascade. The Biochemical journal. 403:139–
148, 2007.  
 238 
 
238 
 
Sanger F: The early days of DNA sequences. Nat.Med. 7:267-268, 2001. 
 
Sano H, Kane S, Sano, E, Miinea CP, Asara JM, Lane WS, Garner CW, Lienhard GE: Insulin-
stimulated  phosphorylation  of  a  Rab  GTPase-activating  protein  regulates  GLUT4  translocation. 
J.Biol.Chem. 278:14599-14602, 2003 
 
Sapkota GP, Deak M, Kieloch A, Morrice N, Goodarzi AA, Smythe C, Shiloh Y, Lees-Miller SP, 
Alessi  DR:  Ionizing  radiation  induces  ataxia  telangiectasia  mutated  kinase  (ATM)-mediated 
phosphorylation of LKB1/STK11 at Thr-366. Biochem.J. 368:507-516, 2002. 
 
Sarbassov DD, Guertin DA, Ali SM, Sabatini DM: Phosphorylation and regulation of Akt/PKB by 
the rictor-mTOR complex. Science 307:1098-1101, 2005. 
 
Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, Sugiyama H, Sugawara A, Yamada K, 
Shimatsu A, Kuzuya H, Nakao K: Antiatherogenic effect of pioglitazone in type 2 diabetic patients 
irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26: 2493–2499, 2003. 
 
Sattar  N,  Gaw  A,  Scherbakova  O,  Ford  I,  O'Reilly  DS,  Haffner  SM,  Isles  C, Macfarlane PW, 
Packard CJ, Cobbe SM, Shepherd J Metabolic syndrome with and without C-reactive protein as a 
predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. 
Circulation 108:414-419, 2003. 
 
Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, Wallace AM, Danesh J, Whincup PH: 
Adiponectin  and  coronary  heart  disease:  a  prospective  study  and  meta-analysis.  Circulation 
114:623-629, 2006. 239 
 
239 
 
 
Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF: A novel serum protein similar to C1q, 
produced exclusively in adipocytes. J.Biol.Chem. 270:26746-26749, 1995.  
 
Schiffrin EL Reactivity of small blood vessels in hypertension: relation with structural changes. 
State of the art lecture. Hypertension 19:1-9, 1992. 
 
Schmid-Antomarchi  H,  De  Weille  J,  Fosset  M,  Lazdunski  M:  The  receptor  for  antidiabetic 
sulfonylureas  controls  the  activity  of  the  ATP-modulated  K+  channel  in  insulin-secreting  cells. 
J.Biol.Chem. 262:15840-15844, 1987. 
 
Schofield I, Malik R, Izzard A, Austin C, Heagerty A: Vascular Structural and Functional Changes 
in Type 2 Diabetes Mellitus. Evidence for the Roles of Abnormal Myogenic Responsiveness and 
Dyslipidemia. Circulation 10:3037-3043, 2002. 
 
Schwartz MW, Seeley RJ, Campfield LA, Burn P, Baskin DG: Identification of targets of leptin 
action in rat hypothalamus. J.Clin.Invest. 98:1101-1106, 1996. 
 
Schwartz MW, Erickson JC, Baskin DG, Palmiter RD: Effect of fasting and leptin deficiency on 
hypothalamic neuropeptide Y gene transcription in vivo revealed by expression of a lacZ reporter 
gene. Endocrinology 139:2629-2635, 1998. 
 
Schwartz MW, Woods SC, Porte D, Seeley RJ, Baskin DG: Central nervous system control of food 
intake. Nature. 404:661–671, 2000. 
 240 
 
240 
 
Semple  RK,  Chatterjee  VK,  O’Rahilly  S:  PPAR  gamma  and  human  metabolic  disease. 
J.Clin.Invest. 116:581-589, 2006. 
 
Senn JJ, Klover PJ, Nowak IA, Mooney RA: Interleukin-6 induces cellular insulin resistance in 
hepatocytes. Diabetes 51:3391-3399, 2002. 
 
Sesti G, Federici M, Hribal ML, Lauro D, Sbraccia P, Lauro R: Defects of the insulin receptor 
substrate (IRS) system in human metabolic disorders. FASEB J. 15:2099-2111, 2001. 
 
Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC:  
The  kinase  LKB1  mediates  glucose  homeostasis  in  liver  and  therapeutic  effects  of  metformin. 
Science 310:1642–1646, 2005.  
 
Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi T, Ouchi N, Walsh 
K: Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-
2-dependent mechanisms. Nat.Med. 11:1096–1103, 2005. 
 
Shimokawa H and Takeshita A: Endothelium-Dependent regulation of the Cardiovascular system. 
Int. Med. 34:939-946, 1995. 
 
Shimokawa H, Yasutake H, Fujii K, Owada MK, Nakaike R, Fukumoto Y, Takayanagi T, Nagao T, 
Egashira K, Fujishima M, Takeshita A: The importance of the hyperpolarizing mechanism increases 
as  the  vessel  size  decreases  in  endothelium-dependent  relaxations  in  rat  mesenteric  circulation. 
J.Cardiovasc.Pharmacol. 5:703-711, 1996. 
 241 
 
241 
 
Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D, Kawamoto M, Johns SJ, 
DeYoung J, Carlson E, Ferrin TE, Herskowitz I, Giacomini KM: Pharmacogenetics Of Membrane 
Transporters Investigators. Evolutionary conservation predicts function of variants of the human 
organic cation transporter, OCT1. Proc.Natl.Acad.Sci.U.S.A. 100:5902-5907, 2003. 
 
Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, 
Burchard  EG,  Brett  CM,  Giacomini  KM:  Effect  of  genetic  variation  in  the  organic  cation 
transporter 1 (OCT1) on metformin action. J.Clin.Invest. 117:1422-1431, 2007. 
 
Stehouwer  CD,  Lambert  J,  Donker  AJ,  van  Hinsberg  VW:  Endothelial  dysfunction  and 
pathogenesis of diabetic angiopathy. Cardiovac.Res. 34:55-68, 1997.  
 
Steinberg  HO,  Baron  AD:  Vascular  Function,  insulin  resistance  and  fatty  acids.  Diabetologia 
45:623-634, 2002. 
 
Sterne J: The present state of knowledge on the mode of action of the antidiabetic diguanides. 
Metabolism 13:791-798, 1964.  
 
Sterne J: Aspects of pharmacology and mechanism of action. Research Clinical Forums 1:13-20, 
1979. 
 
Stühlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao 
PS:  Relationship  between  insulin  resistance  and  an  endogenous  nitric  oxide  synthase  inhibitor. 
JAMA 287: 1420-1426, 2002. 
 242 
 
242 
 
Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, Kapoor O, Szuba A, Malinow MR, 
Wascher TC, Pachinger O, Cooke JP: Endothelial dysfunction induced by hyperhomocyst(e)inemia: 
role of asymmetric dimethylarginine. Circulation 108:933–938, 2003. 
 
Sturgess  NC, Ashford ML, Cook DL, Hales CN: The sulphonylurea receptor may be an ATP-
sensitive potassium channel. Lancet 2:474-5, 1985. 
 
Sullivan JE, Brocklehurst KJ, Marley AE, Carey F, Carling D, Beri RK: Inhibition of lipolysis and 
lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated 
protein kinase. FEBS Lett. 353:33–36, 1994. 
 
Sutherland,  C,  Leighton,  IA  and  Cohen  P:  Inactivation  of  glycogen  synthase  kinase-3β  by 
phosphorylation; new kinase connections in insulin and growth factor signaling. Biochem.J. 296:15-
19, 1993. 
 
Taddei  S,  Salvetti  A:  Endothelial  dysfunction  in  essential  hypertension:  clinical  implications. 
J.Hypertens. 20:1671-674, 2002. 
 
Tamemoto H, Kadowaki T, Tobe K, Yagi T, Sakura H, Hayakawa T, Terauchi Y, Ueki K, Kaburagi 
Y,  Satoh  S,  Sekihara  H,  Yoshioka S, Horikoshi H, Furuta Y, Ikawa Y, Kasuga M, Yazaki Y, 
Aizawa S: Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. 
Nature 372:182-186, 1994. 
 
Tan KC, Xu A, Chow WS, Lam MC, Ai VH, Tam SC, Lam KS: Hypoadiponectinemia is associated 
with impaired endothelium -dependent vasodilation. J.Clin.Endocrinol.Metab 89:765-769, 2004. 243 
 
243 
 
 
Tapon  N,  Ito  N,  Dickson  BJ,  Treisman  JE,  Hariharan  IK.  The  Drosophila  tuberous  sclerosis 
complex gene homologs restrict cell growth and cell proliferation. Cell 105:345–355, 2001. 
 
Teerlink  T:  Determination  of  the  endogenous  nitric  oxide  synthase  inhibitor  asymmetric 
dimethylarginine in biological samples by HPLC. Meth.Mol.Med. 108:263–274, 2005. 
 
Tiikkainen  M,  Häkkinen  AM,  Korsheninnikova  E,  Nyman  T,  Mäkimattila  S,  Yki-Järvinen  H: 
Effects  of  rosiglitazone  and  metformin  on  liver  fat  content,  hepatic  insulin  resistance,  insulin 
clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53:2169-
2176, 2004. 
 
Tomas  E,  Tsao  TS,  Saha  AK,  Murrey  HE,  Zhang  Cc  C,  Itani  SI,  Lodish  HF,  Ruderman  NB: 
Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA 
carboxylase  inhibition  and  AMP-activated  protein  kinase  activation.  Proc.Natl.Acad.Sci.U.S.A. 
99:16309-16313, 2002. 
 
Towler MC, Hardie DG: AMP-activated protein kinase in metabolic control and insulin signaling. 
Circ.Res. 100:328-341, 2007. 
 
Treebak JT, Birk JB, Rose AJ, Kiens B, Richter EA, Wojtaszewski JF: AS160 phosphorylation is 
associated  with  activation  of  alpha2beta2gamma1-  but  not  alpha2beta2gamma3-AMPK  trimeric 
complex in skeletal muscle during exercise in humans. Am.J.Physiol.Endocrinol.Metab. 292:715–
722, 2007.  
 244 
 
244 
 
Trumble G, Smith M, Winder W: Purification and characterization of rat skeletal muscle acetyl-
CoA carboxylase. Eur.J.Biochem. 231:192-198, 1995  
 
UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with 
metformin  on  complications  in  overweight  patients  with  type  2  diabetes  (UKPDS  34).  Lancet 
352:854–865, 1998. 
 
Unger RH, Madison LL, Carter NW: Tolbutamide-phenformin in ketoacidosis-resistant patients. 
JAMA 174:2132-2136, 1960. 
 
Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS: Protection from obesity-induced insulin 
resistance in mice lacking TNF-alpha function. Nature 389:610-614, 1997.  
 
Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, Laaksonen R: Risk of acute 
coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358:2127–2128, 
2001. 
 
Vallance P, Collier J, Moncada S: Effects of endothelium-derived nitric oxide on peripheral arterial 
tone in man. Lancet 2:997-1000, 1989. 
 
Vallance P, Chan N: Endothelial function and nitric oxide: clinical relevance. Heart 85:342-350, 
2001. 
 245 
 
245 
 
Van Weeren PC, De Bruyn KM, De Vries-Smits AM, Van Lint J, Burgering BM: Essential role for 
protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation. Characterization 
of dominant-negative mutant of PKB. J.Biol.Chem. 273:13150-13156, 1998. 
 
Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH: Insulin signalling to mTOR mediated 
by the Akt/PKB substrate PRAS40. Nat. Cell Biol. 9:316-323, 2007. 
 
Villena JA: Induced adiposity and adipocyte hypertrophy in mice lacking the AMP-activated protein 
kinase-alpha2 subunit. Diabetes 53:2242-2249, 2004.  
 
Viollet  B:  The  AMP-activated  protein  kinase  α2  catalytic  subunit  controls  whole-body  insulin 
sensitivity. J.Clin.Invest. 111:91-98, 2003. 
 
Vitale  C,  Mercuro  G,  Cornoldi  A,  Fini  M,  Volterrani  M,  Rosano  GM:  Metformin  improves 
endothelial function in patients with metabolic syndrome. J.Intern.Med. 258:250-256, 2005. 
 
Wada T, Kodaira K, Fujishiro K, Maie K, Tsukiyama E, Fukumoto T, Uchida T, Yamazaki S: 
Correlation  of  ultrasound-measured  common  carotid  artery  stiffness  with  pathological  findings. 
Arterioscler.Thromb.Vasc.Biol. 14:479–482, 1994. 
 
Wajant H, Pfizenmaier K, Scheurich P: Tumor necrosis factor signaling. Cell Death Differ. 10:45-
65, 2003. 
 
Walker RS, Linton AL: Phenethyldiguanide: a dangerous side-effect. Br.Med.J. 2:1005-1006, 1959. 
 246 
 
246 
 
Wallace T, Levy J, Matthews D: Use and abuse of HOMA modeling. Diabetes Care 27:1487-1495, 
2004 
 
Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y: Involvement of organic 
cation  transporter  1  in  hepatic  and  intestinal  distribution  of  metformin.  J.Pharmacol.Exp.Ther. 
302:510–515, 2002. 
 
Wang DS, Kusuhara H, Kato Y, Jonker JW, Schinkel AH, Sugiyama Y: Involvement of organic 
cation transporter 1 in the lactic acidosis caused by metformin. Mol.Pharmacol. 63:844-848, 2003. 
 
Wang TD, Chen WJ, Lin JW, Chen MF, Lee, YT: Effects of rosiglitazone on endothelial function, 
C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the 
metabolic syndrome. Am.J.Cardiol. 93: 362–365, 2004. 
 
Wang ZV, Scherer PE: Adiponectin, cardiovascular function, and hypertension. Hypertension 51:8-
14, 2007. 
 
Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR: Slow glucose removal rate and 
hyperinsulinemia  precede  the  development  of  type  II  diabetes  in  the  offspring  of  the  diabetic 
parents. Ann.Intern.Med. 113:909-912, 1990 
 
Weigert C, Hennige AM, Brischmann T, Beck A, Moeschel K, Schauble M, Brodbeck K, Haring 
HU, Schleicher ED, Lehmann R: The phosphorylation of Ser318 of insulin receptor substrate 1 is 
not per se inhibitory in skeletal muscle cells but is necessary to trigger the attenuation of the insulin-
stimulated signal. J.Biol.Chem. 280:37393-37399, 2005.  247 
 
247 
 
Weyer  C,  Funahashi  T,  Tanaka  S,  Hotta  K,  Matsuzawa  Y,  Pratley  RE,  Tataranni  PA: 
Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and 
hyperinsulinemia. J.Clin.Endocrinol.Metab. 86:1930-1935, 2001. 
 
Wheatcroft SB, Williams IL, Shah AM, Kearney MT: Pathophysiological implications of insulin 
resistance on vascular endothelial function. Diabet.Med. 20:255-268, 2003. 
 
White  MF,  Maron  R,  Kahn  CR:  Insulin  rapidly  stimulates  tyrosine  phosphorylation  of  a  Mr-
185,000 protein in intact cells. Nature 318:183-186, 1985. 
 
White  MF,  Takayama  S,  Kahn  CR:  Differences  in  the  sites  of  phosphorylation  of  the  insulin 
receptor in vivo and in vitro. J.Biol.Chem. 260:9470-9478, 1985. 
 
White MF: The IRS-signalling system: a network of docking proteins that mediate insulin action. 
Mol. Cell Biochem. 182:3-11, 1998.  
 
White  MF:  IRS  proteins  and  the  common  path  to  diabetes.  Am.J.Physiol.Endocrinol.Metab. 
283:E413-E422, 2002. 
 
Winder WW, Hardie DG: Inactivation of acetyl-CoA carboxylase and activation of AMP-activated 
protein kinase in muscle during exercise. Am.J.Physiol.Endocrinol.Metab. 270:299-304, 1996.  
 
Winder WW, Hardie DG: AMP-activated protein kinase, a metabolic master switch: possible roles 
in type 2 diabetes. Am.J.Physiol. 277:1-10, 1999. 
 248 
 
248 
 
Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, Zhang Y, Bernal D, Pons S, 
Shulman  GI,  Bonner-Weir  S,  White  MF:  Disruption  of  IRS-2  causes  type  2  diabetes  in  mice. 
Nature 391:900-904, 1998. 
 
Withers DJ, Burks DJ, Towery HH, Altamuro SL, Flint CL, White MF: Irs-2 coordinates Igf-1 
receptor-mediated beta-cell development and peripheral insulin signalling. Nature 23:32-40, 1999 
 
Witters LA: The blooming of the French lilac. Journal of Clinical Investigation 108:1105–1107, 
2001. 
 
Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, Schlattner U, Wallimann 
T,  Carlson  M,  Carling  D:  LKB1  is  the  upstream  kinase  in  the  AMP-activated  protein  kinase 
cascade. Curr.Biol. 13, 2004–2008, 2003. 
 
Woods A, Dickerson K, Heath R, Hong SP, Momcilovic M, Johnstone SR, Carlson M, Carling D: 
Ca2+/calmodulin-dependent  protein  kinase  kinase-beta  acts  upstream  of  AMP-activated  protein 
kinase in mammalian cells. Cell Metab. 2:21-33, 2005. 
 
Wulffelé MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT: The effect of metformin on 
blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. 
J.Intern.Med. 256:1-14, 2004. 
 
Xing  Y,  Musi  N,  Fuji  N,  Zou  L,  Luptak  I,  Hirshman  MF,  Goodyear  LJ,  Tian  R:  Glucose 
metabolism and energy homeostasis in mouse hearts overexpressing dominant negative α2 subunit 
of AMP-activated protein kinase. J.Biol.Chem. 278: 28372–28377, 2003. 249 
 
249 
 
Yamauchi  T,  Tobe  K,  Tamemoto  H,  Ueki  K,  Kaburagi  Y, Yamamoto-Honda R, Takahashi Y, 
Yoshizawa F, Aizawa S, Akanuma Y, Sonenberg N, Yazaki Y, Kadowaki T: Insulin signalling and 
insulin actions in the muscles and livers of insulin-resistant, insulin receptor substrate 1-deficient 
mice. Mol. Cell Biol. 16:3074-3084, 1996. 
 
Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, 
Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn 
BB, Kadowaki T: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating 
AMP-activated protein kinase. Nat.Med. 8:1288–1295, 2002. 
 
Yang J, Holman GD: Long-term metformin treatment stimulates cardiomyocyte glucose transport 
through  an  AMP-activated  protein  kinase-dependent  reduction  in  GLUT4  endocytosis. 
Endocrinology 147:2728–2736, 2006. 
 
Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockcroft JR, Wilkinson IB: C-Reactive Protein 
Is  Associated  With  Arterial  Stiffness  in  Apparently  Healthy  Individuals. 
Arterioscler.Thromb.Vasc.Biol. 24:969-974, 2004. 
 
Yeni-Komshian H, Carantoni M, Abbasi F and Reaven GM: Relationship between several surrogate 
estimates  of  insulin  resistance  and  quantification  of  insulin-mediated  glucose  disposal  in  490 
healthy, nondiabetic volunteers. Diabetes Care 23:171–175, 2000. 
 
Yki-Järvinen H: Role of insulin resistance in the pathogenesis of NIDDM. Diabetologia 38:1378-
1388, 1995. 
 250 
 
250 
 
Yki-Jäarvinen  H,  Utriainen  T:  Insulin-induced  vasodilatation:  physiology  or  pharmacology? 
Diabetologia 41:369-379, 1998. 
 
Yudkin  JS,  Stehouwer  CD,  Emeis  JJ,  Coppack  SW:  C-reactive  protein  in  healthy  subjects: 
associations  with  obesity,  insulin  resistance,  and  endothelial  dysfunction:  a  potential  role  for 
cytokines originating from adipose tissue? Arterioscler.Thromb.Vasc.Biol. 19:972-978, 1999. 
 
Zang M, Zuccollo A, Hou X, Nagata D, Walsh K, Herscovitz H, Brecher P, Ruderman NB, Cohen 
RA: AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-
resistant human HepG2 cells. J.Biol.Chem. 279:47898–4790, 2004. 
 
Zeng G, Quon MJ: Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct 
measurement in vascular endothelial cells. J.Clin.Invest. 98:894-898, 1996. 
 
Zhang J, Gao Z, Yin J, Quon MJ, Ye J: S6K directly phosphorylates IRS-1 on Ser270 to promote 
insulin  resistance  in  response  to  TNF-alpha  signaling  through  IKK2.  J.Biol.Chem.  283:35375-
35382, 2008. 
 
Zhang L, He H, Balschi JA: Metformin and phenformin activate AMP-activated protein kinase in 
the heart by increasing cytosolic AMP concentration. Am.J.Physiol. Heart  Circ.Physiol. 293:457–
466, 2007. 
 
Zhang  S,  Kim,  KH:  Glucose  activation  of  acetyl-CoA  carboxylase  in  association  with  insulin 
secretion in a pancreatic beta-cell line. J.Endocrinol. 147:33–41, 1995. 
 251 
 
251 
 
Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, 
Musi  N,  Hirshman  MF,  Goodyear  LJ,  Moller  DE:  Role  of  AMP-activated  protein  kinase  in 
mechanism of metformin action. J.Clin.Invest. 108:1167–74, 2001. 
 
Zhou K, Donnelly LA, Kimber CH, Donnan PT, Doney AS, Leese G, Hattersley AT, McCarthy MI, 
Morris  AD,  Palmer  CN,  Pearson  ER:  Reduced-function  SLC22A1  polymorphisms  encoding 
organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes 
58:1434-1439, 2009. 
 
Zimmet PZ, Alberti KG: The changing face of macrovascular disease in non-insulin dependent 
diabetes mellitus: an epidemic in progress. Lancet 350 (Suppl) 1:SI1-SI4, 1997. 
 
Zou MH, Hou XY, Shi CM, Nagata D, Walsh K, Cohen RA: Modulation by peroxynitrite of Akt- 
and AMP-activated kinase-dependent Ser1179 phosphorylation of endothelial nitric oxide synthase. 
J.Biol.Chem. 277:32552-32557, 2002. 
 
Zou  MH,  Kirkpatrick  SS,  Davis  BJ,  Nelson  JS,  Wiles  WG  4th,  Schlattner  U,  Neumann  D, 
Brownlee M, Freeman MB, Goldman MH: Activation of the AMP-activated protein kinase by the 
anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J.Biol.Chem. 
279:43940-43951, 2004. 
 
 
 
 
 